METHODS FOR DETERMINING THE RISK OF A PATIENT BEING NON-RESPONSIVE TO A THERAPEUTIC DOSE OF AN ANTIBODY AND FOR TREATING INFLAMMATORY BOWEL DISEASE, KIT, ANTIBODIES AND USES OF AN ANTIBODY

Genotyping for TNFSF15 polymorphisms identifies non-responsive patients, enabling targeted anti-TL1A antibody therapy to improve IBD symptoms through defined dosing regimens.

BR112025025072A2Pending Publication Date: 2026-11-10GENENTECH INC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
BR112025025072
Authority / Receiving Office
BR · BR
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-05-17
Filing Date
2024-05-17
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Current treatments for inflammatory bowel diseases (IBD), such as ulcerative colitis, are inadequate for many patients, leading to non-response and loss of response, and there is a need for therapies that promote gastrointestinal healing and define biomarkers to guide treatment.

Method used

A method involving genotyping to determine patient haplotype for TNFSF15 polymorphisms to identify responsiveness to anti-TL1A antibody therapy, followed by an induction and maintenance dosing regimen of the antibody to treat IBD.

Benefits of technology

The method effectively identifies non-responsive patients and provides targeted therapy with anti-TL1A antibodies, improving IBD symptoms for at least 12 weeks with defined dosing regimens.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present disclosure provides methods and compositions for determining the risk of a patient being non-responsive to a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody and methods and compositions for treating inflammatory bowel disease (IBD) with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.
Need to check novelty before this filing date? Find Prior Art

Description

1 / 147 “METHODS FOR DETERMINING THE RISK OF A PATIENT BEING NON-RESPONSIVE TO A THERAPEUTIC DOSE OF AN ANTIBODY AND FOR TREATING INFLAMMATORY BOWEL DISEASE, KIT, ANTIBODIES AND USES OF AN ANTIBODY” Cross-reference to related orders

[0001] This application claims priority over U.S. Provisional Application No. 63 / 502,786, filed May 17, 2023; U.S. Provisional Application No. 63 / 647,481, filed May 14, 2024; and U.S. Provisional Application No. 63 / 649,269, filed May 17, 2024, the disclosures of which are incorporated herein by reference in their entirety. List of Sequences

[0002] This application contains a Sequence List that was submitted electronically in XML format and is incorporated herein by reference in its entirety. The said XML copy, created on May 17, 2024, is named 50474-352WO4_Sequence_Listing_5_17_24 and is 75,503 bytes in size. Field of Invention

[0003] The present invention relates to the treatment of the signs and symptoms of inflammatory bowel disease with a tumor necrosis factor-like 1A (TL1A) ligand antibody. Background of the Invention

[0004] Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis (UC), is a chronic inflammatory disorder affecting approximately 1.6 million people in the US and approximately 2.5–3 million people in Europe. To induce remission in patients with moderately to severely active UC, treatment recommendations include appropriate doses of oral corticosteroids, biological therapies such as necrosis factor inhibitors. Petition 870250104631, dated 11 / 14 / 2025, page 159 / 355 2 / 147 tumor-associated urethral syndrome (TNFi) includes infliximab (monotherapy or in combination with azathioprine), adalimumab, ustekinumab, golimumab, the integrin receptor antagonist vedolizumab, and the oral small molecule Janus kinase inhibitor tofacitinib (Rubin et al, 2019 Am J Gastroenterol; 114:384-413). However, non-response and loss of response to treatments have been observed in UC, and therefore, the development of new treatments for UC and IBD still represents an unmet clinical need (Lichtenstein et al 2018 Am J Gastroenterol; 113:481-517).

[0005] Several components of the mucosal immune system—including epithelial cells, innate and adaptive immune cells, cytokines, and chemokines—contribute to the pathogenesis of IBD (Wallace et al, 2014, World J Gastroenterol; 20:6-21). One of the immunological components involved in the pathogenesis of IBD is TNF-like ligand 1A (TL1A, or tissue necrosis factor superfamily member 15 (TNFSF15)). Genome-wide association studies have linked single nucleotide polymorphisms of TNFSF15 with disease severity; for example, an association was observed between the single nucleotide polymorphism rs11554257 and drug-refractory UC compared with healthy controls (Haritunians et al, 2010, Inflammatory bowel diseases; 16: 1830-1840). It has been found that TL1A is upregulated in IBD tissue samples, with the expression level corresponding to the severity of the disease (Bamias et al, 2010, Clin Immunol; 137:242-249).

[0006] T cell-mediated signaling and cytokine production, for example, interferon-γ-producing helper T cells (Th)1, interleukin (IL)-6 and IL-17-producing Th17, and IL-4 and IL-13-producing Th2, are co-stimulated by TL1A binding to death receptor 3 (Migone et al, 2002, Immunity 16; 16:479-492; Takedatsu et al, 2008, Gastroenterology 135; 552-567; Meylan et al 2011; Mucosal Immunity 4; 172 Petition 870250104631, dated 11 / 14 / 2025, p. 160 / 355 3 / 147 185; Meylan et al 2008; Immunity 29; 79-89). As increased cytokine production leads to chronic inflammation, TL1A inhibition may be a therapeutic target for inflammatory diseases, including IBD.

[0007] UC is a chronic inflammatory bowel disease characterized by diffuse mucosal inflammation. The underlying pathophysiology of this disease results from the interaction between genetic susceptibility to immune genes and alterations in the gut microbiome. Current treatments for UC target the activation of immune cells, including non-selective drugs such as corticosteroids, mesalamine, and thiopurines, as well as selective biological agents (anti-TNFα, anti-α4β7, and anti-IL-12 / 23) and small molecule Janus kinase inhibitors. Despite these treatments, many patients experience an inadequate response, as determined by endoscopy, and develop refractory disease.Therefore, there is an urgent need to develop therapies that promote gastrointestinal healing, determined, for example, by endoscopy (called "endoscopic healing"), and to define tissue, blood, and microbiome biomarkers to assist in guiding treatment.

[0008] There is still an unmet need for effective, safe, and well-tolerated treatment for individuals with moderate to severe ulcerative colitis. Characteristic clinical symptoms of CU include bloody diarrhea associated with rectal urgency and tenesmus. The clinical course is marked by exacerbations and remissions. The diagnosis of CU is suspected clinically and confirmed by diagnostic tests and exclusion of infectious causes (Dignass et al., J Crohn's Colitis. 2012; 6(10):965-90). The most severe intestinal manifestations of CU are toxic megacolon and perforation. Extraintestinal complications include arthritis (peripheral or axial involvement), dermatological diseases (erythema nodosum, aphthous stomatitis, and pyoderma gangrenosum), ocular inflammation (uveitis), and hepatic dysfunction (sclerosing cholangitis). Petition 870250104631, dated 11 / 14 / 2025, page 161 / 355 4 / 147 primary). Individuals with UC have an increased risk of colon cancer, and this risk increases with the duration of the disease, as well as with the extent of the colon affected (Rutter et al, 2004 Gastroenterology; 126(2):451-9).

[0009] The goal of drug treatment for UC is to control inflammation and reduce symptoms. Available pharmaceutical therapies are limited, do not always completely eliminate the inflammatory process, and can have significant adverse effects. Therapies for mild to moderate active UC include 5-aminosalicylic acid derivatives and immunosuppressants.

[0010] Genome-wide association studies have linked more than 200 genes to IBD, many of which are associated with underlying dysregulated immunoregulatory functions (de Lange et al 2017, Nat Genet.; 49(2): 256-610). One of the genetic variants most strongly associated with IBD is located at the Tumor Necrosis Factor Superfamily member 15 (TNFSF15) locus (Siakavellas et al 2015; Inflamm. Bowel Dis. 21 (10): 2441-52). Variants in the TNFSF15 gene have been associated with the pathogenesis of several autoimmune diseases—including psoriasis, rheumatoid arthritis, and multiple sclerosis—implying a broad role for TNFSF15 in human inflammatory diseases. In IBD, TNFSF15 variants may confer a higher risk of complications from more aggressive, penetrating, fibrostenotic, and perianal diseases (Yang et al 2014 J Crohns Colitis; 8(10): 1315-26; Tung et al 2014 J Gastroenterl Hepatol; 29(4):273-9).TNFSF15 encodes TNF-like ligand 1A (TL1A), which is highly expressed in human colonic tissue during active colitis (Bamias et al 2013; Curr Opinion Gasteroenterol. 29(6): 597-602).

[0011] The mechanistic impact of TL1A in preclinical models is pleiotropic. Although initial studies demonstrated a pathogenic role of TL1A overexpression in inducing inflammatory responses in Th1, Th17, and group 2 innate lymphoid cells, more recent reports in Petition 870250104631, dated 11 / 14 / 2025, page 162 / 355 5 / 147 mouse models of acute colitis and ileitis have revealed a contrasting protective role for endogenous TL1A in supporting the function of anti-inflammatory regulatory T cells (Treg) and group 3 innate lymphoid cells (Prehn et al, 2004, Clin Immunol 112(1):66-77; Castellanos, et al 2019; Mucosal Immunol.11(5): 1466-1476). Beyond the impact on lymphoid cells, mouse models have revealed a fundamental impact of TL1A overexpression on intestinal fibrosis. Furthermore, in vitro studies of peripheral blood macrophages have revealed a contribution of the TNFSF15 risk haplotype in the synergistic regulation of inflammatory cytokines induced by the NOD2 ligand (Hedl and Abraham, 2014; PNAS 111 (37) 13451-13456). Collectively, these preclinical studies highlight a potential central homeostatic role for TL1A in modulating selective innate and adaptive immune pathways critical for IBD, as well as for the major clinical complication of fibrosis.To date, no study has defined the mechanisms underlying the potential effectiveness of anti-TL1A therapy in humans.

[0012] Preclinical studies in rodent and human cell models of colitis have shown that anti-TL1A antibodies can reduce tissue fibrosis, fibroblast count, and clinical disease score, thus highlighting their potential as biological therapies for IBD (Clarke et al 2002, MAbs 10:664-677; Shih et al 2014 Mucosal Immunol; 7:1492-1503).

[0013] There is a need in the treatment technique for inflammatory bowel diseases, including Crohn's disease and ulcerative colitis, with anti-TNF ligand-like antibody (TL1A) therapy, as well as a need to identify patients who may be responsive or non-responsive to such therapies. This disclosure aims to address those needs. Brief Description of the Invention

[0014] This disclosure provides a method for determining the risk of a patient being unresponsive to a therapeutic dose of a Petition 870250104631, dated 11 / 14 / 2025, page 163 / 355 6 / 147 anti-TNF ligand-like antibody 1A (TL1A), comprising performing a genotyping assay on a patient's biological sample to determine whether the patient is a haplotype B vehicle or a non-haplotype B vehicle for TNFSF15, the assay comprising determining the presence of at least two single nucleotide polymorphisms (SNPs) selected from rs3810936, rs6478108, rs6478109, rs7848647 and rs7869487 in a patient's biological sample, and determining the risk of being non-responsive to the therapeutic dose of an anti-TL1A antibody, wherein the risk is greater in a haplotype B vehicle patient than in a non-haplotype B vehicle patient. The patient may have inflammatory bowel disease (IBD).

[0015] This disclosure provides a method for treating inflammatory bowel disease (IBD) in a patient, the method comprising (a) performing a genotyping assay on a biological sample from the patient to determine whether the patient is a haplotype B carrier or a non-haplotype B carrier for TNFSF15, the assay comprising determining the presence of at least two single nucleotide polymorphisms (SNPs) selected from rs3810936, rs6478108, rs6478109, rs7848647 and rs7869487 in a biological sample from the patient; and (b) administering to the patient an anti-TNF ligand-like antibody 1A (TL1A), where the patient has been determined to be a non-haplotype B carrier.

[0016] In some respects, the anti-TL1A antibody is administered to the patient in an induction dosing regimen sufficient to improve the signs and symptoms of IBD for at least 12 weeks after the start of treatment with the anti-TL1A antibody, said induction dosing regimen comprising a plurality of individual induction doses.

[0017] In some respects, the anti-TL1A antibody is administered to the patient in a maintenance dosing regimen after completion of the induction dosing regimen, said dosing regimen being Petition 870250104631, dated 11 / 14 / 2025, page 164 / 355 7 / 147 maintenance comprises a plurality of individual maintenance doses separated from each other by at least 2 weeks.

[0018] In some respects, the present disclosure describes a method for treating IBD in a patient, the method comprising (a) performing a genotyping assay to determine whether the patient is a haplotype B carrier or a non-haplotype B carrier for TNFSF15, the assay comprising determining the presence of at least two SNPs selected from rs3810936, rs6478108, rs6478109, rs7848647 and rs7869487 in a biological sample from the patient; (b) administering to the patient an anti-TL1A antibody in an induction dosing regimen sufficient to improve the signs and symptoms of IBD for at least 12 weeks after initiation of treatment with the anti-TL1A antibody, said induction dosing regimen comprising a plurality of individual induction doses, wherein the patient was determined to be a non-haplotype B carrier;and (c) administer to the patient a subsequent maintenance dosing regimen after completion of the induction dosing regimen, such maintenance dosing regimen comprising a plurality of individual maintenance doses separated by at least 2 weeks.;

[0019] IBD can be ulcerative colitis (UC). UC can be moderate to severe ulcerative colitis. In some respects, IBD is Crohn's disease (CD).

[0020] In a preferred aspect, the at least two SNPs are SNP rs3810936 and SNP rs7869487.

[0021] In some respects, the genotyping assay comprises the determination of the presence of only two SNPs in the patient's biological sample, where the two SNPs are SNP rs3810936 and SNP rs7869487.

[0022] In some respects, the patient is determined as a Petition 870250104631, dated 11 / 14 / 2025, pp. 165 / 355 8 / 147 not a carrier of haplotype B due to any of the following biomarker statuses in the patient's biological sample: (i) the sample genotype is homozygous for the reference allele at rs3810936 and is homozygous for the alternative allele at rs7869487; (ii) the sample genotype is heterozygous for the reference allele at rs3810936 and is homozygous for the alternative allele at rs7869487; (iii) the sample genotype is homozygous for the alternative allele at rs3810936 and is homozygous for the reference allele at rs7869487; (iv) the sample genotype is homozygous for the alternative allele at rs3810936 and heterozygous for the reference allele at rs7869487; or (v) the sample genotype is homozygous for the alternative allele at rs3810936 and homozygous for the alternative allele at rs7869487.

[0023] In some respects, (a) the genotyping assay comprises determining the presence of SNP rs3810936, SNP rs7869487 and SNP rs7848647 in the patient's biological sample; or (b) the genotyping assay comprises determining the presence of SNP rs3810936, SNP rs7869487 and SNP rs6478109 in the patient's biological sample.

[0024] In some respects, the genotyping assay comprises the determination of the presence of SNP rs3810936, SNP rs7869487, SNP rs6478108 and SNP rs6478109 in the patient's biological sample.

[0025] Genotyping assays may include qPCR. Genotyping assays may include sequencing. Genotyping assays may comprise long-range sequencing or long-read sequencing. Genotyping assays may be performed on a microarray. In some respects, genotyping assays are fluorescence-based assays.

[0026] A biological sample can be any sample obtained from the patient. The biological sample can be a cell sample or a tissue sample. The tissue sample can come from a site of inflammation of the Petition 870250104631, dated 11 / 14 / 2025, page 166 / 355 9 / 147 IBD. The biological sample can be an intestinal biopsy sample. The biological sample can be a blood sample. The biological sample can be buccal cells or tissue. Buccal cells or tissue can be obtained using a buccal swab. Preferably, the biological sample is blood, cells, or buccal tissue.

[0027] In another aspect, the disclosure describes a method for determining the risk of a patient being unresponsive to a therapeutic dose of an anti-TL1A antibody, wherein the patient has inflammatory bowel disease (IBD), the method comprising (a) performing a genotyping assay on a biological sample from the patient to determine whether the patient is a haplotype B vehicle or a non-haplotype B vehicle for TNFSF15, wherein the assay comprises determining the presence of SNP rs3810936 and SNP rs7869487 in a biological sample from the patient, and wherein a non-haplotype B vehicle for TNFSF15 is identified by either of the following biomarker statuses in the biological sample from the patient: (i) the sample genotype is homozygous for the reference allele at rs3810936 and is homozygous for the alternative allele at rs7869487; (ii) the sample genotype is heterozygous for the reference allele at rs3810936 and is homozygous for the alternative allele at rs7869487;(iii) the sample genotype is homozygous for the alternative allele at rs3810936 and is homozygous for the reference allele at rs7869487; (iv) the sample genotype is homozygous for the alternative allele at rs3810936 and is heterozygous for the reference allele at rs7869487; or (v) the sample genotype is homozygous for the alternative allele at rs3810936 and is homozygous for the alternative allele at rs7869487; and (b) identify the patient as having a high risk of not responding to a therapeutic dose of an anti-TL1A antibody if the patient is a haplotype B carrier; or (c) identify the patient as having a low risk of being unresponsive to a therapeutic dose of an anti-TL1A antibody if the patient is a non-haplotype B carrier. In some respects,; Petition 870250104631, dated 11 / 14 / 2025, p. 167 / 355 10 / 147 The patient was determined to be a non-vehicle of haplotype B for TNFSF15, and the method further comprises administering to the patient an effective amount of an anti-TL1A antibody. In some respects, the anti-TL1A antibody is administered to the patient in an induction dosing regimen sufficient to improve the signs and symptoms of IBD for at least 12 weeks after initiation of treatment with the anti-TL1A antibody, said induction dosing regimen comprising a plurality of individual induction doses. In some respects, the anti-TL1A antibody is administered to the patient in a maintenance dosing regimen after completion of the induction dosing regimen, said maintenance dosing regimen comprising a plurality of individual maintenance doses separated by at least 2 weeks.

[0028] In another aspect, the disclosure describes a method for treating IBD in a patient, the method comprising (a) performing a genotyping assay on a biological sample from the patient to determine whether the patient is a haplotype B carrier or a non-haplotype B carrier for TNFSF15, wherein the assay comprises determining the presence of SNP rs3810936 and SNP rs7869487 in a biological sample from the patient, and wherein a non-haplotype B carrier for TNFSF15 is identified by either of the following biomarker statuses in the biological sample from the patient: (i) the sample genotype is homozygous for the reference allele at rs3810936 and is homozygous for the alternative allele at rs7869487; (ii) the sample genotype is heterozygous for the reference allele at rs3810936 and is homozygous for the alternative allele at rs7869487; (iii) the sample genotype is homozygous for the alternative allele at rs3810936 and is homozygous for the reference allele at rs7869487;(iv) the sample genotype is homozygous for the alternative allele at rs3810936 and is heterozygous for the reference allele at rs7869487; or (v) the sample genotype is homozygous for the alternative allele at rs3810936 and is; Petition 870250104631, dated 11 / 14 / 2025, p. 168 / 355 (a) administering to the patient an effective amount of an anti-TL1A antibody, wherein the patient has been determined to be a non-vehicle of haplotype B. In some respects, the anti-TL1A antibody is administered to the patient in an induction dosing regimen sufficient to improve the signs and symptoms of IBD for at least 12 weeks after the start of treatment with the anti-TL1A antibody, wherein said induction dosing regimen comprises a plurality of individual induction doses. In some respects, the anti-TL1A antibody is administered to the patient in a maintenance dosing regimen after completion of the induction dosing regimen, wherein said maintenance dosing regimen comprises a plurality of individual maintenance doses separated from each other by at least 2 weeks.

[0029] In another aspect, the disclosure describes a method for treating IBD in a patient, the method comprising administering to the patient an effective amount of an anti-TL1A antibody, wherein the patient has been determined to be a non-vehicle of haplotype B for TNFSF15 by any of the following biomarker statuses in a biological sample from the patient: (i) the sample genotype is homozygous for the reference allele at rs3810936 and is homozygous for the alternative allele at rs7869487; (ii) the sample genotype is heterozygous for the reference allele at rs3810936 and is homozygous for the alternative allele at rs7869487; (iii) the sample genotype is homozygous for the alternative allele at rs3810936 and is homozygous for the reference allele at rs7869487; (iv) the sample genotype is homozygous for the alternative allele at rs3810936 and heterozygous for the reference allele at rs7869487;or (v) the sample genotype is homozygous for the alternative allele at rs3810936 and homozygous for the alternative allele at rs7869487. In some respects, the anti-TL1A antibody is administered to the patient in an induction dosage regimen sufficient to improve the; Petition 870250104631, dated 11 / 14 / 2025, page 169 / 355 12 / 147 signs and symptoms of IBD for at least 12 weeks after initiation of treatment with the anti-TL1A antibody, wherein the induction dosing regimen comprises a plurality of individual induction doses. In some respects, the anti-TL1A antibody is administered to the patient in a maintenance dosing regimen after completion of the induction dosing regimen, wherein the maintenance dosing regimen comprises a plurality of individual maintenance doses separated by at least 2 weeks.

[0030] Individual induction doses may be administered at least daily, at intervals of at least one day, at intervals of at least 1 week, at intervals of at least 2 weeks, at intervals of at least 3 weeks, at intervals of at least 4 weeks, at intervals of at least 5 weeks, at intervals of at least 6 weeks, at intervals of at least 7 weeks, at intervals of at least 8 weeks, at intervals of at least 9 weeks, at intervals of at least 10 weeks, at intervals of at least 11 weeks, or at intervals of at least 12 weeks. In a preferred aspect, individual induction doses are administered at one-month intervals. In some aspects, individual induction dosages are administered at four-week intervals.

[0031] The individual induction dose may be 1, 5, 10, 25, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 or 1000 mg. In a preferred aspect, the individual induction dose is 50, 150 or 450 mg. In some aspects, each of the individual induction doses is administered at a dose of 50 mg. In some aspects, each of the individual induction doses is administered at a dose of 150 mg. In some aspects, each of the individual induction doses is administered at a dose of 450 mg. Petition 870250104631, dated 11 / 14 / 2025, p. 170 / 355 13 / 147

[0032] Individual induction doses can be administered by any route. Preferably, individual induction doses are administered intravenously or subcutaneously. In some cases, each of the individual induction doses is administered subcutaneously.

[0033] In some respects, the induction dosing regimen comprises four individual induction doses.

[0034] In some respects, the induction dosing regimen comprises four individual induction doses administered at 4-week intervals, wherein each of the individual induction doses is administered subcutaneously at a dose of 50, 150 or 450 mg.

[0035] Individual maintenance doses may be administered at least daily, at intervals of at least one day, at intervals of at least 1 week, at intervals of at least 2 weeks, at intervals of at least 3 weeks, at intervals of at least 1 month, at intervals of at least 2 months, at intervals of at least 3 months, at intervals of at least 4 months, at intervals of at least 5 months, or at intervals of at least 6 months. In a preferred aspect, individual maintenance doses are administered at one-month intervals. In some aspects, individual maintenance dosages are administered at four-week intervals.

[0036] The individual maintenance dose may be 1, 5, 10, 25, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, or 1000 mg. In a preferred aspect, the individual maintenance dose is 50, 150, or 450 mg. In some aspects, each of the individual maintenance doses is administered at a dose of 50 mg. In some aspects, each of the individual maintenance doses is administered at a dose of 150 mg. In some aspects, each of the maintenance doses Petition 870250104631, dated 11 / 14 / 2025, page 171 / 355 14 / 147 individuals are administered at a dose of 450 mg.

[0037] Individual maintenance doses may be administered by any route. Preferably, individual maintenance doses are administered intravenously or subcutaneously. In some respects, each of the individual maintenance doses is administered subcutaneously.

[0038] In some respects, the maintenance dosing regimen comprises at least ten individual maintenance doses.

[0039] In some respects, the induction dosing regimen comprises ten individual maintenance doses administered at 4-week intervals, wherein each of the individual maintenance doses is administered subcutaneously at a dose of 50, 150, or 450 mg. In some respects, each of the individual maintenance doses is administered subcutaneously at a dose of 450 mg.

[0040] The methods described in this document may further comprise (a) determining the expression level of one or more candidate genes in a patient biological sample and (b) identifying that the biological sample contains an abnormal expression level of one or more candidate genes. The one or more candidate genes may be selected from the group consisting of SOWAHB, COLCA2, TBX20, FRZB, HOXB5, NET1, FOXD2, DESI1, PARK2, PKDREJ, IL-1 B, IL-23A, IFNG, IL-12RB1, IL-21 R, IRF4, BATF, CD80 / 86, HLA-DRB5 / DQB1 / DRB1, HLA-DRA, CD40, ICOS, MMP3, MMP7, MMP10 and CHI3L. In a preferred aspect, one or more candidate genes are selected from the group consisting of SOWAHB, COLCA2, TBX20, FRZB, HOXB5, NET1, FOXD2, DESI1, PARK2, and PKDREJ. The expression level of one or more candidate genes can be compared to a baseline expression level that is a) based on the expression level of one or more candidate genes in a healthy individual who does not suffer from IBD. Petition 870250104631, dated 11 / 14 / 2025, p. 172 / 355 15 / 147 or UC; or b) based on an estimated expression level for individuals who are unresponsive to anti-TL1A antibody treatment. The abnormal expression level of one or more candidate genes may be at least 50% higher or lower than the baseline level.

[0041] The methods described may further comprise a) determining the expression level of one or more candidate bacterial strains in a patient stool sample, and b) identifying whether the sample contains an increased or decreased level of one or more candidate bacterial strains. In one aspect, the level of the candidate bacterial strain may be increased, and the candidate bacterial strain is selected from the group consisting of Streptococcus salivarius, Streptococcus parasanguinis, and Haemophilus parainfluenzae. In another aspect, the level of the candidate bacterial strain may be decreased, and the candidate bacterial strain is selected from the group consisting of Ruminococcus albus, Ruminococcus callidus, Ruminococcus bromii, Ruminococcus gnavus, and Bifidobacterium bifidum.

[0042] In another aspect, the disclosure describes a method for treating inflammatory bowel disease (IBD) in a patient, the method comprising (a) performing a genotyping assay to determine whether the patient is a haplotype B carrier or a non-haplotype B carrier for TNFSF15, the assay comprising determining the presence of at least two single nucleotide polymorphisms (SNPs) selected from rs3810936, rs6478108, rs6478109, rs7848647 and rs7869487 in a biological sample from the patient; and (b) administering to the patient an effective amount of an anti-TL1A antibody, where the patient has been determined to be a non-haplotype B carrier; wherein the anti-TL1A antibody comprises an HCDR1 with the sequence shown in SEQ ID NO: 3, an HCDR2 with the sequence shown in SEQ ID NO: 4, an HCDR3 with the sequence shown in SEQ ID NO: 5, an LCDR1 with the sequence shown in SEQ ID NO: 6, an LCDR2 with the Petition 870250104631, dated 11 / 14 / 2025, page 173 / 355 16 / 147 sequence shown in SEQ ID NO: 7 and an LCDR3 with the sequence shown in SEQ ID NO: 8. In some respects, at least two SNPs are SNP rs3810936 and SNP rs7869487. In some respects, the assay consists of determining the presence of only two SNPs in the patient's biological sample, where the two SNPs are SNP rs3810936 and SNP rs7869487.

[0043] The antibody may be any anti-TL1A antibody. Examples include, but are not limited to, afimkibart (also known as PF-06480605 or RVT-3101) from Pfizer / Roivant, PRA023 (also known as tulisoquibart) from Prometheus Biosciences, and C03V from Teva Pharmaceuticals. In one aspect, the anti-TL1A antibody comprises a variable heavy chain region with the sequence shown in SEQ ID NO: 1 and a variable light chain region with the sequence shown in SEQ ID NO: 2. The anti-TL1A antibody may comprise three CDRs of the variable heavy chain region with the sequence shown in SEQ ID NO: 1 and three CDRs of the variable light chain region with the sequence shown in SEQ ID NO: 2.The anti-TL1A antibody may comprise an HCDR1 with the sequence shown in SEQ ID NO: 3 or SEQ ID NO: 68, an HCDR2 with the sequence shown in SEQ ID NO: 4, an HCDR3 with the sequence shown in SEQ ID NO: 5, an LCDR1 with the sequence shown in SEQ ID NO: 6, an LCDR2 with the sequence shown in SEQ ID NO: 7, and an LCDR3 with the sequence shown in SEQ ID NO: 8 (for example, it may comprise CDR sequences according to SEQ ID NOs: 3 to 8 or it may comprise CDR sequences according to SEQ ID NOs: 4 to 8 and 68). In some respects, the anti-TL1A antibody comprises a heavy chain with the sequence shown in SEQ ID NO: 9 and a light chain with the sequence shown in SEQ ID NO: 10. In some respects, the anti-TL1A antibody is afimkibart.

[0044] The anti-TL1A antibody may comprise sequence pairs selected from the group consisting of SEQ ID NOs: 2 and 11; Petition 870250104631, dated 11 / 14 / 2025, page 174 / 355 17 / 147 SEQ ID NOs: 2 e 12; SEQ ID NOs: 2 e 13; SEQ ID NOs: 2 e 14; SEQ ID NOs: 2 e 15; SEQ ID NOs: 2 e 16; SEQ ID NOs: 2 e 17; SEQ ID NOs: 2 e 18; SEQ ID NOs: 2 e 19; SEQ ID NOs: 20 e 24; SEQ ID NOs: 21 e 25; SEQ ID NOs: 22 e 26; SEQ ID NOs: 23 e 27; SEQ ID NOs: 28 e 29; SEQ ID NOs: 30 e 31; SEQ ID NOs: 32 e 33; SEQ ID NOs: 35 e 44; SEQ ID NOs: 53 e 54; SEQ ID NOs: 61 e 62; SEQ ID NOs: 63 e 64; SEQ ID NOs: 65 e 64; SEQ ID NOs: 66 e 64; e SEQ ID NOs: 67 e 64.

[0045] In some respects, the anti-TL1A antibody comprises three CDRs of the variable heavy chain region with the sequence shown in SEQ ID NO: 53 and three CDRs of the variable light chain region with the sequence shown in SEQ ID NO: 54. In some respects, the anti-TL1A antibody comprises an HCDR1 with the sequence shown in SEQ ID NO: 37, an HCDR2 with the sequence shown in SEQ ID NO: 39, an HCDR3 with the sequence shown in SEQ ID NO: 41, an LCDR1 with the sequence shown in SEQ ID NO: 46, an LCDR2 with the sequence shown in SEQ ID NO: 48, and an LCDR3 with the sequence shown in SEQ ID NO: 50. In some respects, the anti-TL1A antibody comprises a variable heavy chain region with the sequence shown in SEQ ID NO: 53 and a variable light chain region with the sequence shown in SEQ ID NO: 54. In some respects, the The anti-TL1A antibody comprises a heavy chain with the sequence shown in SEQ ID NO: 35 and a light chain with the sequence shown in SEQ ID NO: 44.In some respects, the anti-TL1A antibody is tulisoquibart.

[0046] In another aspect, the disclosure describes a method for treating inflammatory bowel disease (IBD) in a patient, the method comprising (a) performing a genotyping assay to determine whether the patient is a haplotype B vehicle or a non-haplotype B vehicle for TNFSF15, the assay comprising determining the presence of at least two single nucleotide polymorphisms (SNPs) selected from rs3810936, Petition 870250104631, dated 11 / 14 / 2025, page 175 / 355 (a) administering to the patient an anti-TL1A antibody, wherein the patient has been determined to be a non-vehicle of haplotype B; wherein the anti-TL1A antibody comprises an HCDR1 with the sequence shown in SEQ ID NO: 37, an HCDR2 with the sequence shown in SEQ ID NO: 39, an HCDR3 with the sequence shown in SEQ ID NO: 41, an LCDR1 with the sequence shown in SEQ ID NO: 46, an LCDR2 with the sequence shown in SEQ ID NO: 48 and an LCDR3 with the sequence shown in SEQ ID NO: 50. In some respects, at least two of the SNPs are SNP rs3810936 and SNP rs7869487. In some aspects, the assay comprises the determination of the presence of only two SNPs in the patient's biological sample, where the two SNPs are SNP rs3810936 and SNP rs7869487. The disclosed treatment methods may additionally include treatment with an IL-23 antagonist.

[0047] In another aspect, the disclosure describes a method for treating inflammatory bowel disease (IBD) in a patient, the method comprising administering to the patient an effective amount of an anti-TNF ligand-like antibody (TL1A) in a dosing regimen comprising an induction dosing regimen and a subsequent maintenance dosing regimen; wherein the induction dosing regimen comprises a plurality of individual induction doses and the maintenance dosing regimen comprises a plurality of individual maintenance doses; wherein the anti-TL1A antibody is administered subcutaneously in the maintenance phase, and wherein the anti-TL1A antibody comprises an HCDR1 with the sequence shown in SEQ ID NO: 3, an HCDR2 with the sequence shown in SEQ ID NO: 4, an HCDR3 with the sequence shown in SEQ ID NO: 5, an LCDR1 with the sequence shown in SEQ ID NO: 6, an LCDR2 with the sequence shown in SEQ ID NO: 7 and an LCDR3 with the Petition 870250104631, dated 11 / 14 / 2025, page 176 / 355 19 / 147 sequence shown in SEQ ID NO: 8.

[0048] In some respects, individual induction doses are separated from each other by at least 1 week, at least 2 weeks, at least 3 weeks, or at least 4 weeks. In some respects, individual induction doses are separated from each other by at least 1 month. In some respects, individual induction doses are administered 4 weeks apart.

[0049] In some respects, the individual induction dose is administered intravenously or subcutaneously. In some respects, each of the individual induction doses is administered subcutaneously.

[0050] In some aspects, the individual induction dose is administered in 50, 150, or 450 mg doses. In some aspects, each individual induction dose is administered in a 50 mg dose. In some aspects, each individual induction dose is administered in a 150 mg dose. In some aspects, each individual induction dose is administered in a 450 mg dose.

[0051] In some respects, the induction dosing regimen comprises four individual induction doses.

[0052] In some respects, the induction dosing regimen comprises four individual induction doses administered at 4-week intervals, wherein each of the individual induction doses is administered subcutaneously at a dose of 50, 150 or 450 mg.

[0053] In some respects, individual maintenance doses are administered at intervals of at least 2 weeks, 3 weeks, or 4 weeks. In some respects, individual maintenance doses are administered at intervals of at least 1 month. In some respects, individual maintenance doses are administered at intervals of 4 weeks. Petition 870250104631, dated 11 / 14 / 2025, page 177 / 355 20 / 147

[0054] In some respects, the individual maintenance dose is administered at 50, 150, or 450 mg. In some respects, each of the individual maintenance doses is administered at a dose of 50 mg. In some respects, each of the individual maintenance doses is administered at a dose of 150 mg. In some respects, each of the individual maintenance doses is administered at a dose of 450 mg.

[0055] In some respects, the maintenance dosing regimen comprises at least ten individual maintenance doses. In some respects, the induction dosing regimen comprises ten individual maintenance doses administered at 4-week intervals, wherein each of the individual maintenance doses is administered subcutaneously at a dose of 50, 150, or 450 mg. In some respects, each of the individual maintenance doses is administered subcutaneously at a dose of 450 mg.

[0056] In another aspect, the disclosure describes a method for treating inflammatory bowel disease (IBD) in a patient, the method comprising administering to the patient an effective amount of an anti-TNF ligand-like antibody (TL1A) in a dosing regimen comprising an induction dosing regimen and a subsequent maintenance dosing regimen; wherein (a) the induction dosing regimen comprises the subcutaneous administration of four individual induction doses of the anti-TL1A antibody at a dose of about 50 mg, 150 mg or 450 mg, wherein the individual induction doses are administered at 4-week intervals; and (b) the maintenance dosing regimen comprises the subcutaneous administration of a plurality of individual maintenance doses of the anti-TL1A antibody at a dose of about 50 mg, 150 mg or 450 mg, wherein the individual maintenance doses are administered at 4-week intervals;and wherein the anti-TL1A antibody comprises an HCDR1 with the sequence shown in SEQ ID NO: 3, an HCDR2 with the sequence; Petition 870250104631, dated 11 / 14 / 2025, page 178 / 355 21 / 147 shown in SEQ ID NO: 4, an HCDR3 with the sequence shown in SEQ ID NO: 5, an LCDR1 with the sequence shown in SEQ ID NO: 6, an LCDR2 with the sequence shown in SEQ ID NO: 7 and an LCDR3 with the sequence shown in SEQ ID NO: 8.

[0057] In another aspect, the disclosure describes a method for treating inflammatory bowel disease (IBD) in a patient, the method comprising administering to the patient an effective amount of an anti-TNF ligand-like antibody (TL1A) in a dosing regimen comprising an induction dosing regimen and a subsequent maintenance dosing regimen; wherein (a) the induction dosing regimen comprises a plurality of individual induction doses, wherein the individual induction doses are separated from each other by at least 1 week, at least 2 weeks, at least 3 weeks, or at least 4 weeks; and (b) the maintenance dosing regimen comprises the subcutaneous administration of a plurality of individual maintenance doses of the anti-TL1A antibody at a dose of about 450 mg, wherein the individual maintenance doses are administered at 4-week intervals;and wherein the anti-TL1A antibody comprises an HCDR1 with the sequence shown in SEQ ID NO: 3, an HCDR2 with the sequence shown in SEQ ID NO: 4, an HCDR3 with the sequence shown in SEQ ID NO: 5, an LCDR1 with the sequence shown in SEQ ID NO: 6, an LCDR2 with the sequence shown in SEQ ID NO: 7 and an LCDR3 with the sequence shown in SEQ ID NO: 8. In some respects, the induction dosing regimen comprises the subcutaneous administration of four individual induction doses of the anti-TL1A antibody at a dose of approximately 450 mg, wherein the individual induction doses are administered at 4-week intervals.

[0058] In some respects, the first dose of the maintenance phase is administered approximately two weeks after the administration of Petition 870250104631, dated 11 / 14 / 2025, p. 179 / 355 22 / 147 final dose of the induction phase.

[0059] In some respects, the dosing regimen lasts about 52 weeks.

[0060] In some respects, the anti-TL1A antibody comprises a variable heavy chain region with the sequence shown in SEQ ID NO: 1 and a variable light chain region with the sequence shown in SEQ ID NO: 2. In some respects, the anti-TL1A antibody comprises a heavy chain with the sequence shown in SEQ ID NO: 9 and a light chain with the sequence shown in SEQ ID NO: 10. In some respects, the anti-TL1A antibody is afimkibart.

[0061] In some respects, the patient was determined to be a non-vehicle of haplotype B for TNFSF15.

[0062] In some respects, IBD is ulcerative colitis (UC). In some respects, UC is moderate to severe UC.

[0063] In some respects, in a population of patients treated according to the method, the treatment results in an increase in the proportion of patients who achieved clinical remission at the end of the induction phase, compared with a reference population. In some respects, the induction phase lasts approximately 14 weeks, and the treatment results in an increase in the proportion of patients who achieved clinical remission at Week 14. In some respects, at least approximately 15% of patients in the patient population achieved clinical remission at Week 14. In some respects, at least approximately 40% of patients in the patient population achieved clinical remission at Week 14.

[0064] In some respects, in a population of patients treated according to the method, the treatment results in an increase in the proportion of patients who achieved clinical remission at the end of the maintenance phase, compared with a reference population. In some Petition 870250104631, dated 11 / 14 / 2025, pp. 180 / 355 In some aspects, the dosage regimen lasts approximately 56 weeks, and treatment results in an increase in the proportion of patients who achieved clinical remission by Week 56. In some aspects, at least approximately 20% of patients in the patient population achieved clinical remission by Week 56. In some aspects, at least approximately 55% of patients in the patient population achieved clinical remission by Week 56.

[0065] In some respects, clinical remission is defined as a total Mayo Score < 2, with no individual subscores >1. In some respects, IBD is UC and clinical remission is a modified Mayo Score (mMS) < 2 with stool frequency (SFS) subscore = 0 or 1, rectal bleeding (RBS) subscore = 0, and endoscopic subscore (ES) = 0 or 1.

[0066] In some respects, in a population of patients treated according to the method, the treatment results in an increase in the proportion of patients who achieved endoscopic improvement at the end of the induction phase, compared with a reference population. In some respects, the induction phase lasts approximately 14 weeks, and the treatment results in an increase in the proportion of patients who achieved endoscopic improvement at Week 14. In some respects, at least approximately 25% of patients in the patient population achieved endoscopic improvement at Week 14. In some respects, at least approximately 50% of patients in the patient population achieved endoscopic improvement at Week 14.

[0067] In some respects, in a population of patients treated according to the method, the treatment results in an increase in the proportion of patients who achieved endoscopic improvement at the end of the maintenance phase, compared with a reference population. In some respects, the dosing regimen has a duration of approximately 56 weeks, and the Petition 870250104631, dated 11 / 14 / 2025, page 181 / 355 24 / 147 treatment results in an increase in the proportion of patients who achieved endoscopic improvement at Week 56. In some respects, at least about 20% of patients in the patient population achieved endoscopic improvement at Week 56. In some respects, at least about 65% of patients in the patient population achieved endoscopic improvement at Week 56.

[0068] In some respects, clinical remission is an endoscopic subscore of 0 or 1.

[0069] In some respects, in a population of patients treated according to the method, the treatment results in an increase in the proportion of patients who achieved endoscopic remission, clinical response, symptomatic remission, or deep remission at the end of the induction phase, compared with a reference population.

[0070] In some respects, in a population of patients treated according to the method, the treatment results in an increase in the proportion of patients who achieved endoscopic remission, clinical response, symptomatic remission, or deep remission at the end of the maintenance phase, compared with a reference population.

[0071] In some respects, the reference population is a population of patients who have not been treated with an anti-TL1A antibody. In some respects, the reference population is a population of patients who have been treated with a placebo.

[0072] In another aspect, the disclosure describes a kit containing an antibody similar to the TNF ligand 1A (TL1A) and a package insert with instructions for the use of the antibody in the treatment of inflammatory bowel disease (IBD) in a patient who requires it, according to any of the methods provided in this document.

[0073] In another aspect, the disclosure describes an antibody Petition 870250104631, dated 11 / 14 / 2025, p. 182 / 355 25 / 147 anti-TL1A for use in the treatment of IBD in a patient, wherein (a) a genotyping assay must be performed to determine whether the patient is a haplotype B carrier or a non-haplotype B carrier for TNFSF15, the assay comprising determining the presence of at least two single nucleotide polymorphisms (SNPs) selected from rs3810936, rs6478108, rs6478109, rs7848647 and rs7869487 in a biological sample from the patient; and (b) an effective amount of anti-TL1A antibody must be administered to the patient, wherein the patient has been determined to be a non-haplotype B carrier.

[0074] In another aspect, the disclosure describes an anti-TL1A antibody for use in the treatment of IBD in a patient, wherein (a) a genotyping assay is to be performed to determine whether the patient is a haplotype B carrier or a non-haplotype B carrier for TNFSF15, the assay comprising determining the presence of at least two SNPs selected from rs3810936, rs6478108, rs6478109, rs7848647 and rs7869487 in a biological sample from the patient; (b) the anti-TL1A antibody is to be administered to the patient in an induction dosing regimen sufficient to improve the signs and symptoms of IBD for at least 12 weeks after initiation of treatment with the anti-TL1A antibody, said induction dosing regimen comprising a plurality of individual induction doses, wherein the patient was determined to be a non-haplotype B carrier;(c) the anti-TL1A antibody should be administered to the patient in a subsequent maintenance dosing regimen after completion of the induction dosing regimen, said maintenance dosing regimen comprising a plurality of individual maintenance doses separated from each other by at least 2 weeks.

[0075] In another aspect, the disclosure describes an anti-TL1A antibody for use in the treatment of IBD in a patient, wherein (a) an assay Petition 870250104631, dated 11 / 14 / 2025, page 183 / 355 26 / 147 genotyping must be performed on a patient's biological sample to determine whether the patient is a haplotype B carrier or a non-haplotype B carrier for TNFSF15, wherein the assay comprises determining the presence of SNP rs3810936 and SNP rs7869487 in a patient's biological sample, and wherein a non-haplotype B carrier for TNFSF15 is identified by either of the following biomarker statuses in the patient's biological sample: (i) the sample genotype is homozygous for the reference allele at rs3810936 and is homozygous for the alternative allele at rs7869487; (ii) the sample genotype is heterozygous for the reference allele at rs3810936 and is homozygous for the alternative allele at rs7869487; (iii) the sample genotype is homozygous for the alternative allele at rs3810936 and is homozygous for the reference allele at rs7869487;(iv) the sample genotype is homozygous for the alternative allele at rs3810936 and is heterozygous for the reference allele at rs7869487; or (v) the sample genotype is homozygous for the alternative allele at rs3810936 and is homozygous for the alternative allele at rs7869487; and (b) an effective amount of anti-TL1A antibody should be administered to the patient, where the patient has been determined to be a non-vehicle of haplotype B.

[0076] In another aspect, the disclosure describes an anti-TL1A antibody for use in the treatment of IBD in a patient, wherein an effective amount of the anti-TL1A antibody is to be administered to the patient; wherein the patient has been determined to be a non-vehicle of haplotype B for TNFSF15 by any of the following biomarker statuses in a biological sample from the patient: (i) the sample genotype is homozygous for the reference allele at rs3810936 and is homozygous for the alternative allele at rs7869487; (ii) the sample genotype is heterozygous for the reference allele at rs3810936 and is homozygous for the alternative allele at rs7869487; (iii) the sample genotype is homozygous for the alternative allele at rs3810936 and is homozygous for the reference allele at rs7869487; (iv) the genotype of the sample Petition 870250104631, dated 11 / 14 / 2025, p. 184 / 355 27 / 147 is homozygous for the alternative allele at rs3810936 and is heterozygous for the reference allele at rs7869487; or (v) the sample genotype is homozygous for the alternative allele at rs3810936 and is homozygous for the alternative allele at rs7869487.

[0077] In another aspect, the disclosure describes an anti-TL1A antibody for use in the treatment of IBD in a patient, wherein: (a) a genotyping assay is to be performed to determine whether the patient is a haplotype B vehicle or a non-haplotype B vehicle for TNFSF15, the assay comprising determining the presence of at least two SNPs selected from rs3810936, rs6478108, rs6478109, rs7848647 and rs7869487 in a biological sample from the patient; and (b) an effective amount of the anti-TL1A antibody is to be administered to the patient, wherein it has been determined that the patient is not a haplotype B vehicle; wherein the anti-TL1A antibody comprises an HCDR1 with the sequence shown in SEQ ID NO: 3, an HCDR2 with the sequence shown in SEQ ID NO: 4, an HCDR3 with the sequence shown in SEQ ID NO: 5, an LCDR1 with the sequence shown in SEQ ID NO: 6, an LCDR2 with the sequence shown in SEQ ID NO: 7 and an LCDR3 with the sequence shown in SEQ ID NO: 8.

[0078] In another aspect, the disclosure describes an anti-TL1A antibody for use in the treatment of IBD in a patient, wherein (a) a genotyping assay is to be performed to determine whether the patient is a haplotype B carrier or a non-haplotype B carrier for TNFSF15, the assay comprising determining the presence of at least two SNPs selected from rs3810936, rs6478108, rs6478109, rs7848647 and rs7869487 in a biological sample from the patient; and (b) the anti-TL1A antibody is to be administered to the patient, wherein the patient has been determined to be a non-haplotype B carrier; wherein the anti-TL1A antibody comprises an HCDR1 with the sequence shown in SEQ ID NO: 37, an HCDR2 with the Petition 870250104631, dated 11 / 14 / 2025, pp. 185 / 355 28 / 147 sequence shown in SEQ ID NO: 39, an HCDR3 with the sequence shown in SEQ ID NO: 41, an LCDR1 with the sequence shown in SEQ ID NO: 46, an LCDR2 with the sequence shown in SEQ ID NO: 48 and an LCDR3 with the sequence shown in SEQ ID NO: 50.

[0079] In another aspect, the disclosure describes an anti-TL1A antibody for use in the treatment of an IBD in a patient, wherein an effective amount of the anti-TL1A antibody is to be administered to the individual in a dosing regimen comprising an induction dosing regimen and a subsequent maintenance dosing regimen; wherein the induction dosing regimen comprises a plurality of individual induction doses and the maintenance dosing regimen comprises a plurality of individual maintenance doses; wherein the anti-TL1A antibody is administered subcutaneously in the maintenance phase, and wherein the anti-TL1A antibody comprises an HCDR1 with the sequence shown in SEQ ID NO: 3, an HCDR2 with the sequence shown in SEQ ID NO: 4, an HCDR3 with the sequence shown in SEQ ID NO: 5, an LCDR1 with the sequence shown in SEQ ID NO: 6, an LCDR2 with the sequence shown in SEQ ID NO: 7 and an LCDR3 with the sequence shown in SEQ ID NO: 8.

[0080] In another aspect, the disclosure describes an anti-TL1A antibody for use in the treatment of an IBD in a patient, wherein an effective amount of the anti-TL1A antibody is to be administered to the individual in a dosing regimen comprising an induction dosing regimen and a subsequent maintenance dosing regimen, wherein (a) the induction dosing regimen comprises the subcutaneous administration of four individual induction doses of the anti-TL1A antibody at a dose of approximately 50 mg, 150 mg or 450 mg, where individual induction doses are administered at 4-week intervals; and (b) the maintenance dosing regimen comprises the subcutaneous administration of a plurality of doses of Petition 870250104631, dated 11 / 14 / 2025, pp. 186 / 355 29 / 147 Individual maintenance doses of anti-TL1A antibody are administered at a dose of approximately 50 mg, 150 mg, or 450 mg, wherein the individual maintenance doses are administered at 4-week intervals, and wherein the anti-TL1A antibody comprises an HCDR1 with the sequence shown in SEQ ID NO: 3, an HCDR2 with the sequence shown in SEQ ID NO: 4, an HCDR3 with the sequence shown in SEQ ID NO: 5, an LCDR1 with the sequence shown in SEQ ID NO: 6, an LCDR2 with the sequence shown in SEQ ID NO: 7, and an LCDR3 with the sequence shown in SEQ ID NO: 8.

[0081] In another aspect, the disclosure describes an anti-TL1A antibody for use in the treatment of an inflammatory bowel disease (IBD) in a patient, wherein an effective amount of the anti-TL1A antibody is to be administered to the individual in a dosing regimen comprising an induction dosing regimen and a subsequent maintenance dosing regimen, wherein: (a) the induction dosing regimen comprises a plurality of individual induction doses, wherein the individual induction doses are separated from each other by at least 1 week, at least 2 weeks, at least 3 weeks, or at least 4 weeks;(b) the maintenance dosing regimen comprises the subcutaneous administration of a plurality of individual maintenance doses of anti-TL1A antibody at a dose of approximately 450 mg, wherein the individual maintenance doses are administered at 4-week intervals, and wherein the anti-TL1A antibody comprises an HCDR1 with the sequence shown in SEQ ID NO: 3, an HCDR2 with the sequence shown in SEQ ID NO: 4, an HCDR3 with the sequence shown in SEQ ID NO: 5, an LCDR1 with the sequence shown in SEQ ID NO: 6, an LCDR2 with the sequence shown in SEQ ID NO: 7, and an LCDR3 with the sequence shown in SEQ ID NO: 8.;

[0082] In another aspect, the disclosure describes the use of an anti-TL1A antibody in the manufacture of a drug to treat IBD in a Petition 870250104631, dated 11 / 14 / 2025, p. 187 / 355 30 / 147 patient, wherein: (a) a genotyping assay shall be performed to determine whether the patient is a haplotype B carrier or a non-haplotype B carrier for TNFSF15, the assay comprising determining the presence of at least two SNPs selected from rs3810936, rs6478108, rs6478109, rs7848647 and rs7869487 in a biological sample from the patient; and (b) an effective amount of anti-TL1A antibody shall be administered to the patient, wherein the patient has been determined to be a non-haplotype B carrier.

[0083] In another aspect, the disclosure describes the use of an anti-TL1A antibody in the manufacture of a medicinal product to treat IBD in a patient, wherein (a) a genotyping assay is to be performed to determine whether the patient is a haplotype B carrier or a non-haplotype B carrier for TNFSF15, the assay comprising determining the presence of at least two SNPs selected from rs3810936, rs6478108, rs6478109, rs7848647 and rs7869487 in a biological sample from the patient; (b) the anti-TL1A antibody is to be administered to the patient in an induction dosing regimen sufficient to improve the signs and symptoms of IBD for at least 12 weeks after initiation of treatment with the anti-TL1A antibody, said induction dosing regimen comprising a plurality of individual induction doses, wherein the patient was determined to be a non-haplotype B carrier;(c) the anti-TL1A antibody should be administered to the patient in a subsequent maintenance dosing regimen after completion of the induction dosing regimen, said maintenance dosing regimen comprising a plurality of individual maintenance doses separated from each other by at least 2 weeks.

[0084] In another aspect, the disclosure describes the use of an anti-TL1A antibody in the manufacture of a drug to treat IBD in a patient, wherein (a) a genotyping assay must be performed in a Petition 870250104631, dated 11 / 14 / 2025, pp. 188 / 355 31 / 147 patient biological sample to determine whether the patient is a haplotype B carrier or a non-haplotype B carrier for TNFSF15, wherein the assay comprises determining the presence of SNP rs3810936 and SNP rs7869487 in a patient biological sample, and wherein a non-haplotype B carrier for TNFSF15 is identified by either of the following biomarker statuses in the patient biological sample: (i) the sample genotype is homozygous for the reference allele at rs3810936 and is homozygous for the alternative allele at rs7869487; (ii) the sample genotype is heterozygous for the reference allele at rs3810936 and is homozygous for the alternative allele at rs7869487; (iii) the sample genotype is homozygous for the alternative allele at rs3810936 and is homozygous for the reference allele at rs7869487; (iv) the sample genotype is homozygous for the alternative allele at rs3810936 and is heterozygous for the reference allele at rs7869487;or (v) the sample genotype is homozygous for the alternative allele at rs3810936 and is homozygous for the alternative allele at rs7869487; and (b) an effective amount of anti-TL1A antibody must be administered to the patient, where the patient has been determined to be a non-vehicle of haplotype B.;

[0085] In another aspect, the disclosure describes the use of an anti-TL1A antibody in the manufacture of a drug to treat IBD in a patient, wherein an effective amount of the anti-TL1A antibody is to be administered to the patient, and wherein the patient has been determined to be a non-vehicle of haplotype B for TNFSF15 by any of the following biomarker statuses in a biological sample from the patient: (i) the sample genotype is homozygous for the reference allele at rs3810936 and is homozygous for the alternative allele at rs7869487; (ii) the sample genotype is heterozygous for the reference allele at rs3810936 and is homozygous for the alternative allele at rs7869487; (iii) the sample genotype is homozygous for the alternative allele at rs3810936 and is homozygous for the reference allele at rs7869487; (iv) the Petition 870250104631, dated 11 / 14 / 2025, p. 189 / 355 32 / 147 the sample genotype is homozygous for the alternative allele at rs3810936 and is heterozygous for the reference allele at rs7869487; or (v) the sample genotype is homozygous for the alternative allele at rs3810936 and is homozygous for the alternative allele at rs7869487.

[0086] In another aspect, the disclosure describes the use of an anti-TL1A antibody in the manufacture of a drug to treat IBD in a patient, wherein: (a) a genotyping assay must be performed to determine whether the patient is a haplotype B vehicle or a non-haplotype B vehicle for TNFSF15, the assay comprising determining the presence of at least two SNPs selected from rs3810936, rs6478108, rs6478109, rs7848647 and rs7869487 in a biological sample from the patient;and (b) an effective amount of anti-TL1A antibody must be administered to the patient, wherein the patient has been determined to be a non-vehicle of haplotype B, and wherein the anti-TL1A antibody comprises an HCDR1 with the sequence shown in SEQ ID NO: 3, an HCDR2 with the sequence shown in SEQ ID NO: 4, an HCDR3 with the sequence shown in SEQ ID NO: 5, an LCDR1 with the sequence shown in SEQ ID NO: 6, an LCDR2 with the sequence shown in SEQ ID NO: 7 and an LCDR3 with the sequence shown in SEQ ID NO: 8.;

[0087] In another aspect, the disclosure describes the use of an anti-TL1A antibody in the manufacture of a drug to treat IBD in a patient, wherein (a) a genotyping assay is to be performed to determine whether the patient is a haplotype B carrier or a non-haplotype B carrier for TNFSF15, the assay comprising determining the presence of at least two SNPs selected from rs3810936, rs6478108, rs6478109, rs7848647 and rs7869487 in a biological sample from the patient; and (b) the anti-TL1A antibody is to be administered to the patient, wherein the patient has been determined to be a non-haplotype B carrier, and wherein the Petition 870250104631, dated 11 / 14 / 2025, pp. 190 / 355 33 / 147 anti-TL1A antibody comprises an HCDR1 with the sequence shown in SEQ ID NO: 37, an HCDR2 with the sequence shown in SEQ ID NO: 39, an HCDR3 with the sequence shown in SEQ ID NO: 41, an LCDR1 with the sequence shown in SEQ ID NO: 46, an LCDR2 with the sequence shown in SEQ ID NO: 48 and an LCDR3 with the sequence shown in SEQ ID NO: 50.

[0088] In another aspect, the disclosure describes the use of an anti-TL1A antibody in the manufacture of a medicinal product to treat an IBD in a patient, wherein an effective amount of the anti-TL1A antibody is to be administered to the individual in a dosing regimen comprising an induction dosing regimen and a subsequent maintenance dosing regimen; wherein the induction dosing regimen comprises a plurality of individual induction doses and the maintenance dosing regimen comprises a plurality of individual maintenance doses; wherein the anti-TL1A antibody is administered subcutaneously in the maintenance phase, and wherein the anti-TL1A antibody comprises an HCDR1 with the sequence shown in SEQ ID NO: 3, an HCDR2 with the sequence shown in SEQ ID NO: 4, an HCDR3 with the sequence shown in SEQ ID NO: 5, an LCDR1 with the sequence shown in SEQ ID NO: 6, an LCDR2 with the sequence shown in SEQ ID NO: 7 and an LCDR3 with the sequence shown in SEQ ID NO: 8.

[0089] In another aspect, the disclosure describes the use of an anti-TL1A antibody in the manufacture of a medicament to treat an IBD in a patient, wherein an effective amount of the anti-TL1A antibody is to be administered to the individual in a dosing regimen comprising an induction dosing regimen and a subsequent maintenance dosing regimen, wherein (a) the induction dosing regimen comprises the subcutaneous administration of four individual induction doses of the antibody. Petition 870250104631, dated 11 / 14 / 2025, pp. 191 / 355 34 / 147 anti-TL1A at a dose of approximately 50 mg, 150 mg, or 450 mg, wherein the individual induction doses are administered 4 weeks apart; and (b) the maintenance dosing regimen comprises the subcutaneous administration of a plurality of individual maintenance doses of the anti-TL1A antibody at a dose of approximately 50 mg, 150 mg, or 450 mg, wherein the individual maintenance doses are administered 4 weeks apart, and wherein the anti-TL1A antibody comprises an HCDR1 with the sequence shown in SEQ ID NO: 3, an HCDR2 with the sequence shown in SEQ ID NO: 4, an HCDR3 with the sequence shown in SEQ ID NO: 5, an LCDR1 with the sequence shown in SEQ ID NO: 6, an LCDR2 with the sequence shown in SEQ ID NO: 7, and an LCDR3 with the sequence shown in SEQ ID NO: 8.

[0090] In another aspect, the disclosure describes the use of an anti-TL1A antibody in the manufacture of a medicinal product to treat an inflammatory bowel disease (IBD) in a patient, wherein an effective amount of the anti-TL1A antibody is to be administered to the individual in a dosing regimen comprising an induction dosing regimen and a subsequent maintenance dosing regimen, wherein (a) the induction dosing regimen comprises a plurality of individual induction doses, wherein the individual induction doses are separated from each other by at least 1 week, at least 2 weeks, at least 3 weeks, or at least 4 weeks;(b) the maintenance dosing regimen comprises the subcutaneous administration of a plurality of individual maintenance doses of anti-TL1A antibody at a dose of approximately 450 mg, wherein the individual maintenance doses are administered at 4-week intervals, and wherein the anti-TL1A antibody comprises an HCDR1 with the sequence shown in SEQ ID NO: 3, an HCDR2 with the sequence shown in SEQ ID NO: 4, an HCDR3 with the sequence shown in SEQ ID NO: 5, an LCDR1 with the sequence shown in SEQ ID NO: 6, an LCDR2 with the; Petition 870250104631, dated 11 / 14 / 2025, pp. 192 / 355 35 / 147 sequence shown in SEQ ID NO: 7 and an LCDR3 with the sequence shown in SEQ ID NO: 8.

[0091] In some respects, the patient is a human being.

[0092] Any of the above aspects, or any other aspect described in this document, may be combined with any other aspect.

[0093] Unless defined otherwise, all technical and scientific terms used in this document have the same meaning as is commonly understood by a person skilled in the art to which this disclosure pertains. In this Descriptive Report, singular forms also include the plural, unless the context clearly indicates otherwise; as examples, the terms “a”, “an” and “the” are understood as singular or plural and the term “or” is understood as inclusive. As an example, “an element” means one or more elements.

[0094] Although methods and materials similar or equivalent to those described herein may be used in the practice or testing of this disclosure, suitable methods and materials are described below. All publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety. The references cited herein are not admitted as prior art with respect to the claimed disclosure. In case of conflict, this Descriptive Report, including the definitions, shall prevail. Furthermore, the materials, methods and examples are merely illustrative and are not intended to be limiting. Other features and advantages of the disclosure will become apparent from the detailed description and claims that follow. Brief Description of the Figures

[0095] FIGURE 1 is an illustration showing the location of five single nucleotide polymorphisms (SNPs) at the TNFSF15 gene loci. Petition 870250104631, dated 11 / 14 / 2025, page 193 / 355 36 / 147

[0096] FIGURE 2 is a schematic diagram showing the flowchart for the TL1A 2-SNP test. qPCR = quantitative PCR.

[0097] FIGURE 3 is a schematic diagram showing the design of the TUSCANY-2 study. After a screening period, subjects received four monthly doses of afimkibart during a 12-week induction period (50 mg, 150 mg, or 450 mg) and then received monthly doses of afimkibart during a maintenance period (50 mg, 150 mg, or 450 mg). SC = subcutaneous. Outcomes assessed at Weeks 14 and 56 were clinical remission and endoscopic improvement.

[0098] FIGURE 4A is a bar graph showing the percentage of patients who received at least one dose of the indicated dose of afimkibart or placebo in the induction phase of the TUSCANY-2 study and achieved clinical remission (defined as Modified Mayo Score (mMS) < 2 with stool frequency (SFS) subscore = 0 or 1, rectal bleeding (RBS) subscore = 0, and endoscopic (ES) subscore = 0 or 1) at Week 14. Unadjusted outcome rates with 90% confidence intervals are shown.

[0099] FIGURE 4B is a bar graph showing the percentage of patients who received at least one dose of the indicated dose of afimkibart or placebo in the induction phase of the TUSCANY-2 study and showed endoscopic improvement at Week 14. Unadjusted outcome rates with 90% confidence intervals are shown.

[00100] FIGURE 5 is a bar graph showing the percentage of patients who received at least one dose of the indicated dose of afimkibart or placebo in the maintenance phase of the TUSCANY2 study and achieved clinical remission (defined as Modified Mayo Score (mMS) < 2 with stool frequency (SFS) subscore = 0 or 1, rectal bleeding (RBS) subscore = 0, and endoscopic subscore = 0). Petition 870250104631, dated 11 / 14 / 2025, pp. 194 / 355 37 / 147 (ES) = 0 or 1) at Week 14 or Week 56. Unadjusted outcome rates with 90% confidence intervals are shown.

[00101] FIGURE 6 is a bar graph showing the percentage of patients who received at least one dose of the indicated dose of afimkibart or placebo in the maintenance phase of the TUSCANY2 study and experienced endoscopic improvement at Week 14 or Week 56. Unadjusted outcome rates with 90% confidence intervals are shown.

[00102] FIGURE 7A is a set of bar graphs showing the percentage of patients treated with afimkibart or placebo in the induction phase of the TUSCANY-2 study who achieved clinical remission (according to the modified Mayo Score (mMS)) at Week 14. Pbo: placebo. Positive biomarker: non-TNFSF15 haplotype B vehicle.

[00103] FIGURE 7B is a set of bar graphs showing the percentage of patients treated with afimkibart or placebo in the induction phase of the TUSCANY-2 study who showed endoscopic improvement at Week 14. Pbo: placebo. Positive biomarker: non-TNFSF15 haplotype B vehicle.

[00104] FIGURE 8A is a set of bar graphs showing the percentage of patients treated with afimkibart or placebo in the induction phase of the TUSCANY-2 study who achieved clinical remission at Week 14. IR: intolerance, inadequate response, or loss of response to prior advanced therapy (tumor necrosis factor (TNF) agent, anti-integrin agent, anti-IL-12 / 23 agent, and / or Janus kinase (JAK) inhibitor). Non-IR: naive to failure of an advanced therapy.

[00105] FIGURE 8B is a set of bar graphs showing the percentage of patients treated with afimkibart or placebo in the induction phase of the TUSCANY-2 study who experienced endoscopic improvement in Petition 870250104631, dated 11 / 14 / 2025, pp. 195 / 355 38 / 147 Week 14. IR: intolerance, inadequate response, or loss of response to prior advanced therapy (tumor necrosis factor (TNF) agent, anti-integrin agent, anti-IL-12 / 23 agent, and / or Janus kinase (JAK) inhibitor). Non-IR: naive to failure of prior advanced therapy.

[00106] FIGURE 9A is a set of bar graphs showing the percentage of patients treated with afimkibart or placebo in the induction phase of the TUSCANY-2 study who achieved clinical remission at Week 14. IR: intolerance, inadequate response, or loss of response to a previously administered therapy comprising an anti-TNF agent. Non-IR: patients naive to failure of a therapy comprising an anti-TNF agent.

[00107] FIGURE 9B is a set of bar graphs showing the percentage of patients treated with afimkibart or placebo in the induction phase of the TUSCANY-2 study who experienced endoscopic improvement at Week 14. IR: intolerance, inadequate response, or loss of response to a previously administered therapy comprising an anti-TNF agent. Non-IR: patients naive to failure of a therapy comprising an anti-TNF agent.

[00108] Figure 10 is a set of bar graphs showing the percentage of biomarker-evaluable, biomarker-positive, and biomarker-negative patients treated with afimkibart or placebo in the induction phase of the TUSCANY-2 study who experienced clinical remission (left) or endoscopic improvement (right) at Week 14. Biomarker positive: non-TNFSF15 haplotype B vehicle. Biomarker negative: TNFSF15 haplotype B vehicle. Unadjusted outcome rates with 90% confidence intervals are shown. Detailed Description of the Invention I. Clinical Management and Treatment Methods

[00109] One of the main goals of emerging therapies is to use genomics and transcriptomics in baseline participants, which Petition 870250104631, dated 11 / 14 / 2025, pp. 196 / 355 39 / 147 can help stratify and maximize therapeutic efficacy while minimizing risk. This disclosure provides methods for optimizing clinical management using anti-TL1A treatment. In some embodiments, the methods provided herein optimize clinical management using anti-TL1A to treat inflammatory bowel disease, such as Crohn's disease (CD) or ulcerative colitis (UC), including any of the treatment methods described in Section II below and / or known in the art, for example, as described in U.S. Patents Nos. 10822422, US10138296, US11292848, US9068003, US10590201, US9896511, US8642741, US9290576, US8728482, US8263743, US9416185, US10322174, US10689439, US11440954, US11220549, US11767364, US Patent Publication No. 2023 / 0235070 and US Patent Publication No. US20240059799A1, the contents of which are incorporated herein by reference in their entirety. Any of the methods described in this section (i.e., Section I) may be used for treatment with any of the anti-TL1A antibodies described in Section IV below. A. TNFSF15 haplotypes and risk of non-responsiveness

[00110] In some respects, any of the methods, uses or compositions for use provided in this document comprises the determination of a patient's TNFSF15 haplotype (for example, it comprises the determination of whether a patient is (a) a TL1A haplotype B carrier or (b) a TL1A haplotype B non-carrier). The methods, uses or compositions for use may further include treatment decision-making based on the patient's TNFSF15 haplotype (for example, the decision to administer an anti-TL1A antibody (for example, an anti-TL1A antibody provided in Section IV of this document, for example, afimkibart, tulisoquibart or TEV-48574) or an anti-DR3 antibody to the patient).

[00111] The TNFSF15 B haplotype is defined as a TCATC on the positive strand at all five single nucleotide polymorphism (SNP) sites. Petition 870250104631, dated 11 / 14 / 2025, page 197 / 355 40 / 147 rs3810936, rs6478108, rs6478109, rs7848647, and rs7869487 are located at TL1A gene loci on chromosome 9, encompassing a 28 kb region around TNFSF15, the gene that encodes TL1A (Figure 1). The TNFSF15 B haplotype and other TNFSF15 haplotypes are shown in Table 1.

[00112] The TNFSF15 haplotype B has been associated with susceptibility to disease and / or TL1A expression in Japanese and European cohorts. Data suggest that Jewish patients with Crohn's disease (CD) carrying the haplotype B have more severe disease. Phase 2a and 2b studies show differential effects between the carrier and non-carrier subpopulations of haplotype B. Data from internal UC studies corroborate the specificity of haplotype B status in predicting response to anti-TL1A therapy.

[00113] A TNFSF15 haplotype B non-vehicle is any individual who does not possess the TCATC allele on the positive strand of maternal or paternal chromosome 9. Haplotype B non-vehicle individuals demonstrate moderate tissue expression of TL1A and an enhanced response to anti-TL1A therapy.

[00114] TL1A haplotype determination can be performed using a 2-SNP assay. The two SNPs can be any two SNPs selected from rs3810936, rs6478108, rs6478109, rs7848647, and rs7869487 to differentiate haplotype B from non-haplotype B (vehicle vs. non-vehicle). In one aspect, the two SNPs are rs3810936 and rs7869487. In a preferred aspect, SNPs rs3810936 and rs7869487 can differentiate haplotype B from non-haplotype B (vehicle vs. non-vehicle). The determination can be made as follows: Step 1: evaluate SNP rs7869487 in a biological sample from the patient. If (T / T), then the patient is identified as not carrying haplotype B. If (C / C) or (C / T), proceed to Step 2. Step 2: evaluate SNP rs3810936. If (C / C), the patient is identified as not carrying haplotype B. If (T / T) or (C / T), the patient is identified as carrying haplotype B (probability >99%). Petition 870250104631, dated 11 / 14 / 2025, pp. 198 / 355 41 / 147 Table 1. Single Nucleotide Polymorphisms of TNFSF15 Haplotype B Haplotype rs3810936 rs6478108 rs6478109 rs7848647 rs7869487 ACTGCTBTCATCCTCATTDTT GCTECCATCFCCGCC

[00115] The average misclassification rate with the 2SNP analysis above is extremely low and allows for immediate use in clinical trials. 41% of American individuals (of multiple ancestral origins) and individuals of European ancestry (combined) were haplotype B carriers, with an average misclassification rate of ~0.5%. Individuals of European ancestry showed a higher frequency of haplotype B carriers compared to American individuals (of multiple ancestral origins). 49.2% of individuals of East Asian and South Asian ancestry (combined) were haplotype B carriers, with an average misclassification rate of ~1.6%. Individuals of East Asian ancestry represent the largest population of haplotype B carriers (~66%). 8.32% of individuals of African ancestry were haplotype B carriers; no misclassifications were identified in this population.In an assessment of 2SNP analysis in phase 2 studies, 62 / 192 samples were heterozygous or homozygous for the minority allele frequency (MAF) at rs7869487 or rs3810936. All 62 individuals were considered positive for haplotype B - 0% mischaracterization. methods for determining the risk of non-responsiveness

[00116] The present description provides methods for determining the risk of a patient being unresponsive to a therapeutic dose of an anti-TNF ligand-like antibody (TL1A) (for example, an anti-TL1A antibody provided in Section IV of this document, for example, afimkibart, tulisoquibart or TEV-48574) or an anti-DR3 antibody, comprising (a) Petition 870250104631, dated 11 / 14 / 2025, pp. 199 / 355 42 / 147 perform a genotyping assay on a patient's biological sample to determine whether the patient is a haplotype B vehicle or a non-haplotype B vehicle for TNFSF15, the assay comprising determining the presence of at least two single nucleotide polymorphisms (SNPs) selected from rs3810936, rs6478108, rs6478109, rs7848647 and rs7869487 in a patient's biological sample, and (b) determining the risk of being non-responsive to a therapeutic dose of an anti-TL1A antibody or an anti-DR3 antibody, wherein: (i) the risk is higher in a haplotype B vehicle patient than in a non-haplotype B vehicle patient; (ii) the risk of being non-responsive is lower in a non-haplotype B vehicle patient than in a haplotype B vehicle patient; and / or (iii) the probability of being responsive is greater in a non-carrier patient of haplotype B than in a carrier patient of haplotype B.Determining the presence of at least two SNPs indicates that the patient is a carrier of haplotype B. The patient may have inflammatory bowel disease (IBD). In a preferred aspect, the at least two SNPs are SNP rs3810936 and SNP rs7869487.

[00117] In another aspect, the present disclosure provides a method for determining the risk of a patient being unresponsive to a therapeutic dose of an anti-TL1A antibody (for example, an anti-TL1A antibody provided in Section IV of this document, for example, afimkibart, tulisoquibart or TEV-48574) or an anti-DR3 antibody comprising (a) performing a genotyping assay on a biological sample from the patient to determine whether the patient is a haplotype B carrier or a non-haplotype B carrier for TNFSF15, the assay comprising determining the presence of at least two single nucleotide polymorphisms (SNPs) comprising r3810936 and rs7869487 in a biological sample from the patient and (b) determining the risk of being unresponsive to the therapeutic dose of an anti-TL1A antibody or an anti-DR3 antibody, wherein: (i) the risk is higher in a haplotype B carrier patient B than in a patient who is not a haplotype carrier. Petition 870250104631, dated 11 / 14 / 2025, pp. 200 / 355 43 / 147 B; (ii) the risk of being non-responsive is lower in a non-B haplotype carrier patient than in a B haplotype carrier patient; and / or (iii) the probability of being responsive is higher in a non-B haplotype carrier patient than in a B haplotype carrier patient.

[00118] In another aspect, the present disclosure provides a method for determining the risk of a patient being unresponsive to a therapeutic dose of an anti-TL1A antibody (for example, an anti-TL1A antibody provided in Section IV of this document, for example, afimkibart, tulisoquibart or TEV-48574) or an anti-DR3 antibody comprising (a) performing a genotyping assay on a biological sample from the patient to determine whether the patient is a haplotype B vehicle or a non-haplotype B vehicle for TNFSF15, the assay comprising determining the presence of the two single nucleotide polymorphisms (SNPs) r3810936 and rs7869487 in a biological sample from the patient and (b) determining the risk of being unresponsive to the therapeutic dose of an anti-TL1A antibody or an anti-DR3 antibody, wherein: (i) the risk is greater in a haplotype B vehicle patient than in a patient who is not a carrier of haplotype B;(ii) the risk of non-response is lower in a non-B haplotype carrier patient than in a B haplotype carrier patient; and / or (iii) the probability of being responsive is higher in a non-B haplotype carrier patient than in a B haplotype carrier patient.

[00119] In one aspect, the present disclosure provides a method for determining the risk of a patient being unresponsive to a therapeutic dose of an anti-TL1A antibody or an anti-DR3 antibody, the method comprising: (a) perform a genotyping assay on a biological sample from the patient to determine whether the patient is a haplotype B carrier or not a haplotype B carrier for TNFSF15, wherein the assay comprises determining Petition 870250104631, dated 11 / 14 / 2025, page 201 / 355 44 / 147 the presence of SNP rs3810936 and SNP rs7869487 in a patient's biological sample, and in which a non-B haplotype vehicle for TNFSF15 is identified by any of the following biomarker statuses in the patient's biological sample: (i) the sample genotype is homozygous for the reference allele at rs3810936 (i.e., the sample is T / T at rs3810936) and is homozygous for the alternative allele at rs7869487 (i.e., the sample is T / T at rs7869487); (ii) the sample genotype is heterozygous for the reference allele at rs3810936 (i.e., the sample is C / T at rs3810936) and is homozygous for the alternative allele at rs7869487 (i.e., the sample is T / T at rs7869487); (iii) the sample genotype is homozygous for the alternative allele at rs3810936 (i.e., the sample is C / C at rs3810936) and is homozygous for the reference allele at rs7869487 (i.e., the sample is C / C at rs7869487); (iv) the sample genotype is homozygous for the alternative allele at rs3810936 (i.e., the sample is C / C at rs3810936) and is heterozygous for the reference allele at rs7869487 (i.e., the sample is T / C at rs7869487); or (v) the sample genotype is homozygous for the alternative allele at rs3810936 (i.e., the sample is C / C at rs3810936) and is homozygous for the alternative allele at rs7869487 (i.e., the sample is T / T at rs7869487); and (b) identify the patient as having a high risk of being unresponsive to a therapeutic dose of an anti-TL1A antibody or an anti-DR3 antibody if the patient is a haplotype B carrier; or (c) identify the patient as being at low risk of being unresponsive to a therapeutic dose of an anti-TL1A antibody or an anti-DR3 antibody if the patient is a non-vehicle carrier of haplotype B. Treatment methods for IBD based on TNFSF15 haplotype

[00120] In another aspect, the disclosure provides a method for treating inflammatory bowel disease (IBD) in a patient, the method Petition 870250104631, dated 11 / 14 / 2025, page 202 / 355 45 / 147 comprising (a) performing a genotyping assay to determine whether the patient is a haplotype B carrier or a non-haplotype B carrier for TNFSF15, the assay comprising determining the presence of at least two single nucleotide polymorphisms (SNPs) selected from rs3810936, rs6478108, rs6478109, rs7848647 and rs7869487 in a biological sample from the patient; and (b) administering to the patient an effective amount of an anti-TL1A antibody (e.g., an anti-TL1A antibody provided in Section IV hereof, e.g., afimkibart, tulisoquibart or TEV48574) or an anti-DR3 antibody, where the patient has been determined to be a non-haplotype B carrier.

[00121] In some embodiments, the anti-TL1A antibody is administered to the patient in an induction dosing regimen (e.g., it is administered to the patient in an induction dosing regimen sufficient to improve the signs and symptoms of IBD for at least 12 weeks after the start of treatment with the anti-TL1A antibody, said induction dosing regimen comprising a plurality of individual induction doses).

[00122] In some embodiments, the anti-TL1A antibody is administered to the patient in a maintenance dosing regimen following an induction dosing regimen (e.g., it is administered to the patient in a maintenance dosing regimen after completion of the induction dosing regimen, said maintenance dosing regimen comprising a plurality of individual maintenance doses separated from each other by at least 2 weeks). Exemplary induction and maintenance dosing regimens are provided in Section II below.

[00123] Thus, in some respects, the disclosure provides a method for treating IBD in a patient, the method comprising (a) performing a genotyping assay to determine whether the patient is a haplotype B vehicle or a non-haplotype B vehicle for TNFSF15, the assay Petition 870250104631, dated 11 / 14 / 2025, page 203 / 355 46 / 147 comprising determining the presence of at least two SNPs selected from rs3810936, rs6478108, rs6478109, rs7848647 and rs7869487 in a biological sample from the patient; (b) administering to the patient an anti-TL1A antibody in an induction dosing regimen sufficient to improve the signs and symptoms of IBD for at least 12 weeks after initiation of treatment with the anti-TL1A antibody, said induction dosing regimen comprising a plurality of individual induction doses, wherein the patient was determined to be a non-vehicle of haplotype B; and (c) administering to the patient a subsequent maintenance dosing regimen after completion of the induction dosing regimen, said maintenance dosing regimen comprising a plurality of individual maintenance doses separated from each other by at least 2 weeks.

[00124] In some embodiments, at least two SNPs are SNP rs3810936 and SNP rs7869487. In some embodiments, the assay comprises determining the presence of only two SNPs in the patient's biological sample, where the two SNPs are SNP rs3810936 and SNP rs7869487. At the position of SNP rs3810936, the wild-type nucleotide (“reference allele”) is “T” and the alternative allele is “C”. At the position of SNP rs7869487, the wild-type nucleotide (“reference allele”) is “C” and the alternative allele is “T”.

[00125] In some embodiments, a non-vehicle haplotype B for TNFSF15 is identified by any of the following biomarker statuses in the patient's biological sample: (i) the sample genotype is homozygous for the reference allele at rs3810936 (i.e., the sample is T / T at rs3810936) and is homozygous for the alternative allele at rs7869487 (i.e., the sample is T / T at rs7869487); (ii) the sample genotype is heterozygous for the reference allele at rs3810936 (for example, the sample is C / T at rs3810936) and is homozygous Petition 870250104631, dated 11 / 14 / 2025, pp. 204 / 355 47 / 147 for the alternative allele in rs7869487 (i.e., the sample is T / T in rs7869487); (iii) the sample genotype is homozygous for the alternative allele at rs3810936 (i.e., the sample is C / C at rs3810936) and is homozygous for the reference allele at rs7869487 (i.e., the sample is C / C at rs7869487); (iv) the sample genotype is homozygous for the alternative allele at rs3810936 (i.e., the sample is C / C at rs3810936) and is heterozygous for the reference allele at rs7869487 (i.e., the sample is T / C at rs7869487); or (v) the sample genotype is homozygous for the alternative allele at rs3810936 (i.e., the sample is C / C at rs3810936) and is homozygous for the alternative allele at rs7869487 (i.e., the sample is T / T at rs7869487).

[00126] In some embodiments, at least two SNPs comprise SNP rs3810936, SNP rs7869487, and SNP rs7848647. In some embodiments, the assay comprises determining the presence of only three SNPs in the patient's biological sample, where the three SNPs are SNP rs3810936, SNP rs7869487, and SNP rs7848647. In some embodiments, the assay comprises determining the presence of only three SNPs in the patient's biological sample, where the three SNPs are SNP rs3810936, SNP rs7869487, and SNP rs6478109.

[00127] In some embodiments, the at least two SNPs comprise SNP rs3810936, SNP rs7869487, SNP rs6478108, and SNP rs6478109. In some embodiments, the assay comprises determining the presence of only four SNPs in the patient's biological sample, where the four SNPs are SNP rs3810936, SNP rs7869487, SNP rs6478108, and SNP rs6478109.

[00128] Thus, in some respects, disclosure provides a method for treating IBD in a patient, the method comprising: (a) perform a genotyping assay on a biological sample Petition 870250104631, dated 11 / 14 / 2025, pp. 205 / 355 48 / 147 of the patient to determine whether the patient is a haplotype B carrier or a non-haplotype B carrier for TNFSF15, wherein the assay comprises determining the presence of SNP rs3810936 and SNP rs7869487 in a biological sample from the patient, and wherein a non-haplotype B carrier for TNFSF15 is identified by any of the following biomarker statuses in the biological sample from the patient: (i) the sample genotype is homozygous for the reference allele at rs3810936 (i.e., the sample is T / T at rs3810936) and is homozygous for the alternative allele at rs7869487 (i.e., the sample is T / T at rs7869487); (ii) the sample genotype is heterozygous for the reference allele at rs3810936 (i.e., the sample is C / T at rs3810936) and is homozygous for the alternative allele at rs7869487 (i.e., the sample is T / T at rs7869487); (iii) the sample genotype is homozygous for the alternative allele at rs3810936 (i.e., the sample is C / C at rs3810936) and is homozygous for the reference allele at rs7869487 (i.e., the sample is C / C at rs7869487); (iv) the sample genotype is homozygous for the alternative allele at rs3810936 (i.e., the sample is C / C at rs3810936) and is heterozygous for the reference allele at rs7869487 (i.e., the sample is T / C at rs7869487); or (v) the sample genotype is homozygous for the alternative allele at rs3810936 (i.e., the sample is C / C at rs3810936) and is homozygous for the alternative allele at rs7869487 (i.e., the sample is T / T at rs7869487); (b) administering an anti-TL1A antibody or an anti-DR3 antibody to a patient who has been determined to be a non-vehicle carrier of haplotype B. In some embodiments, the anti-TL1A antibody is administered to the patient in an induction dosing regimen (e.g., it is administered to the patient in an induction dosing regimen sufficient to improve the signs and symptoms of IBD for at least 12 weeks after initiation of antibody treatment). Petition 870250104631, dated 11 / 14 / 2025, pp. 206 / 355 49 / 147 anti-TL1A or anti-DR3, the said induction dosing regimen comprising a plurality of individual induction doses). In some embodiments, the anti-TL1A antibody is additionally administered to the patient in a maintenance dosing regimen following an induction dosing regimen (e.g., it is administered to the patient in a subsequent maintenance dosing regimen after completion of an induction dosing regimen, the said maintenance dosing regimen comprising a plurality of individual maintenance doses separated from each other by at least 2 weeks).

[00129] In another aspect, the disclosure provides a method for treating IBD in a patient, the method comprising (a) administering to the patient an effective amount of an anti-TL1A antibody in an induction dosing regimen (for example, an induction dosing regimen sufficient to improve the signs and symptoms of IBD for at least 12 weeks after the start of treatment with the anti-TL1A antibody, said induction dosing regimen comprising a plurality of individual induction doses); and (b) administering to the patient an effective amount of an anti-TL1A antibody in a subsequent maintenance dosing regimen after completion of the induction dosing regimen, for example, a maintenance dosing regimen comprising a plurality of individual maintenance doses separated from each other by at least 2 weeks;where the patient has been determined to be a non-vehicle of haplotype B for TNFSF15, and a non-vehicle of haplotype B for TNFSF15 is identified by any of the following biomarker statuses in a biological sample from the patient: (i) the sample genotype is homozygous for the reference allele at rs3810936 (i.e., the sample is T / T at rs3810936) and is homozygous for the alternative allele at rs7869487 (i.e., the sample is T / T at rs7869487); Petition 870250104631, dated 11 / 14 / 2025, pp. 207 / 355 50 / 147 (ii) the sample genotype is heterozygous for the reference allele at rs3810936 (i.e., the sample is C / T at rs3810936) and is homozygous for the alternative allele at rs7869487 (i.e., the sample is T / T at rs7869487); (iii) the sample genotype is homozygous for the alternative allele at rs3810936 (i.e., the sample is C / C at rs3810936) and is homozygous for the reference allele at rs7869487 (i.e., the sample is C / C at rs7869487); (iv) the sample genotype is homozygous for the alternative allele at rs3810936 (i.e., the sample is C / C at rs3810936) and is heterozygous for the reference allele at rs7869487 (i.e., the sample is T / C at rs7869487); or the sample genotype is homozygous for the alternative allele at rs3810936 (i.e., the sample is C / C at rs3810936) and is homozygous for the alternative allele at rs7869487 (i.e., the sample is T / T at rs7869487).

[00130] In some embodiments of any of the above aspects, the anti-TL1A antibody comprises an HCDR1 (CDR H1) with the sequence shown in SEQ ID NO: 3, an HCDR2 (CDR H2) with the sequence shown in SEQ ID NO: 4, an HCDR3 (CDR H3) with the sequence shown in SEQ ID NO: 5, an LCDR1 (CDR L1) with the sequence shown in SEQ ID NO: 6, an LCDR2 (CDR L2) with the sequence shown in SEQ ID NO: 7, and an LCDR3 (CDR L3) with the sequence shown in SEQ ID NO: 8. In some embodiments of any of the above aspects, the anti-TL1A antibody comprises an HCDR1 (CDR H1) with the sequence shown in SEQ ID NO: 68, an HCDR2 (CDR H2) with the sequence shown in SEQ ID NO: 4, an HCDR3 (CDR H3) with the The sequence shown in SEQ ID NO: 5 is an LCDR1 (CDR L1) with the sequence shown in SEQ ID NO: 6, an LCDR2 (CDR L2) with the sequence shown in SEQ ID NO: 7, and an LCDR3 (CDR L3) with the sequence shown in SEQ ID NO: 8. In some embodiments, the anti-TL1A antibody is afimkibart. Petition 870250104631, dated 11 / 14 / 2025, pp. 208 / 355 51 / 147

[00131] In some embodiments of any of the above aspects, the anti-TL1A antibody comprises a CDR-H1 with the sequence shown in SEQ ID NO: 37, a CDR-H2 with the sequence shown in SEQ ID NO: 39, a CDR-H3 with the sequence shown in SEQ ID NO: 41, a CDR-L1 with the sequence shown in SEQ ID NO: 46, a CDR-L2 with the sequence shown in SEQ ID NO: 48, and a CDR-L3 with the sequence shown in SEQ ID NO: 50. In some embodiments, the anti-TL1A antibody is tulisoquibart.

[00132] In some embodiments of any of the above aspects, the anti-TL1A antibody has the HVR sequences of TEV-48574. In some embodiments, the anti-TL1A antibody is TEV-48574.

[00133] In some realizations of any of the above aspects, IBD is ulcerative colitis. In some realizations, UC is moderate to severe UC. Tests to determine the TNFSF15 haplotype

[00134] Any appropriate method may be used to determine whether a patient is a carrier or a non-carrier of haplotype B for TNFSF15. For example, any appropriate method may be used to determine a patient's genotype at one or more positions of at least two SNPs selected from rs3810936, rs6478108, rs6478109, rs7848647, and rs7869487 in a biological sample from the patient. Exemplary methods for determining a patient's TNFSF15 haplotype are provided in this document.

[00135] In some embodiments, the genotyping assay used in any of the methods provided in this document comprises the use of quantitative PCR (qPCR).

[00136] In some embodiments, the genotyping assay comprises sequencing (e.g., DNA sequencing). In Petition 870250104631, dated 11 / 14 / 2025, pp. 209 / 355 52 / 147 some achievements, the genotyping assay comprises long read sequencing.

[00137] In some embodiments, the genotyping assay is a fluorescence-based assay. In some embodiments, the genotyping assay is a fluorescence-based qPCR assay, such as a Taqman™ qPCR assay.

[00138] The biological sample may be any appropriate sample containing genomic DNA. In some embodiments, the biological sample is blood. In some embodiments, the biological sample is or comprises buccal cells. B. Expression level of candidate genes

[00139] In some respects, any of the methods, uses or compositions for use provided herein comprise the determination of the expression of one or more candidate genes (as described below) in a patient sample. The methods, uses or compositions for use may additionally include treatment decision-making based on the patient's gene expression.

[00140] In some aspects of the disclosure, the method additionally comprises the steps of: a) determining the expression level of one or more candidate genes in a patient sample, b) identifying whether the sample contains an abnormal expression level of one or more candidate genes, c) administering the induction dosing regimen or the individual induction dose of anti-TL1A antibody to a patient.

[00141] Determining whether a patient has an abnormal expression level of one or more candidate genes can be done by obtaining or having a sample obtained from the patient. The sample can be a tissue sample. The sample can be a tissue sample from an IBD inflammation site. The sample can be a peripheral blood sample. A Petition 870250104631, dated 11 / 14 / 2025, pp. 210 / 355 Sample 53 / 147 may be an intestinal biopsy sample.

[00142] The method may additionally comprise performing or having performed an assay on the sample to determine whether the patient expresses abnormal levels of one or more candidate genes.

[00143] In some respects, if the sample contains abnormal levels of one or more candidate genes, the method provides for the additional step of administering an induction dosage regimen or an induction dose of anti-TL1A antibody to the patient.

[00144] In some respects, the risk of the patient being unresponsive to an induction dosing regimen or to an individual induction dose of an anti-TL1A antibody is lower in a patient with abnormal levels of one or more candidate genes.

[00145] In some respects, the disclosure describes a method for treating inflammatory bowel disease (IBD) in a patient, comprising the steps of: a) determining the expression level of one or more candidate genes in a sample from the patient, b) identifying that the sample contains an abnormal expression level of one or more candidate genes, and c) administering an induction dosing regimen or an individual induction dose of an anti-TNF ligand-like antibody 1A (TL1A) to the patient.

[00146] One or more candidate genes may be selected from the group consisting of IL-1B, IL-23A, IFNG, IL-12RB1, IL-21R, IRF4, BATF, CD80 / 86, HLA-DRB5 / DQB1 / DRB1, HLA-DRA, CD40, ICOS, MMP3, MMP7, MMP10, and CHI3L. One or more candidate genes may be selected from the group consisting of IL-1B, IL-23A, IFNG, IL-12RB1, IL-21R, IRF4, and BATF. One or more candidate genes may be selected from the group consisting of CD80 / 86, HLA-DRB5 / DQB1 / DRB1, HLA-DRA, CD40, and ICOS. One or more candidate genes may be selected from Petition 870250104631, dated 11 / 14 / 2025, p. 211 / 355 54 / 147 of the group consisting of MMP3, MMP7, MMP10 and CHI3L.

[00147] The one or more candidate genes can be selected from the group consisting of SOWAHB, COLCA2, TBX20, FRZB, HOXB5, NET1, FOXD2, DESI1, PARK2, PKDREJ, IL-1B, IL-23A, IFNG, IL-12RB1, IL21R, IRF4, BATF, CD80 / 86, HLA-DRB5 / DQB1 / DRB1, HLA-DRA, CD40, ICOS, MMP3, MMP7, MMP10 and CHI3L.

[00148] One or more candidate genes may be selected from the group consisting of SOWAHB, COLCA2, TBX20, FRZB, HOXB5, NET1, FOXD2, DESI1, PARK2, and PKDREJ. One or more candidate genes may include SOWAHB. One or more candidate genes may include SOWAHB and at least one or more candidate genes selected from the group consisting of COLCA2, TBX20, FRZB, HOXB5, NET1, FOXD2, DESI1, PARK2, and PKDREJ. One or more candidate genes may include SOWAHB and COLCA2, and at least one or more candidate genes selected from the group consisting of SOWAHB, COLCA2, TBX20, FRZB, HOXB5, NET1, FOXD2, DESI1, PARK2, and PKDREJ. One or more candidate genes may include SOWAHB, COLCA2, and TBX20, and at least one or more candidate genes selected from the group consisting of FRZB, HOXB5, NET1, FOXD2, DESI1, PARK2, and PKDREJ.

[00149] In some respects, the method allows determining the expression level of 2, or 3, or 4, or 5, or 6, or 7, or 8, or 9 or 10 of the selected candidate genes from the group consisting of SOWAHB, COLCA2, TBX20, FRZB, HOXB5, NET1, FOXD2, DESI1, PARK2 and PKDREJ.

[00150] The level of abnormal expression of one or more candidate genes may be based on the levels of mRNA or protein expressed from the candidate genes.

[00151] The level of abnormal expression of one or more candidate genes may be based on the mRNA levels of the genes. Petition 870250104631, dated 11 / 14 / 2025, p. 212 / 355 55 / 147 candidates.

[00152] The expression level of one or more candidate genes can be compared to a baseline expression level, which is based on the expression level of one or more candidate genes in a healthy individual who does not suffer from IBD or UC.

[00153] The expression level of one or more candidate genes can be compared to a baseline expression level, based on an estimate of the expression level in individuals who are unresponsive to treatment with anti-TL1A antibodies.

[00154] The abnormal expression level of one or more candidate genes may be at least 50% higher or lower than the baseline level. The abnormal expression level of one or more candidate genes may be at least 2 times, 5 times, 10 times, 50 times, 100 times, 500 times, or 1000 times higher or lower than the baseline level.

[00155] In some respects, when one or more candidate genes are selected from the group consisting of SOWAHB, COLCA2, FRZB, HOXB5, NET1, FOXD2, PARK2, and PKDREJ, the level of abnormal expression may be elevated. In some respects, when one or more candidate genes are selected from the group consisting of TBX20 and DESI1, the level of abnormal expression is reduced. C. Levels of bacterial strains

[00156] In some respects, any of the methods, uses or compositions of use provided herein comprise the determination of the level of one or more bacterial strains (as described below) in a stool sample from a patient. The methods, uses or compositions of use may additionally include making treatment decisions based on the levels of the bacterial strains in the sample.

[00157] In some respects, disclosure includes the steps Petition 870250104631, dated 11 / 14 / 2025, pp. 213 / 355 56 / 147 of: a) determining the level of one or more candidate bacterial strains in a patient stool sample, b) identifying that the stool sample contains a high level of one or more candidate bacterial strains, c) administering the anti-TL1A antibody induction dose to a patient.

[00158] In some respects, the candidate bacterial strain is selected from the group consisting of Streptococcus salivarius, Streptococcus parasanguinis, and Haemophilus parainfluenzae.

[00159] In some respects, disclosure comprises the steps of: a) determining the level of one or more candidate bacterial strains in a stool sample from the patient, b) identifying that the stool sample contains a reduced level of one or more candidate bacterial strains, c) administering the induction dose of anti-TL1A antibody to a patient.

[00160] In some aspects, the candidate bacterial strain is selected from the group consisting of Ruminococcus albus, Ruminococcus callidus, Ruminococcus bromii, Ruminococcus gnavus and Bifidobacterium bifidum.

[00161] In some respects, the level of one or more candidate bacterial strains is compared to a baseline bacterial level, which is based on the level of one or more candidate bacterial strains in a healthy individual who does not suffer from IBD or UC. In some respects, the level of one or more candidate bacterial strains is compared to a baseline bacterial level, based on an estimate of the level of these candidate bacterial strains in individuals who are unresponsive to treatment with anti-TL1A antibodies.

[00162] In some respects, the level of one or more candidate bacterial strains is at least 50% higher or lower than the baseline bacterial level, 2 times, 5 times, 10 times, 20 times, 50 times, 100 times, 500 times or 1000 times higher. Petition 870250104631, dated 11 / 14 / 2025, pp. 214 / 355 57 / 147

[00163] In some respects, disclosure additionally includes treatment with an IL-23 antagonist. D. Methods for identifying a patient likely to be BENEFITING FROM TREATMENT BASED ON ABNORMAL GENE EXPRESSION

[00164] The disclosure provides a method for identifying a patient with inflammatory bowel disease as being likely to benefit from initial or continued treatment with anti-TL1A antibody therapy and, optionally, treating said patient, wherein said method comprises: (a) identifying a patient as having an abnormal level of one or more candidate genes, selected from the group consisting of SOWAHB, COLCA2, TBX20, FRZB, HOXB5, NET1, FOXD2, DESI1, PARK2, PKDREJ, IL-1B, IL-23A, IFNG, IL-12RB1, IL-21R, IRF4, BATF, CD80 / 86, HLA-DRB5 / DQB1 / DRB1, HLA-DRA, CD40, ICOS, MMP3, MMP7, MMP10 and CHI3L; and optionally includes additionally (b) administering or having administered to said patient an anti-TL1A antibody in conditions where one or more selected from the group consist of inflammatory macrophages, TH17, ILC3, OX40, OX40L, IFNγ, ILC2, IL-13, MMP, tissue remodeling, fibrosis, intestinal population of S. salivarius, intestinal population of S.The intestinal population of H. parainfluenzae in the aforementioned patient is reduced after the aforementioned administration. II. Treatment methods for inflammatory bowel disease with Anti-TL1A antibodies

[00165] In some respects, the disclosure describes a method for treating an inflammatory bowel disease (IBD) (e.g., ulcerative colitis (UC) or Crohn's disease (CD)) in a patient (e.g., a human), the method comprising administering to the patient an effective amount of an anti-TNF ligand-like antibody (TL1A) (e.g., an anti-TL1A antibody provided in Section IV hereof) in a Petition 870250104631, dated 11 / 14 / 2025, pp. 215 / 355 58 / 147 Dosage regimen comprising an induction phase (induction dosage regimen) and a subsequent maintenance phase (maintenance dosage regimen), wherein the induction dosage regimen comprises a plurality of individual induction doses and the maintenance dosage regimen comprises a plurality of individual maintenance doses, and wherein the anti-TL1A antibody is administered subcutaneously in the maintenance phase. In some embodiments, the anti-TL1A antibody comprises an HCDR1 with the sequence shown in SEQ ID NO: 3, an HCDR2 with the sequence shown in SEQ ID NO: 4, an HCDR3 with the sequence shown in SEQ ID NO: 5, an LCDR1 with the sequence shown in SEQ ID NO: 6, an LCDR2 with the sequence shown in SEQ ID NO: 7, and an LCDR3 with the sequence shown in SEQ ID NO: 8.In some embodiments, the anti-TL1A antibody comprises an HCDR1 with the sequence shown in SEQ ID NO: 68, an HCDR2 with the sequence shown in SEQ ID NO: 4, an HCDR3 with the sequence shown in SEQ ID NO: 5, an LCDR1 with the sequence shown in SEQ ID NO: 6, an LCDR2 with the sequence shown in SEQ ID NO: 7, and an LCDR3 with the sequence shown in SEQ ID NO: 8. In some embodiments, the anti-TL1A antibody is afimkibart.

[00166] As a general principle, the treatment of IBD with anti-TL1A antibodies is described in PCT Publication No. WO 2021 / 260577 and U.S. Patent Application Publication No. 2023 / 0235070, which are incorporated herein by reference for all purposes.

[00167] In some aspects of any of the treatment methods provided in this document, IBD is ulcerative colitis (e.g., moderate to severe ulcerative colitis).

[00168] In some aspects of any of the treatment methods provided in this document, it has been determined that the patient has a relatively low risk of being non-responsive to a dose. Petition 870250104631, dated 11 / 14 / 2025, pp. 216 / 355 59 / 147 therapeutic anti-TL1A antibody. In some respects, the patient was determined to be a non-vehicle of haplotype B for TNFSF15. Methods for determining a patient's risk of non-responsiveness and for determining whether a patient is a haplotype B vehicle for TNFSF15 are provided, for example, in Section I of this document. A. Induction Phase

[00169] Any of the methods provided in this document may involve the administration of an anti-TL1A antibody in an induction phase. The induction phase may involve the administration of one or more doses of the anti-TL1A antibody.

[00170] In some aspects where the induction phase comprises the administration of at least two doses of anti-TL1A antibody, the time interval between each individual induction dose may be the same. Individual induction dosages may be administered at least daily, at least one day apart, at least 1 week apart, at least 2 weeks apart, at least 3 weeks apart, at least 4 weeks apart, at least 5 weeks apart, at least 6 weeks apart, at least 7 weeks apart, at least 8 weeks apart, at least 9 weeks apart, at least 10 weeks apart, at least 11 weeks apart, or at least 12 weeks apart. In a preferred aspect, individual induction dosages are administered one month apart.In a preferred setting, individual induction doses are administered at four-week intervals (Q4W).

[00171] In some respects, the induction phase comprises the administration of four doses of anti-TL1A antibody. In some respects, the doses of anti-TL1A antibody are administered at intervals of approximately 4 Petition 870250104631, dated 11 / 14 / 2025, p. 217 / 355 60 / 147 weeks (for example, they are administered 4 weeks apart). In some respects, the induction phase lasts about 14 weeks, and (a) the first dose of anti-TL1A antibody is administered on Day 1 of Week 60 / 147. 0; (b) the second dose of anti-TL1A antibody is administered on Day 1 of the Week 4; (c) the third dose of anti-TL1A antibody is administered on Day 1 of Week 8; and (d) the fourth dose of anti-TL1A antibody is administered on Day 1 of Week 8. 12.

[00172] The individual induction dose may be 1, 5, 10, 25, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, or 1000 mg of anti-TL1A antibody. In a preferred aspect, the individual induction dose is 50, 150, or 450 mg of anti-TL1A antibody. In one aspect, the individual induction dose is 450 mg of anti-TL1A antibody (e.g., each individual induction dose is administered at a dose of 450 mg). Alternatively, the individual induction dose is 150 mg of anti-TL1A antibody (e.g., each individual induction dose is administered at a dose of 150 mg). Alternatively, the individual induction dose is 50 mg of anti-TL1A antibody (e.g., each individual induction dose is administered at a dose of 50 mg). Individual induction doses can be administered by any route. Preferably, individual induction doses are administered subcutaneously.In one aspect, the individual induction dose is 50, 150, or 450 mg administered subcutaneously. In one aspect, the individual induction dose is 50, 150, or 450 mg, administered subcutaneously monthly. In one aspect, the individual induction dose is 50, 150, or 450 mg, administered subcutaneously every four weeks (Q4W).

[00173] In some respects, in the induction phase, the antiTL1A antibody is administered subcutaneously (SC) at a dose of approximately 450 mg (e.g., a single 450 mg dose) (e.g., each dose in the induction phase). Petition 870250104631, dated 11 / 14 / 2025, pp. 218 / 355 61 / 147 involves the subcutaneous administration of approximately 450 mg (e.g., 450 mg) of anti-TL1A antibody. B. Maintenance Phase

[00174] Any of the methods provided in this document may comprise the subcutaneous administration of an anti-TL1A antibody in a maintenance phase following the administration of the anti-TL1A antibody in the induction phase. The maintenance phase may comprise the administration of one or more doses of the anti-TL1A antibody.

[00175] The maintenance phase may be initiated at any appropriate time after the induction phase. In some aspects, the first dose of the maintenance phase is administered approximately two weeks (e.g., two weeks) after the administration of the last dose of the induction phase. For example, in aspects where the induction phase comprises the administration of four doses of anti-TL1A antibody, the first dose of the maintenance phase may be administered approximately two weeks (e.g., two weeks) after the administration of the last dose of the induction phase.

[00176] In some aspects where the maintenance phase comprises the administration of at least two doses of anti-TL1A antibody, the time interval between each of the individual maintenance doses may be the same. Individual maintenance doses may be administered at least daily, with an interval of at least one day, with an interval of at least 1 week, with an interval of at least 2 weeks, with an interval of at least 3 weeks, with an interval of at least 1 month, with an interval of at least 2 months, with an interval of at least 3 months, with an interval of at least 4 months, with an interval of at least 5 months, or with an interval of at least 6 months. In a preferred aspect, individual maintenance doses are administered with an interval of one month. In a preferred aspect, individual maintenance doses are administered with an interval Petition 870250104631, dated 11 / 14 / 2025, p. 219 / 355 62 / 147 over four weeks.

[00177] In some respects, the maintenance phase comprises the administration of anti-TL1A antibody every four weeks (Q4W).

[00178] The individual maintenance dose may be 1.5, 10, 25, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 or 1000 mg. In a preferred aspect, the individual maintenance dose is 50, 150 or 450 mg. In one aspect, the individual maintenance dose is approximately 450 mg (e.g., 450 mg). Individual maintenance dosages may be administered by any route. Preferably, individual maintenance dosages are administered subcutaneously. In one aspect, the individual maintenance dose is 50, 150, or 450 mg administered subcutaneously. In another aspect, the individual maintenance dose is 450 mg of the anti-TL1A antibody (e.g., each individual maintenance dose is administered subcutaneously at a dose of 450 mg). In the other aspect, the individual maintenance dose is 150 mg of the anti-TL1A antibody (e.g., each individual maintenance dose is administered subcutaneously at a dose of 150 mg).In another aspect, the individual maintenance dose is 50 mg of anti-TL1A antibody (for example, each individual maintenance dose is administered subcutaneously at a dose of 50 mg). In one aspect, the individual maintenance dose is 50, 150, or 450 mg, administered subcutaneously monthly.

[00179] In some respects, the maintenance phase comprises the administration of at least 10 doses of anti-TL1A antibody (for example, it comprises 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more than 20 doses of anti-TL1A antibody administered in a Q4W dosing regimen). In some respects, the maintenance phase comprises the administration of 10 doses of anti-TL1A antibody (for example, it comprises ten doses of anti-TL1A antibody administered in a Q4W dosing regimen). Petition 870250104631, dated 11 / 14 / 2025, pp. 220 / 355 63 / 147

[00180] Thus, in some respects, the disclosure provides a method for treating an IBD in a patient, the method comprising administering to the patient an effective amount of an anti-TL1A antibody in a dosing regimen comprising an induction dosing regimen and a subsequent maintenance dosing regimen; wherein (a) the induction dosing regimen comprises the subcutaneous administration of four individual induction doses of the anti-TL1A antibody at a dose of approximately 50 mg, 150 mg or 450 mg (e.g., a dose of 50 mg, 150 mg or 450 mg), wherein the individual induction doses are administered at 4-week intervals; and (b) the maintenance dosing regimen comprises the subcutaneous administration of a plurality of individual maintenance doses of anti-TL1A antibody at a dose of approximately 50 mg, 150 mg or 450 mg (e.g., a dose of 50 mg, 150 mg or 450 mg), wherein the individual maintenance doses are administered at 4-week intervals;and wherein the anti-TL1A antibody comprises: an HCDR1 with the sequence shown in SEQ ID NO: 3, an HCDR2 with the sequence shown in SEQ ID NO: 4, an HCDR3 with the sequence shown in SEQ ID NO: 5, an LCDR1 with the sequence shown in SEQ ID NO: 6, an LCDR2 with the sequence shown in SEQ ID NO: 7 and an LCDR3 with the sequence shown in SEQ ID NO: 8. In some respects, the anti-TL1A antibody is afimkibart.;

[00181] In some respects, the disclosure provides a method for treating IBD in a patient, the method comprising administering to the patient an effective amount of an anti-TL1A antibody in a dosing regimen comprising an induction dosing regimen and a subsequent maintenance dosing regimen; wherein (a) the induction dosing regimen comprises the subcutaneous administration of four individual induction doses of the anti-TL1A antibody at a dose of approximately 450 mg (e.g., a 450 mg dose), wherein the individual induction doses are administered with a Petition 870250104631, dated 11 / 14 / 2025, pp. 221 / 355 64 / 147 at 4-week intervals; and (b) the maintenance dosing regimen comprises the subcutaneous administration of a plurality of individual maintenance doses of anti-TL1A antibody at a dose of approximately 450 mg (e.g., a 450 mg dose), wherein the individual maintenance doses are administered at 4-week intervals; and wherein the anti-TL1A antibody comprises an HCDR1 with the sequence shown in SEQ ID NO: 3, an HCDR2 with the sequence shown in SEQ ID NO: 4, an HCDR3 with the sequence shown in SEQ ID NO: 5, an LCDR1 with the sequence shown in SEQ ID NO: 6, an LCDR2 with the sequence shown in SEQ ID NO: 7, and an LCDR3 with the sequence shown in SEQ ID NO: 8.

[00182] In some respects, the disclosure describes a method for treating an IBD in a patient, the method comprising administering to the patient an effective amount of an anti-TL1A antibody in a dosing regimen comprising an induction dosing regimen and a subsequent maintenance dosing regimen; wherein (a) the induction dosing regimen comprises the subcutaneous administration of four individual induction doses of the anti-TL1A antibody at a dose of approximately 50 mg, 150 mg or 450 mg (e.g., a dose of 50 mg, 150 mg or 450 mg), wherein the individual induction doses are administered at 4-week intervals; and (b) the maintenance dosing regimen comprises the subcutaneous administration of a plurality of individual maintenance doses of anti-TL1A antibody at a dose of approximately 50 mg, 150 mg or 450 mg (e.g., a dose of 50 mg, 150 mg or 450 mg), wherein the individual maintenance doses are administered at 4-week intervals;and wherein the anti-TL1A antibody comprises: an HCDR1 with the sequence shown in SEQ ID NO: 68, an HCDR2 with the sequence shown in SEQ ID NO: 4, an HCDR3 with the sequence shown in SEQ ID NO: 5, an LCDR1 with the sequence shown in SEQ ID NO: 6, an LCDR2 with the sequence shown in SEQ ID NO: 7; Petition 870250104631, dated 11 / 14 / 2025, pp. 222 / 355 65 / 147 an LCDR3 with the sequence shown in SEQ ID NO: 8. In some respects, the anti-TL1A antibody is afimkibart.

[00183] In some respects, the disclosure provides a method for treating IBD in a patient, the method comprising administering to the patient an effective amount of an anti-TL1A antibody in a dosing regimen comprising an induction dosing regimen and a subsequent maintenance dosing regimen; wherein (a) the induction dosing regimen comprises the subcutaneous administration of four individual induction doses of the anti-TL1A antibody at a dose of approximately 450 mg (e.g., one 450 mg dose), wherein the individual induction doses are administered at 4-week intervals; and (b) the maintenance dosing regimen comprises the subcutaneous administration of a plurality of individual maintenance doses of the anti-TL1A antibody at a dose of approximately 450 mg (e.g., one 450 mg dose), wherein the individual maintenance doses are administered at 4-week intervals;and wherein the anti-TL1A antibody comprises an HCDR1 with the sequence shown in SEQ ID NO: 68, an HCDR2 with the sequence shown in SEQ ID NO: 4, an HCDR3 with the sequence shown in SEQ ID NO: 5, an LCDR1 with the sequence shown in SEQ ID NO: 6, an LCDR2 with the sequence shown in SEQ ID NO: 7 and an LCDR3 with the sequence shown in SEQ ID NO: 8.;

[00184] In some respects, the dosage regimen, comprising the induction phase and the maintenance phase, lasts approximately 52 weeks (for example, it lasts 52 weeks). C. Response to Treatment Clinical response

[00185] Following the induction dosing regimen and / or maintenance dosing regimen, the patient may experience improvement in the signs and symptoms of IBD, characterized by a clinical response. The term “response” Petition 870250104631, dated 11 / 14 / 2025, pp. 223 / 355 A clinical score of 66 / 147 can be defined as a reduction of at least 3 points in the total Mayo score from baseline, with a variation of at least 30%, accompanied by a reduction of at least one point or an absolute score of 0 or 1 in the rectal bleeding subscore.

[00186] The abbreviation “Mayo” refers to the Mayo Scoring System for Assessment of Ulcerative Colitis Activity. The “Adaptive Mayo Score” refers to the Adaptive Mayo Scoring system, which has 3 sub-scores of the Mayo Score, ranging from 0 to 9, without the physician global assessment (PGA) sub-score.

[00187] In some respects, in a population of patients treated according to any of the methods provided in this document, the treatment results in an increase in the proportion of patients who achieved a clinical response at the end of the induction phase, compared with a reference population. For example, in some respects, the induction phase lasts approximately 14 weeks, and treatment results in an increase in the proportion of patients who achieved a clinical response by Week 14. For example, in some respects, at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 95%, or 99% of patients (e.g., 1-10%, 10-20%, 20-30%, 30-40%, 50-50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% of patients) in the patient population achieved a clinical response. a clinical response in Week 14.In some respects, the proportion of patients in the patient population who achieved a clinical response at Week 14 is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 95%, or 99% higher than the proportion of patients who achieved a clinical response at Week 14 in the reference population.

[00188] In some respects, in a population of patients treated according to any of the methods comprising the phase of Petition 870250104631, dated 11 / 14 / 2025, pp. 224 / 355 67 / 147 maintenance described in this document, the treatment results in an increase in the proportion of patients who achieved a clinical response at the end of the maintenance phase, compared to the reference population. For example, in some aspects, the dosing regimen lasts approximately 56 weeks, and the treatment results in an increase in the proportion of patients who achieved a clinical response by Week 56. For example, in some aspects, at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 95%, or 99% of patients (e.g., 1-10%, 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% of patients) in the patient population achieved a response. Clinical practice in Week 56.In some respects, the proportion of patients in the patient population who achieved a clinical response at Week 56 is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 95%, or 99% higher than the proportion of patients who achieved a clinical response at Week 56 in the reference population.

[00189] In any of the methods provided in this document, the reference population may be any population that serves as an appropriate control. For example, in some respects, the reference population is a population of individuals with IBD (e.g., moderately or severely active UC) who have not been treated with an anti-TL1A antibody (e.g., have been treated with a placebo). Endoscopic Response

[00190] Following the induction dosing regimen and / or the maintenance dosing regimen, the patient may experience an improvement in the signs and symptoms of IBD, characterized by an endoscopic response. The term “endoscopic response” refers to a Mayo endoscopy subscore of 0 or 1. Petition 870250104631, dated 11 / 14 / 2025, pp. 225 / 355 68 / 147 Clinical Remission

[00191] After the induction dosage regimen and / or maintenance dosage regimen, the patient may experience improvement in the signs and symptoms of IBD, characterized by clinical remission.

[00192] In some aspects, in a population of patients treated according to any of the methods provided in this document, treatment results in an increase in the proportion of patients who achieved clinical remission at the end of the induction phase, compared with a reference population. For example, in some aspects, the induction phase lasts approximately 14 weeks, and treatment results in an increase in the proportion of patients who achieved clinical remission at Week 14. In some aspects, at least 1%, 5%, 10%, 15%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35% 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49% 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 80%, 95%, or 99% of patients (e.g., 1-10%, 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% of patients) in the patient population achieved clinical remission by Week 14. In some respects, at least approximately 15% of patients in the patient population achieved clinical remission by Week 14. In some respects, at least approximately 40% of patients in the patient population achieved clinical remission by Week 14. In some respects, between 15% and 45.2% of patients in the patient population achieved clinical remission by Week 14. 14. In some respects, 23.3%, 23.9%, 25.5%, 29.8%, 31.8%, or 35% of patients in the patient population achieved clinical remission by Week 14.

[00193] In some respects, the proportion of patients in the patient population who achieved clinical remission at Week 14 is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, Petition 870250104631, dated 11 / 14 / 2025, pp. 226 / 355 69 / 147 70%, 75%, 80%, 85%, 80%, 95%, or 99% higher than the proportion of patients who achieved clinical remission at Week 14 in the reference population.

[00194] In some aspects, in a population of patients treated according to any of the methods comprising the maintenance phase provided in this document, the treatment results in an increase in the proportion of patients who achieved clinical remission at the end of the maintenance phase, compared with a reference population. For example, in some aspects, the dosing regimen has a duration of approximately 56 weeks, and the treatment results in an increase in the proportion of patients who achieved clinical remission at Week 56. In some aspects, at least 1%, 5%, 10%, 15%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41% 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 55%, 60%, 65%, 70%, 75% 80%, 85%, 80%, 95%, or 99% of patients (e.g., 1-10%, 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% of patients) in the patient population achieved clinical remission at Week 56. In some aspects, at least about 20% of patients in the patient population achieved clinical remission at Week 56. In some aspects, at least about 55% of patients in the patient population achieved clinical remission at Week 56. In some aspects, between 19.4% and 56.5% of patients in the patient population achieved clinical remission at Week 56. In some aspects, 31.0%, 34.6%, 35.7%, 38.5% or 39.3% of patients in the patient population achieved clinical remission by Week 56.

[00195] In some respects, the proportion of patients in the patient population who achieved clinical remission at Week 56 is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 95%, or 99% higher than the proportion of patients who achieved clinical remission at Week 56 in the reference population. Petition 870250104631, dated 11 / 14 / 2025, pp. 227 / 355 70 / 147

[00196] In some respects, in a population of patients treated according to any of the methods comprising the maintenance phase provided in this document, treatment results in an increase in the proportion of patients who maintain remission throughout the maintenance phase, compared with a reference population. For example, in some respects, the induction phase lasts approximately 14 weeks, the full dosing regimen lasts approximately 56 weeks, and treatment results in an increase in the proportion of patients who achieve clinical remission at Week 14 and Week 56.

[00197] In some respects, clinical remission is defined as a modified Mayo score (mMS) < 2 with stool frequency (SFS) subscore = 0 or 1, rectal bleeding (RBS) subscore = 0, and endoscopic subscore (ES) = 0 or 1.

[00198] In other respects, the term “clinical remission” is based on the total Mayo score of 12 points: total Mayo score <□ 2 with no individual subscores >1. In some respects, the Adapted (Modified) Mayo score is defined as endoscopic subscore = 0 or 1, decrease >= 1 point from baseline to achieve a stool frequency subscore = 0 or 1 and rectal bleeding subscore = 0. In some respects, the Adapted (Modified) Mayo score is defined as endoscopic subscore = 0 or 1, stool frequency subscore = 0 or 1 with no increase from baseline and rectal bleeding subscore = 0. Endoscopic Remission

[00199] Following the induction dosing regimen and / or the maintenance dosing regimen, the patient may experience improvement in the signs and symptoms of IBD, characterized by endoscopic remission. The term “endoscopic remission” refers to a Mayo endoscopic subscore of Petition 870250104631, dated 11 / 14 / 2025, pp. 228 / 355 71 / 147 0. In some respects, the patient achieves endoscopic remission at the end of the induction phase or earlier, for example, at or before Week 14 of treatment. In some respects, in a population of patients treated according to any of the methods provided in this document, treatment results in an increase in the proportion of patients who achieved endoscopic remission at the end of the induction phase, compared to a reference population. In some respects, the patient achieves endoscopic remission at the end of or earlier of the maintenance phase, for example, at or before Week 56 of treatment. In some respects, in a population of patients treated according to any of the methods provided in this document, treatment results in an increase in the proportion of patients who achieved endoscopic remission at the end of the maintenance phase, compared to a reference population. Deep Remission

[00200] Following the induction dosing regimen and / or the maintenance dosing regimen, the patient may experience improvement in the signs and symptoms of IBD, characterized by deep remission. The term “deep remission” refers to a total Mayo score of 2 points or less, with no individual subscore greater than 1 point and with 0 in the endoscopic and rectal bleeding subscores.

[00201] In some respects, in a population of patients treated according to any of the methods provided in this document, the treatment results in an increase in the proportion of patients who achieved deep remission at the end of the induction phase, compared with a reference population. In some respects, the patient experiences deep remission at the end of the maintenance phase or earlier, for example, at or before Week 56 of treatment. In some respects, in a population of patients treated according to any of the methods provided in this document Petition 870250104631, dated 11 / 14 / 2025, pp. 229 / 355 72 / 147 of this document, the treatment results in an increase in the proportion of patients who achieved deep remission at the end of the maintenance phase, compared to a reference population. Symptomatic Remission

[00202] Following the induction dosing regimen and / or the maintenance dosing regimen, the patient may experience improvement in the signs and symptoms of IBD, characterized by symptomatic remission. The term “symptomatic remission” refers to a total Mayo score of 2 points or less, with no individual subscore greater than 1 point, and with rectal bleeding and stool frequency subscores equal to 0.

[00203] In some respects, in a population of patients treated according to any of the methods provided in this document, treatment results in an increase in the proportion of patients who achieved symptomatic remission at the end of the induction phase, compared with a reference population. In some respects, the patient achieves symptomatic remission at the end of the maintenance phase or earlier, for example, at or before Week 56 of treatment. In some respects, in a population of patients treated according to any of the methods provided in this document, treatment results in an increase in the proportion of patients who achieved symptomatic remission at the end of the maintenance phase, compared with a reference population. Endoscopic Enhancement

[00204] Following the induction dosing regimen and / or the maintenance dosing regimen, the patient may experience improvement in the signs and symptoms of IBD, characterized by endoscopic improvement. The term “endoscopic improvement” (“EI”) refers to a decrease of >1 point in the Mayo endoscopic subscore or an absolute endoscopic score <1. In some respects, endoscopic improvement is defined as a subscore Petition 870250104631, dated 11 / 14 / 2025, pp. 230 / 355 73 / 147 endoscopic = 0 or 1.

[00205] In some aspects, the patient shows endoscopic improvement at the end of the induction phase or earlier, for example, at or before Week 14 of treatment. In some aspects, in a population of patients treated according to any of the methods described herein, treatment results in an increase in the proportion of patients who achieved endoscopic improvement at the end of the induction phase, compared with a reference population. For example, in some aspects, the induction phase lasts approximately 14 weeks, and treatment results in an increase in the proportion of patients who achieved endoscopic improvement at Week 14. In some aspects, at least 1%, 5%, 10%, 15%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35% 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49% 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 80%, 95%, or 99% of patients (e.g., 1-10%, 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% of patients) in the patient population showed endoscopic improvement at Week 14. In some aspects, at least approximately 25% of patients in the patient population achieved endoscopic improvement at Week 14. In some aspects, at least approximately 50% of patients in the patient population achieved endoscopic improvement at Week 14. In some aspects, between 9.6% and 53.5% of patients in the patient population showed endoscopic improvement at Week 14. 14. In some aspects, 38.3%, 40.4%, or 40.9% of patients in the patient population showed endoscopic improvement at Week 14.

[00206] In some respects, the proportion of patients in the patient population who experienced endoscopic improvement at Week 14 is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 95%, or 99% greater than the proportion of Petition 870250104631, dated 11 / 14 / 2025, pp. 231 / 355 74 / 147 patients who showed endoscopic improvement at Week 14 in the reference population.

[00207] In some respects, the patient shows endoscopic improvement at the end of the maintenance phase or earlier, for example, at or before Week 56 of treatment. In some respects, in a population of patients treated according to any of the methods provided in this document, the treatment results in an increase in the proportion of patients who achieved endoscopic improvement at the end of the maintenance phase, compared with a reference population. In some respects, at least 1%, 5%, 10%, 15%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42% 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 55%, 60%, 65%, 70%, 75%, 80% 85%, 80%, 95%, or 99% of patients (e.g., 1-10%, 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% of patients) in the patient population showed endoscopic improvement at Week 56. In some aspects, at least 20% of patients in the patient population showed endoscopic improvement at Week 56. In some aspects, at least 65% of patients in the patient population showed endoscopic improvement at Week 56. In some aspects, between 23.8% and 66.7% of patients in the patient population showed endoscopic improvement at Week 56. In some aspects, 38.1%, 39.3%, or 50.0% of patients in the patient population showed endoscopic improvement. in Week 56.

[00208] In some respects, the proportion of patients in the patient population who achieved endoscopic improvement at Week 56 is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 95%, or 99% higher than the proportion of patients who achieved endoscopic improvement at Week 56 in the reference population. Petition 870250104631, dated 11 / 14 / 2025, pp. 232 / 355 75 / 147 Improvement in IBD Signs and Symptoms

[00209] After the induction dosing regimen and / or the maintenance dosing regimen, the patient may experience improvement in the signs and symptoms of IBD, which is maintained as long as the patient receives the maintenance dosing regimen.

[00210] In some aspects of the disclosure, the induction dosing regimen and / or the maintenance dosing regimen with the anti-TL1A antibody effectively improve the signs and symptoms of IBD for at least 14 weeks after initiation of treatment with the anti-TL1A antibody. This improvement in the signs and symptoms of IBD can be characterized by an improvement in the Mayo endoscopic subscore. The reduction in the patient's Mayo endoscopic subscore may be at least 1, 2, or 3 whole numbers.

[00211] Improvement in IBD signs and symptoms can be characterized by the patient having a Mayo endoscopic subscore of 0, 1, 2, or 3. Improvement in IBD signs and symptoms can be characterized by the patient having a total Mayo score of 0, 1, 2, or 3. Improvement in IBD signs and symptoms can be characterized by the patient having a Robarts Histopathological Index (RHI) of less than 5. Improvement in IBD signs and symptoms can be characterized by the patient having a Geboes Index of less than 3.2.

[00212] Improvement in IBD signs and symptoms can be maintained during the maintenance dosing regimen for at least 2, 3, 4, 6, or 12 months. D. Pre-treatment

[00213] In some respects, the patient was previously treated with corticosteroids prior to administration of the anti-TL1A antibody. In some respects, the patient was previously treated with one or more treatments selected from the group consisting of necrosis factor inhibitors. Petition 870250104631, dated 11 / 14 / 2025, pp. 233 / 355 76 / 147 tumor-fighting agents, anti-integrins, azathioprine, 6-mercaptopurine, and methotrexate.

[00214] In some respects, the patient was previously treated with IBD therapy (e.g., UC therapy) and had an inadequate response to therapy, loss of response to therapy, and / or intolerance to therapy. In some respects, the therapy was conventional UC therapy, for example, it consisted of the administration of a steroid or an immunosuppressant (e.g., the patient had an inadequate response, loss of response, and / or intolerance to a steroid or an immunosuppressant).

[00215] In some respects, the therapy was advanced for UC, for example, it included the administration of an antitumor necrosis factor (TNF) agent, an anti-integrin agent, an anti-IL12 / IL23 agent, and / or a Janus kinase (JAK) inhibitor (e.g., the patient had an inadequate response, loss of response, and / or intolerance to an anti-TNF agent, an anti-integrin agent, an anti-IL12 / IL23 agent, and / or a JAK inhibitor). Thus, in some respects, the patient had received prior advanced therapy at baseline (e.g., before the administration of the first dose of the induction phase). In other respects, the patient had not received prior advanced therapy at baseline. E. Fecal Calprotectin and hsCRP

[00216] In some respects, the patient exhibits a reduction in fecal calprotectin from baseline of at least 50% during the course of treatment (e.g., from week 2 to week 26 of treatment). In some respects, the patient exhibits a reduction in fecal calprotectin from baseline of at least 60% from week 2 to week 26 of treatment. In some respects, the patient exhibits a reduction in high-sensitivity C-reactive protein (hsCRP) from baseline from week 2 to week 26 of treatment. Petition 870250104631, dated 11 / 14 / 2025, pp. 234 / 355 77 / 147 F. Inflammatory Bowel Diseases

[00217] In some respects, IBD is ulcerative colitis (UC). In some respects, the patient has moderate to severe ulcerative colitis. The term moderate to severe ulcerative colitis is defined as having an Adapted Mayo score of 5 to 9, with an endoscopic subscore of 2 or 3 and / or as a total Mayo score of at least 6 and an endoscopic subscore of at least 2.

[00218] In some respects, IBD is Crohn's disease (CD). In some respects, the patient has moderate to severe CD. The term moderate to severe CD is defined by the Crohn's Disease Activity Index (CDAI) and the Simplified Endoscopic Score for CD (SES-DC).

[00219] In some aspects, the patient has a diagnosis of ulcerative colitis, indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis, or active diverticular disease. Ill. Kits

[00220] The disclosure also provides kits containing any or all of the anti-TL1A antibodies described herein. The disclosure kits include one or more containers containing an anti-TL1A antibody described herein and instructions for use according to any of the disclosure methods described herein. In general, these instructions include a description of the administration of the anti-TL1A antibody for the therapeutic treatments described above. In some aspects, kits are provided for the preparation of a single-dose administration unit. In certain aspects, the kit may contain a first container with dehydrated protein and a second container with an aqueous formulation. In certain aspects, kits containing pre-filled single- and multi-chamber syringes (e.g., liquid and lyophilized syringes) are included.

[00221] Instructions for the use of an anti-TL1A antibody generally include information on dosage, dosing schedule, and route of administration. Petition 870250104631, dated 11 / 14 / 2025, pages 235 / 355 78 / 147 administration for the intended treatment. Containers may be unit dose, bulk packs (e.g., multidose packs) or subunit doses. The instructions provided in the kits of this disclosure are normally written instructions on a label or package insert (e.g., a sheet of paper included in the kit), but machine-readable instructions (e.g., instructions contained on a magnetic or optical storage disk) are also acceptable.

[00222] The kits in this disclosure are in suitable packaging. Suitable packaging includes, but is not limited to, vials, ampoules, jars, flexible packaging (e.g., sealed plastic or Mylar bags) and the like. Packaging for use in combination with a specific device, such as an inhaler, a nasal delivery device (e.g., an atomizer) or an infusion device, such as a mini-pump, is also contemplated. A kit may have a sterile access port (e.g., the container may be an intravenous solution bag or a vial with a cap that can be pierced with a hypodermic needle). The container may also have a sterile access port (e.g., it may be an intravenous solution bag or a vial with a cap that can be pierced with a hypodermic needle). At least one of the active agents in the composition is an anti-TL1A antibody. The container may additionally contain a second pharmaceutically active agent.

[00223] The kits may optionally provide additional components, such as buffer solutions and interpretive information. Typically, the kit comprises a container and a label or leaflet(s) printed on or attached to the container. IV. Anti-TL1A and Anti-DR3 antibodies

[00224] The methods of the present disclosure include the administration of an anti-TL1A antibody. Anti-TL1A antibodies exemplifying the disclosure are shown in Table 2 and below. Anti-DR3 antibodies exemplifying the disclosure are also provided below. Petition 870250104631, dated 11 / 14 / 2025, pp. 236 / 355 79 / 147 Table 2. Example Antibody Sequences from the Disclosure SEQ ID Number Description Aminoacid Sequence 1 Afimkibart VH QVQLVQSGAEVKKPGASVKV SCKASGYDFTYYGISWVRQA PGQGLEWMGWISTYNGNTH YARMLQGRVTMTTDTSTRTA YMELRSLRSDDTAVYYCARE NYYGSGAYRGGMDVWGQG TTVTVSS 2 Afimkibart VL EIVLTQSPATLSLSPGERATL SCRASQSVSSYLAWYQQKP GQAPRLLIYDASNRATGIPAR FSGSGSGTDFTLTISSLEPED FAVYYCQQRSNWPWTFGQG TKVEIK 3 Afimkibart HCDR1 (CDR-H1) YYGIS 4 Afimkibart HCDR2 (CDR-H2) WISTYNGNTHYARMLQG 5 Afimkibart HCDR3 (CDR-H3) ENYYGSGAYRGGMDV 6 Afimkibart LCDR1 (CDR-L1) RASQSVSSYLA 7 Afimkibart LCDR2 (CDR-L2) DASNRAT 8 Afimkibart LCDR3 (CDR-L3) QQRSNWPWT 9 Afimkibart HC QVQLVQSGAEVKKPGASVKV SCKASGYDFTYYGISWVRQA PGQGLEWMGWISTYNGNTH YARMLQGRVTMTTDTSTRTA YMELRSLRSDDTAVYYCARE NYYGSGAYRGGMDVWGQG TTVTVSSASTKGPSVFPLAPS SKSTSGGTAALGCLVKDYFP EPVTVSWNSGALTSGVHTFP AVLQSSGLYSLSSVVTVPSSS LGTQTYICNVNHKPSNTKVD KKVEPKSCDKTHTCPPCPAP EAAGAPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEV KFNWYVDGVEVHNAKTKPR EEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPI EKTISKAKGQPREPQVYTLPP SREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT TPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALH NHYTQKSLSLSPG Petition 870250104631, dated 11 / 14 / 2025, pp. 237 / 355 80 / 147 Número de SEQ ID Descrição Sequência de Aminoácidos 10 Afimkibart LC EIVLTQSPATLSLSPGERATL SCRASQSVSSYLAWYQQKP GQAPRLLIYDASNRATGIPAR FSGSGSGTDFTLTISSLEPED FAVYYCQQRSNWPWTFGQG TKVEIKRTVAAPSVFIFPPSDE QLKSGTASVVCLLNNFYPRE AKVQWKVDNALQSGNSQES VTEQDSKDSTYSLSSTLTLSK ADYEKHKVYACEVTHQGLSS PVTKSFNRGEC 11 1D1-1.27_VH QVQLVQSGAEVKKPGASVKV SCKASGYDFTYYGISWVRQA PGQGLEWMGWISTYNGNTH YARMLQGRVTMTTDTSTRTA YMELRSLRSDDTAVYYCARE NYYGSGSYRGGMDVWGQG TTVTVSS 12 1D1-1.28_VH QVQLVQSGAEVKKPGASVKV SCKASGYDFTYYGISWVRQA PGQGLEWMGWISTYNGNKH YARMLQGRVTMTTDTSTRTA YMELRSLRSDDTAVYYCARE NYYGSGSYRGGMDVWGQG TTVTVSS 13 1D1-1.29_VH QVQLVQSGAEVKKPGASVKV SCKASGYDFTYYGISWVRQA PGQGLEWMGWISTYNGGTH YARMLQGRVTMTTDTSTRTA YMELRSLRSDDTAVYYCARE NYYGSGSYRGGMDVWGQG TTVTVSS 14 1D1-1.30_VH QVQLVQSGAEVKKPGASVKV SCKASGYDFTYYGISWVRQA PGQGLEWMGWISTYNGVTH YARMLQGRVTMTTDTSTRTA YMELRSLRSDDTAVYYCARE NYYGSGSYRGGMDVWGQG TTVTVSS 15 1D1-1.32_VH QVQLVQSGAEVKKPGASVKV SCKASGYDFTYYGISWVRQA PGQGLEWMGWISTYNGGTH YARMLQGRVTMTTDTSTRTA YMELRSLRSDDTAVYYCARE NYYGSGAYRGGMDAWGQG TTVTVSS 16 1D1-1.33_VH QVQLVQSGAEVKKPGASVKV SCKASGYDFTYYGISWVRQA PGQGLEWMGWISTYNGVTH YARMLQGRVTMTTDTSTRTA YMELRSLRSDDTAVYYCARE NYYGSGAYRGGMDAWGQG TTVTVSS. Petition: 870250104631, on November 14, 2025, p. 238 / 355 81 / 147 Sequence Number ID Description Amino Acid Sequence 17 1D1-1.34_VH QVQLVQSGAEVKKPGASVKV SCKASGYDFTYYGISWVRQA PGQGLEWMGWISTYNGKTH YARMHQGRVTMTTDTSTRTA YMELRSLRSDDTAVYYCARE NYYGSGAYRGGMDAWGQG TTVTVSS 18 15A9_VH QVQLVQSGAEVKKPGASLKV SCKASGYPFTNYGISWVRQA PGQGLEWMGWISTYNGNTH YAQKLQGRVTMTTDTSTTTA YMDLRSLRSDDTAVYYCARE NYYGSGSYRGGMDVWGQG TTVTVSS 19 15C11_VH QVQLVQSGAEVKKPGASVKV SCKASGYSFTTYGISWVRQA PGQGLEWMGWISTYNGNTH YAQKLQGRVTMTTDTSTRTA YMELRSLRSDDTAVYYCARE NYYGSGSYRGGMDVWGQG TTVTVSS 20 7D4_VH QVQLVQSGAEVKKPGASVKV SCKASGYTFTSYGINWVRQA PGQGLEWMGWISTYNGNTN SAQKLQGRVTMTTDTSTSTA YMELRSLRSDDTAVYYCARA HSSSWFDAFDIWGQGTMVT VSS 21 26B11_VH QVQLVESGGGVVQPGRSLR LSCAASGFTFSSFAMHWVRQ APGKGLEWVALIPFDGSSNY YADSVKGRFTISRDNSKNTLY LQMNSLRAEDTAVYYCARDR NYYGSGSFSFDAFDIWGQGT LVTVSS 22 9B3_VH QVQLVESGGGVVQPGRSLR LSCAASGFTFSNYALHWVRQ APGKGLEWVALISYDGSDKY YADSVKGRFAISRDNSKNTLY LQMNSLRAEDTAVYYCARDR EYCTYSSCSYDAFDIWGQGT MVTVSS 23 22F9_VH QVQLVQSGAEVKKPGASVKV SCKASGYTFTSYAMHWVRQ APGQRLEWMGWINAGNGNT KYSQKFQGRVTITRDTSASTA YMELSSLRSEDTAVYYCARG YSSAWFDAFDIWGQGTMVT VSS. Petition: 870250104631, on November 14, 2025, p. 239 / 355 82 / 147 SEQ ID Number Description Amino Acid Sequence 24 7D4_VL AIQLTQSPSSLSASVGDRVTI TCRASQGISSALAWYQQKPG KAPKLLIYDASSLESGVPSRF SGSGSGTDFTLTISSLQPEDF ATYYCQQFNSYPLTFGGGTK VEIK 25 26B11_VL DIQMTQSPSSLSASVGDRVTI TCRASQGISNWLAWYQQKP EKAPKSLIYAASSLQSGVPSR FSGSGSGTDFTLTISSLQPED FATYYCQQYNSYPYTFGQGT KLEIK 26 9B3_VL DIQMTQSPSSLSASVGDRVTI TCRASQGISSWLAWYQQKP EKAPKSLIYAASSLQSGVPSR FSGSGSGTDFTLTISSLQPED YATYYCQQYNSYPYTFGQGT KLEIK 27 22F9_VL AIQLTQSPSSLSASVGDRVTI TCRASQGISSALAWYQQKPG KAPKLLIYDASSLESGVPSRF SGSGSGTDFTLTISSLQPEDF ATYYCQQFNSYPLTFGGGTK VEIK 28 SEQ ID NO: 18 de WO 2012 / 064682 EVQLLESGGGLVQPGKSLRL SCAVSGFTFSTYGMNWVRQ APGKGLEWVSSISGTGRTTY HADSVQGRFTVSRDNSKNIL YLQMNSLRADDTAVYFCTKE RGDYYYGVFDYWGQGTLVT VSS 29 SEQ ID NO: 26 de WO 2012 / 064682 DIQMTQSPSTLSASVGDRVTI TCRASQTISSWLAWYQQTPE KAPKLLIYAASNLQSGVPSRF SSGSGTEFTLTISSLQPDDF ATYYCQQYHRSWTFGQGTK VEIT Petition: 870250104631, on November 14, 2025, p. 240 / 355 83 / 147 Número de SEQ ID Description Sequência de Aminoacidos 30 C320-168 huIgG1-EFN de WO 2013 / 044298 QVQLVQSGAEVKKPGASVKV SCKASGYTFTSYDINWVRQA PGQGLEWMGWLNPNSGNT GYAQKFQGRVTMTRNTSIST AYMELSSLRSEDTAVYYCAR EVPETAAFEYWGQGTLVS SASTKGPSVFPLASSKSTS GGTAALGCLVKDYFPEPVTV SWNSGALTSGVHTFPAVLQS SGLYSLSSVVTVPSSSLGTQT YICVNNHKPSNTKVDKKVEP KSCDKTHTCPPCPAPEAAGA PSVFLPPPKPKDTLMISRTPE VTCVVVDVSHEDPEVKFNWY VDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKE YCKKVSNKALPAPIEKTISKAK GQPREPQVYTLPPSREEMTK NQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDS DGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKS LSLSPGK 31 C320-168 huLambda de WO 2013 / 044298 QSVLTQPPSVSGAPGQRVTI SCTSSSSDIGAGLGVHWYQQ LPGTAKPLLIYGYYNRPSGVP DRFSGSKSGTSASLTIGLLP EDEGDYYCQSYDGTLSALFG GGTKLTVLGQPKAAPSVTLF PPSSEELQANKATLVCLISDF YPGAVTVAWKADSSPVKAGV ETTTPSKQSNNKYAASSYLSL TPEQWKSHRSYSCQVTHEG STVEKTVAPTECS 32 VH C320-179 de WO 2013 / 044298 QVQLVQSGAEVKKPGASVKV SCKASGYTFTSYDINWVRQA PGQGLEWMGWLNPNSGNT GYAQKFQGRVTMTADRSTST AYMELSSLRSEDTAVYCAR EVPETAAFEYWGQGTLVTVS S 33 VLC320-179 of WO 2013 / 044298 QSVLTQPPSVSGAPGQRVTI SCTSSSSDIGAGLGVHWYQQ LPGTAPKLLIEGYYNRPSGVP DRFSGSKSGTSASLTITGLLP EDEGDYYCQSYDGTLSALFG GGTKLTVLG Petition 870250104631, dated 11 / 14 / 2025, pp. 241 / 355 84 / 147 Sequence Number ID Description Amino Acid Sequence 34 Afimkibart HC (with C-terminal lysine) QVQLVQSGAEVKKPGASVKV SCKASGYDFTYYGISWVRQA PGQGLEWMGWISTYNGNTH YARMLQGRVTMTTDTSTRTA YMELRSLRSDDTAVYYCARE NYYGSGAYRGGMDVWGQG TTVTVSSASTKGPSVFPLAPS SKSTSGGTAALGCLVKDYFP EPVTVSWNSGALTSGVHTFP AVLQSSGLYSLSSVVTVPSSS LGTQTYICNVNHKPSNTKVD KKVEPKSCDKTHTCPPCPAP EAAGAPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEV KFNWYVDGVEVHNAKTKPR EEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPI EKTISKAKGQPREPQVYTLPP SREEMTKNQVSLTCLVKGFY PSDIAVEWESNGQPENNYKT TPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALH NHYTQKSLSLSPGK 35 Tulisoquibarte HC QVQLVQSGAEVKKPGASVKV SCKASGFDIQDTYMHWVKQ RPGQGLEWMGRIDPASGHT KYDPKFQVRVTITRDTSTSTV YLELSSLRSEDTAVYYCARS GGLPDVWGQGTTVTVSSAS TKGPSVFPLAPSSKSTSGGT AALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSSLGTQTYIC NVNHKPSNTKVDKKVEPKSC DKTHTCPPCPAPEAAGGPSV FLFPPKPKDTLMISRTPEVTC VVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYNSTY RVVSVLTVLHQDWLNGKEYK CKVSNKALAAPIEKTISKAKG QPREPQVYTLPPSRDELTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPPVLDSD GSFFLYSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSL SLSPGK 36 Tulisoquibarte HFR1 QVQLVQSGAEVKKPGASVKV SCKASGFDIQ 37 Tulisoquibarte CDR-H1 DTYFRM 38H Tulisoquibarte HFR1 WVKQRPGQGLEWMG 39 Tulisoquibarte CDR-H2 RIDPASGHTKYDPKFQV Petition 870250104631, of 14 / 11 / 2025, p. 242 / 355 85 / 147 Número de SEQ ID Descrição Sequência de Aminoácidos 40 Tulisoquibarte HFR3 RVTITRDTSTSTVYLELSSLR SEDTAVYYCAR 41 Tulisoquibarte CDR-H3 SGGLPDV 42 Tulisoquibarte HFR4 WGQGTTVTVSS 43 Tulisoquibarte HC Cauda ASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSS GLYSLSSVVTVPSSSLGTQTY ICNVNHKPSNTKVDKKVEPK SCDKTHTCPPCPAPEAAGGP SVFLFPPKPKDTLMISRTPEV TCVVVDVSHEDPEVKFNWYV DGVEVHNAKTKPREEQYNST LC EIVLTQSPGTLSLSPGERATL SCRASSSVSYMYWYQQKPG QAPRPLIYATSNLASGIPDRF SGSGSGTDFTLTISRLEPEDF AVYYCQQWEGNPRTFGGGT KLEIKRTVAAPSVFIFPPSDEQ LKSGTASVVCLLNNFYPREA KVQWKVDNALQSGNSQESV TEQDSKDSTYSLSSTLTLSKA DYEKHKVYACEVTHQGLSSP VTKSFNRGEC 45 Tulisoquibarte LFR1 EIVLTQSPGTLSLSPGERATL SC 46 Tulisoquibarte CDR-L1 RASSSVSYMY 47 Tulisoquibarte LFR2 WYQQKPGQAPRPLIY 48 Tulisoquibarte CDR-L2 ATSNLAS 49 Tulisoquibarte LFR3 GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC 50 Tulisoquibarte CDR-L3 QQWEGNPRT 51 Tulisoquibarte LFR4 FGGGTKLEIKRTV 52 Tulisoquibarte LC Cauda AAPSVFIFPPSDEQLKSGTAS VVCLLNNFYPREAKVQWKVD NALQSGNSQESKDSKDSSKTYSKTLY ACEVTHQGLSSPVTKSFNRG EC Petition 870250104631, of 14 / 11 / 2025, p. 243 / 355 86 / 147 SEQ Number ID Description Amino Acid Sequence 53 Tulisoquibarte VH QVQLVQSGAEVKKPGASVKV SCKASGFDIQDTYMHWVKQ RPGQGLEWMGRIDPASGHT KYDPKFQVRVTITRDTSTSTV YLELSSLEDTAVGGWGGWGTVGTVGTV Tulisoquibarte VL EIVLTQSPGTLSLSPGERATL SCRASSSVSYMYWYQQKPG QAPRPLIYATSNLASGIPDRF SGSGSGTDFTLTISRLEPEDF AVYYCQWEGNPRTFGGGT KLEIKRTV 55 SEQ ID NO: 15 da Patente dos EUA No. 1016 (variant 1016. DR-HH 1816). 320-587) GYTFTSYDIN 56 SEQ ID NO: 21 of U.S. Patent No. 10.138.296 (CDR-H2 of variant 320-587) WLNPNSGYTG 57 SEQ ID NO: 17 of U.S. Patent No. 10.138-38 (CDR-H2). 320-587) EVPETAAFEY 58 SEQ ID NO: 18 of U.S. Patent No. 10.138.296 (CDR-L1 of variant 320-587) TSSSSDIGAGLGVH 59 SEQ ID NO: 19 of U.S. Patent No. 10.138.26 (CDR-L1). 320-587) GYYNRPS 60 SEQ ID NO: 22 of US Patent No. 10,138,296 (CDR-L3 of variant 320-587) QSWDGTLSAL 61 SEQ ID NO: 3 of US Pat.296 (VH of variant 320-587) QVQLVQSGAEVKKPGASVKV SCKASGYTFTSYDINWVRQA PGQGLEWMGWLNPNSGYT GYAQKFQGRVTMTADRSTST AYMELSSLRSEDTAVYYCAR EVPETAAFEYWGQGTLVTVS S 62 SEQ ID NO: 4 of US Patent No. 10,138,296 (VL of variant 320-587) QSVLTQPPSVSGAPGQRVTI SCTSSSSDIGAGLGVHWYQQ LPGTAPKLLIEGYYNRPSGVP DRFSGSKSGTSASLTITGLLP EDEGDYYCQSWDGTLSALF GGGTKLTVLG. Petition 870250104631, dated 11 / 14 / 2025, pp. 244 / 355 87 / 147 SEQ ID Number Description Amino Acid Sequence 63 SEQ ID NO: 60 of U.S. Patent No. 10,138,296 (HC) QVQLVQSGAEVKKPGASVKV SCKASGYTFTSYDINWVRQAP GQGLEWMGWLNPNSGYTGY AQKFQGRVTMTADRSTSTAY MELSSLRSEDTAVYYCAREVP ETAAFEYWGQGTLVTVSSAST KGPSVFPLAPSSKSTSGGTAA LGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSSGLYSL SSVVTVPSSSLGTQTYICNVN HKPSNTKVDKKVEPKSCDKTH TCPPCPAPELLGGPSVFLFPP KPKDTLMISRTPEVTCVVVDV SHEDPEVKFNWYVDGVEVHN AKTKPREEQYNSTYRVVSVLT U.S. Patent No. 10.138.296 (LC) VTVAWKADSSPVKAGVETTTP SKQSNNKYAASSYLSLTPEQ WKSHRSYSCQVTHEGSTVEK TVAPTECS 65 SEQ ID Nos: 60 and 62 of U.S. Patent No. 10,138.296 (HC with L234A / L235A / G237A) LGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSSGLYSL SSVVTVPSSSLGTQTYICNVN HKPSNTKVDKKVEPKSCDKTH TCPPCPAPEAAGAPSVFLFPP KPKDTLMISRTPEVTCVVVDV SHEDPEVKFNWYVDGVEVHN AKTKPREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKVSNKA LPAPIEKTISKAKGQPREPQVY TLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTV DKSRWQQGNVFSCSVMHEAL HNHYTQKSLSLSPG. Petition 870250104631, dated 11 / 14 / 2025, pages 245 / 355 88 / 147 SEQ ID Number Description Amino Acid Sequence 66 SEQ ID Nos: 60 and 64 of U.S. Patent No. 10,138,296 (HC with YTE) QVQLVQSGAEVKKPGASVKV SCKASGYTFTSYDINWVRQA PGQGLEWMGWLNPNSGYT GYAQKFQGRVTMTADRSTST AYMELSSLRSEDTAVYYCAR EVPETAAFEYWGQGTLVTVS SASTKGPSVFPLAPSSKSTS GGTAALGCLVKDYFPEPVTV SWNSGALTSGVHTFPAVLQS SGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKKVEP KSCDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLYITREPE VTCVVVDVSHEDPEVKFNWY VDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTISKAK GQPREPQVYTLPPSRDELTK NQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDS DGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKS LSLSPG 67 SEQ ID NOs: 60 and 66 of US Patent No. 10,138.296 (HC with L235A / G237A) GGTAALGCLVKDYFPEPVTV SWNSGALTSGVHTFPAVLQS SGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKKVEP KSCDKTHTCPPCPAPELAGA PSVFLFPPKPKDTLMISRTPE VTCVVVDVSHEDPEVKFNWY VDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTISKAK GQPREPQVYTLPPSRDELTK NQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDS DGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKS LSLSPG 68 Long version Afimkibart of HCDR1 (CDR-H1) GYDFTYYGIS 69 Heavy chain structure region 1 (HFR1) Afimkibart QVQLVQSGAEVKKPGASVKV SCKASGYDFT 70 HFR2 Afimkibart WVRQAPGQGLEWMG 71 HFR3 Afimkibart RVTMTTDTSTRTAYMELRSL RSDDTAVYYCAR. Petition 870250104631, dated 11 / 14 / 2025, pp. 246 / 355 89 / 147 Sequence Number ID Description Amino Acid Sequence 72 Afimkibart HFR4 WGQGTTVTVSS 73 Afimkibart of the light chain structure region 1 (LFR1) EIVLTQSPATLSLSPGERATL SC 74 Afimkibart LFR2 WYQQKPGQAPRLLIY 75 Afimkibart LFR3 GIPARFSGSGSGTDFTLTISS LEPEDFAVYYC 76 Afimkibart LFR4 FGQGTKVEIKRTV 77 Afimkibart of the short version of HFR1 QVQLVQSGAEVKKPGASVKV SCKAS

[00225] In some aspects of the disclosure, the anti-TL1A antibody comprises three CDRs of the variable heavy chain region with the sequence shown in SEQ ID NO: 1 and three CDRs of the variable light chain region with the sequence shown in SEQ ID NO: 2.

[00226] In some aspects of the disclosure, the anti-TL1A antibody comprises an HCDR1 (CDR H1) with the sequence shown in SEQ ID NO: 3, an HCDR2 (CDR H2) with the sequence shown in SEQ ID NO: 4, an HCDR3 (CDR H3) with the sequence shown in SEQ ID NO: 5, an LCDR1 (CDR L1) with the sequence shown in SEQ ID NO: 6, an LCDR2 (CDR L2) with the sequence shown in SEQ ID NO: 7, and an LCDR3 (CDR L3) with the sequence shown in SEQ ID NO: 8. In some aspects, the anti-TL1A antibody comprises one, two, three, four, five, six, seven, or all eight sequences of the structure region shown in SEQ ID NOs: 69-76.

[00227] In some aspects of the disclosure, the anti-TL1A antibody comprises an HCDR1 (CDR H1) with the sequence shown in SEQ ID NO: 68, an HCDR2 (CDR H2) with the sequence shown in SEQ ID NO: 4, an HCDR3 (CDR H3) with the sequence shown in SEQ ID NO: 5, an LCDR1 (CDR L1) with the sequence shown in SEQ ID NO: 6, an LCDR2 (CDR L2) with the sequence shown in SEQ ID NO: 7, and an LCDR3 (CDR L3) with the sequence shown in SEQ ID NO: 8. In some aspects, the anti-TL1A antibody comprises one, two, three, four, five, six, seven, or all eight Petition 870250104631, dated 11 / 14 / 2025, pp. 247 / 355 90 / 147 sequences of the structure region shown in SEQ ID Nos: 70-77.

[00228] In some aspects of the disclosure, the anti-TL1A antibody comprises a variable heavy chain region with the sequence shown in SEQ ID NO: 1 and a variable light chain region with the sequence shown in SEQ ID NO: 2.

[00229] In some aspects of the disclosure, the anti-TL1A antibody comprises a heavy chain with the sequence shown in SEQ ID NO: 34. In some embodiments, the anti-TL1A antibody comprises a heavy chain with the sequence shown in SEQ ID NO: 34 and a light chain with the sequence shown in SEQ ID NO: 10, wherein the C-terminal lysine (K) of the amino acid sequence of the heavy chain in SEQ ID NO: 34 is optional. In some embodiments, the heavy chain does not have the C-terminal lysine (K). In some embodiments, the heavy chain has the sequence shown in SEQ ID NO: 9. In some embodiments, the anti-TL1A antibody comprises a heavy chain with the sequence shown in SEQ ID NO: 9 and a light chain with the sequence shown in SEQ ID NO: 10.

[00230] In some aspects of the disclosure, the anti-TL1A antibody is afimkibart (also known as RO7790121, RVT-3101 or PF06480605).

[00231] In some aspects of the disclosure, the anti-TL1A antibody comprises a VH encoded by the nucleic acid sequence of the vector insert deposited as 1 D1 1.31 VH with ATCC accession number PTA-120639 and a VL encoded by the nucleic acid sequence of the vector insert deposited as 1 D1 1.31 VL with ATCC accession number PTA-120640.

[00232] In some aspects of the disclosure, the anti-TL1A antibody competes for binding with an anti-TL1A antibody comprising a variable heavy chain region with the sequence shown in SEQ ID NO: 1 and a variable light chain region with the sequence shown in SEQ ID NO: 2. Petition 870250104631, dated 11 / 14 / 2025, pp. 248 / 355 91 / 147

[00233] In some aspects of the disclosure, the anti-TL1A antibody competes for binding with an antibody comprising a VH encoded by the nucleic acid sequence of the vector insert deposited as 1D1 1.31 VH with ATCC accession number PTA-120639 and a VL encoded by the nucleic acid sequence of the vector insert deposited as 1D1 1.31 VL with ATCC accession number PTA-120640.

[00234] In some aspects of the disclosure, the anti-TL1A antibody comprises sequence pairs selected from the group consisting of SEQ ID NOs: 2 and 11; SEQ ID NOs: 2 and 12; SEQ ID NOs: 2 and 13; SEQ ID NOs: 2 and 14; SEQ ID NOs: 2 and 15; SEQ ID NOs: 2 and 16; SEQ ID NOs: 2 and 17; SEQ ID NOs: 2 and 18; SEQ ID NOs: 2 and 19; SEQ ID NOs: 20 and 24; SEQ ID NOs: 21 and 25; SEQ ID NOs: 22 and 26; SEQ ID NOs: 23 and 27; SEQ ID NOs: 28 and 29; SEQ ID NOs: 30 and 31; SEQ ID NOs: 32 and 33; SEQ ID NOs: 35 and 44; SEQ ID NOs: 53 and 54; SEQ ID NOs: 61 and 62; SEQ ID NOs: 63 and 64; SEQ ID NOs: 65 and 64; SEQ ID NOs: 66 and 64; and SEQ ID NOs: 67 and 64.

[00235] In some aspects of the disclosure, the anti-TL1A antibody comprises a CDR-H1 with the sequence shown in SEQ ID NO: 37, a CDR-H2 with the sequence shown in SEQ ID NO: 39, a CDR-H3 with the sequence shown in SEQ ID NO: 41, a CDR-L1 with the sequence shown in SEQ ID NO: 46, a CDR-L2 with the sequence shown in SEQ ID NO: 48 and a CDR-L3 with the sequence shown in SEQ ID NO: 50.

[00236] In some aspects of the disclosure, the anti-TL1A antibody comprises heavy chain structure regions, as shown in SEQ ID NOs: 36, 38, 40 and 42, and / or comprises light chain structure regions, as shown in SEQ ID NOs: 45, 47, 49 and 51.

[00237] In some aspects of the disclosure, the anti-TL1A antibody comprises a variable heavy chain region with the sequence shown in SEQ ID NO: 53 and a variable light chain region with the sequence Petition 870250104631, dated 11 / 14 / 2025, pp. 249 / 355 92 / 147 shown in SEQ ID NO: 54.

[00238] In some aspects of the disclosure, the anti-TL1A antibody comprises a heavy chain tail sequence as provided in SEQ ID NO: 43. In some aspects of the disclosure, the anti-TL1A antibody comprises a light chain tail sequence as provided in SEQ ID NO: 52.

[00239] In some aspects of the disclosure, the anti-TL1A antibody comprises a heavy chain with the sequence shown in SEQ ID NO: 35 and / or a light chain with the sequence shown in SEQ ID NO: 44. In some aspects of the disclosure, the anti-TL1A antibody comprises a heavy chain with the sequence shown in SEQ ID NO: 35 and a light chain with the sequence shown in SEQ ID NO: 44.

[00240] In some aspects of disclosure, the anti-TL1A antibody is tulisoquibarte.

[00241] In some respects, the antibody used in any of the methods, compositions, uses and compositions for use provided herein is an anti-TL1A antibody described in Table 2A of U.S. Patent No. 11,136,386, which is incorporated herein by reference in its entirety.

[00242] In some respects, the antibody used in any of the methods, compositions, uses and compositions for use provided herein is an anti-DR3 antibody described in Table 2A of U.S. Patent No. 11,136,386, which is incorporated herein by reference in its entirety.

[00243] In some aspects of any of the methods, compositions, uses and compositions for use provided herein, the anti-TL1A antibody is an anti-TL1A antibody provided in U.S. Patent No. 10,322,174, U.S. Patent No. 10,689,439, U.S. Patent No. 11,292,848, Petition 870250104631, dated 11 / 14 / 2025, pp. 250 / 355 93 / 147 U.S. Patent Nos. 10,138,296, 10,822,422, and 11,220,549, which are incorporated herein by reference in their entirety. In some embodiments, the anti-TL1A antibody comprises the CDR sequences of clone 320-179 provided in U.S. Patent No. 10,689,439. In some embodiments, the anti-TL1A antibody is clone 320-179 provided in U.S. Patent No. 10,689,439.

[00244] In some aspects of the disclosure, the anti-TL1A antibody comprises a CDR-H1 with the sequence shown in SEQ ID NO: 55, a CDR-H2 with the sequence shown in SEQ ID NO: 56, a CDR-H3 with the sequence shown in SEQ ID NO: 57, a CDR-L1 with the sequence shown in SEQ ID NO: 58, a CDR-L2 with the sequence shown in SEQ ID NO: 59 and a CDR-L3 with the sequence shown in SEQ ID NO: 60.

[00245] In some aspects of the disclosure, the anti-TL1A antibody comprises a variable heavy chain region with the sequence shown in SEQ ID NO: 61 and a variable light chain region with the sequence shown in SEQ ID NO: 62.

[00246] In some aspects of the disclosure, the anti-TL1A antibody comprises a heavy chain with the sequence shown in SEQ ID NO: 63, 65, 66 or 67 and / or a light chain with the sequence shown in SEQ ID NO: 64. In some aspects of the disclosure, the anti-TL1A antibody comprises a heavy chain with the sequence shown in SEQ ID NO: 63, 65, 66 or 67 and a light chain with the sequence shown in SEQ ID NO: 64. In some aspects of the disclosure, the anti-TL1A antibody comprises a heavy chain with the sequence shown in SEQ ID NO: 63 and a light chain with the sequence shown in SEQ ID NO: 64. In some aspects of the disclosure, the anti-TL1A antibody comprises a heavy chain with the sequence shown in SEQ ID NO: 65 and a light chain with the sequence shown in SEQ ID NO: 64. In some aspects of the disclosure, the anti-TL1A antibody comprises Petition 870250104631, dated 11 / 14 / 2025, pp. 251 / 355 94 / 147 a heavy chain with the sequence shown in SEQ ID NO: 66 and a light chain with the sequence shown in SEQ ID NO: 64. In some aspects of the disclosure, the anti-TL1A antibody comprises a heavy chain with the sequence shown in SEQ ID NO: 67 and a light chain with the sequence shown in SEQ ID NO: 64.

[00247] In some aspects of the disclosure, the anti-TL1A antibody is TEV-48574.

[00248] In some aspects of the disclosure, the anti-TL1A antibody is C03V.

[00249] In some aspects of the disclosure, the anti-TL1A antibody is SPY002.

[00250] The antibodies described in this document can be produced by any method known in the art. For the production of hybridoma cell lines, the route and immunization schedule of the host animal are generally in accordance with established and conventional techniques for antibody stimulation and production, as further described in this document. General techniques for the production of human and mouse antibodies are known in the art and / or described in this document.

[00251] Any mammalian individual, including humans or antibody-producing cells derived from them, is considered to be manipulable to serve as a basis for the production of mammalian cell lines, including human and hybridoma cell lines. Typically, the host animal is inoculated intraperitoneally, intramuscularly, orally, subcutaneously, intraplantarly, and / or intradermally with an amount of immunogen, including as described herein.

[00252] Hybridomas can be prepared from immortalized lymphocytes and myeloma cells using the general hybridization technique of Petition 870250104631, dated 11 / 14 / 2025, pp. 252 / 355 95 / 147 somatic cells from Kohler, B. and Milstein, C., Nature 256:495-497, 1975, or modified by Buck, DW, et al., In Vitro, 18:377-381, 1982. Available myeloma cell lines, including, without limitation, X63-Ag8653 and those from the Salk Institute, Cell Distribution Center, San Diego, California, USA, can be used for hybridization. Generally, the technique involves fusing myeloma cells and lymphoid cells using a fusing agent, such as polyethylene glycol, or by electrical means well known to those skilled in the art. After fusion, the cells are separated from the fusion medium and cultured in a selective growth medium, such as hypoxanthine-aminopterin-thymidine (HAT) medium, to eliminate unhybridized parent cells. Any of the culture media described in this document, supplemented with serum or not, can be used for the cultivation of hybridomas that secrete monoclonal antibodies.As an alternative to the cell fusion technique, EBV-immortalized B cells can be used to produce the monoclonal antibodies described in the disclosure subject. Hybridomas are expanded and subcloned, if desired, and the supernatants are analyzed for anti-immunogenic activity using conventional immunoassay procedures (e.g., radioimmunoassay, enzyme immunoassay, or fluorescence immunoassay).

[00253] Hybridomas that can be used as a source of antibodies include all derivatives, descendant cells of parental hybridomas that produce monoclonal antibodies.

[00254] The antibody-producing hybridomas used in this disclosure can be cultured in vitro or in vivo using known procedures. Monoclonal antibodies can be isolated from culture media or body fluids by conventional immunoglobulin purification procedures such as ammonium sulfate precipitation, gel electrophoresis, dialysis, chromatography, and ultrafiltration, if desired. Undesired activity, if present, can be removed, for example, by passing through Petition 870250104631, dated 11 / 14 / 2025, pp. 253 / 355 96 / 147 preparation on adsorbents made of the immunogen bound to a solid phase and eluting or releasing the desired antibodies from the immunogen. Immunization of a host animal with cells expressing the target antibody (e.g., PD-1), a human target protein (e.g., PD-1), or a fragment containing the target amino acid sequence conjugated to an immunogenic protein in the species to be immunized, e.g., limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor, using a bifunctional or derivatizing agent, e.g., maleimidobenzoyl sulfosuccinimide ester (conjugation via cysteine ​​residues), N-hydroxysuccinimide (via lysine residues), glutaraldehyde, succinic anhydride, SOC, or R1N=C=NR, where R and R1 are different alkyl groups, can generate a population of antibodies (e.g., monoclonal antibodies).

[00255] If desired, the antibody (monoclonal or polyclonal) of interest can be sequenced and the polynucleotide sequence can then be cloned into a vector for expression or propagation. The sequence encoding the antibody of interest can be maintained in a vector within a host cell, which can then be expanded and frozen for future use. Production of recombinant monoclonal antibodies in cell culture can be accomplished by cloning antibody genes from B cells using methods known in the art. See, for example, Tiller et al., J. Immunol. Methods 329, 112, 2008; U.S. Patent No. 7,314,622.

[00256] In some respects, antibodies can be produced using hybridoma technology. It is considered that any mammalian individual, including humans or antibody-producing cells derived from them, can be manipulated to serve as a basis for the production of mammalian hybridoma cell lines, including humans. The route and immunization scheme of the host animal generally follow established and conventional techniques for antibody stimulation and production. Petition 870250104631, dated 11 / 14 / 2025, pp. 254 / 355 97 / 147 as further described in this document. Typically, the host animal is inoculated intraperitoneally, intramuscularly, orally, subcutaneously, intraplantarly and / or intradermally with an amount of immunogen, including as described in this document.

[00257] In some respects, the antibodies described in this document are glycosylated at conserved positions in their constant regions (Jefferis and Lund, 1997, Chem. Immunol. 65:111-128; Wright and Morrison, 1997, TibTECH 15:26-32). The oligosaccharide side chains of immunoglobulins affect protein function (Boyd et al., 1996, Mol. Immunol. 32:1311-1318; Wittwe and Howard, 1990, Biochem. 29:4175-4180) and the intramolecular interaction between parts of the glycoprotein, which can affect the conformation and the three-dimensional surface presented by the glycoprotein (Jefferis and Lund, supra; Wyss and Wagner, 1996, Current Opin. Biotech. 7:409-416). Oligosaccharides can also be used to target a specific glycoprotein or molecules based on specific recognition structures. Antibody glycosylation has also been reported as a factor affecting antibody-dependent cellular cytotoxicity (ADCC).In particular, antibodies produced by CHO cells with tetracycline-regulated expression of β(1,4)-N-acetylglucosaminyltransferase III (GnTIII), a glycosyltransferase that catalyzes the formation of GlcNAc bisector, showed enhanced ADCC activity (Umana et al., 1999, Nature Biotech. 17: 176-180).

[00258] Antibody glycosylation is typically of the N-linked or O-linked type. N-linked refers to the binding of the carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine, asparagine-X-threonine, and asparagine-X-cysteine, where X is any amino acid except proline, are the recognition sequences for the enzymatic binding of the carbohydrate moiety to the asparagine side chain. Thus, the presence of any of these tripeptide sequences in a Petition 870250104631, dated 11 / 14 / 2025, pp. 255 / 355 98 / 147 polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the linking of one of the sugars N-acetylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine can also be used.

[00259] The addition of glycosylation sites to the antibody is conveniently accomplished by altering the amino acid sequence so that it contains one or more of the tripeptide sequences described above (for N-linked glycosylation sites). The alteration can also be made by adding or replacing one or more serine or threonine residues to the original antibody sequence (for O-linked glycosylation sites).

[00260] The glycosylation pattern of antibodies can also be altered without the underlying nucleotide sequence being changed. Glycosylation largely depends on the host cell used to express the antibody. Since the cell type used for the expression of recombinant glycoproteins, for example, antibodies, as potential therapeutic agents, is rarely the native cell, variations in the glycosylation pattern of antibodies can be expected (see, for example, Hse et al., 1997, J. Biol. Chem. 272:9062-9070).

[00261] In addition to the choice of host cells, factors affecting glycosylation during recombinant antibody production include growth mode, culture medium formulation, culture density, oxygenation, pH, purification methods, and the like. Several methods have been proposed to alter the glycosylation pattern obtained in a given host organism, including the introduction or overexpression of certain enzymes involved in oligosaccharide production (U.S. Patents Nos. 5,047,335; 5,510,261 and 5,278,299). Glycosylation, or certain types of glycosylation, can be enzymatically removed from the glycoprotein, for example, using endoglucosidase H (Endo H), N-glucosidase F, endoglucosidase Petition 870250104631, dated 11 / 14 / 2025, pp. 256 / 355 99 / 147 F1, F2 endoglucosidase, and F3 endoglucosidase. Furthermore, the recombinant host cell can be genetically engineered to exhibit defects in the processing of certain types of polysaccharides. These and other similar techniques are well-known in the art.

[00262] Other modification methods include the use of coupling techniques known in the art, including, but not limited to, enzymatic means, oxidative substitution, and chelation. The modifications can be used, for example, for the binding of markers for immunoassay. The modified polypeptides are produced using procedures established in the art and can undergo screening using standard assays known in the art. V. Polynucleotides, Vectors and Host Cells

[00263] The disclosure also provides polynucleotides encoding any of the anti-TL1A antibodies as described herein. The polynucleotides can be produced and expressed by procedures known in the art.

[00264] In another aspect, the disclosure provides compositions (such as pharmaceutical compositions) comprising any of the polynucleotides of the disclosure, for use in one or more methods of the disclosure. In some aspects, the composition comprises an expression vector comprising a polynucleotide encoding any of the antiTL1A antibodies described herein, for use in one or more methods of the disclosure.

[00265] In another aspect, an isolated cell line that produces the anti-TL1A antibodies described in this document is provided for use in one or more methods of disclosure.

[00266] This disclosure also covers polynucleotides complementary to any of these sequences. Polynucleotides may Petition 870250104631, dated 11 / 14 / 2025, pp. 257 / 355 100 / 147 can be single-stranded (coding or antisense) or double-stranded, and can be DNA molecules (genomic, cDNA, or synthetic) or RNA. RNA molecules include HnRNA molecules, which contain introns and correspond to a DNA molecule in a one-to-one fashion, and mRNA molecules, which do not contain introns. Additional coding or non-coding sequences may, but do not necessarily, be present in a disclosure polynucleotide, and a polynucleotide may, but not necessarily, be linked to other molecules and / or support materials.

[00267] Polynucleotides may comprise a native sequence (i.e., an endogenous sequence encoding an antibody or a fragment thereof) or may comprise a variant of such a sequence. Polynucleotide variants contain one or more substitutions, additions, deletions, and / or insertions such that the immunoreactivity of the encoded polypeptide is not diminished relative to a native immunoreactive molecule. The effect on the immunoreactivity of the encoded polypeptide can generally be assessed as described herein. The variants preferably exhibit at least about 70% identity, more preferably at least about 80% identity, even more preferably at least about 90% identity, and most preferably at least about 95% identity with a polynucleotide sequence encoding a native antibody or a fragment thereof. VI. Compositions and Formulations A. Compositions

[00268] The disclosure also describes pharmaceutical compositions comprising an effective amount of an antiTL1A antibody, as described in this document, and such pharmaceutical compositions for use in treatment methods, as described in this document. Examples of such compositions, as well as the form of Petition 870250104631, dated 11 / 14 / 2025, pp. 258 / 355 101 / 147 formulations are also described in this document. It is understood that the compositions may contain more than one anti-TL1A antibody.

[00269] The composition used in the disclosure may additionally comprise pharmaceutically acceptable vehicles, excipients or stabilizers (Remington: The Science and Practice of Pharmacy, 20th ed., 2000, Lippincott Williams and Wilkins, ed. K.E. Hoover), in the form of lyophilized formulations or aqueous solutions.

[00270] Acceptable vehicles, excipients or stabilizers are not toxic to receptors at the indicated dosages and concentrations and may include buffers such as phosphate, citrate and other organic acids; antioxidants, including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzylammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkylparabens such as methylparaben or propylparaben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight polypeptides (less than about 10 residues); proteins, such as serum albumin, gelatin or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine or lysine; Monosaccharides, disaccharides and other carbohydrates, including glucose, mannose or dextrans; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol;Salt-forming counterions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or non-ionic surfactants such as TWEEN™, PLURONICS™, or polyethylene glycol (PEG). Pharmaceutically acceptable excipients are further described in this document.

[00271] The anti-TL1A antibody, and compositions thereof, may also be used in conjunction with, or administered separately, simultaneously or sequentially with, other agents that serve to increase and / or complement the efficacy of the agents. Petition 870250104631, dated 11 / 14 / 2025, pp. 259 / 355 102 / 147 B. Formulations

[00272] The therapeutic formulations of the anti-TL1A antibody used in accordance with this disclosure are prepared for storage by mixing the protein to the desired degree of purity with optional pharmaceutically acceptable vehicles, excipients or stabilizers (Remington, The Science and Practice of Pharmacy 20th Ed. Mack Publishing, 2000), in the form of lyophilized formulations or aqueous solutions. Acceptable vehicles, excipients or stabilizers are not toxic to receptors at the dosages and concentrations employed and may include buffers such as phosphate, citrate and other organic acids; salts such as sodium chloride; antioxidants, including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzylammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkylparabens, such as methylparaben or propylparaben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol);Low molecular weight polypeptides (less than about 10 residues); proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates, including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or nonionic surfactants such as TWEEN™, PLURONICS™, or polyethylene glycol (PEG).

[00273] Liposomes that may contain anti-TL1A antibody are prepared by methods known in the art, such as those described in Epstein et al., Proc. Natl. Acad. Sci. USA 82:3688 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA 77:4030 (1980); and in U.S. Patents Nos. 4,485,045 and 4,544,545. Liposomes with prolonged circulation time are described in Petition 870250104631, dated 11 / 14 / 2025, pp. 260 / 355 103 / 147 US Patent No. 5,013,556. Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derived phosphatidylethanolamine (PEG-PE). The liposomes are extruded through filters with pores of defined size to produce liposomes with the desired diameter.

[00274] Active ingredients can also be encapsulated in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, such as hydroxymethylcellulose or gelatin microcapsules and poly(methyl methacrylate) microcapsules, respectively, in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules) or in macroemulsions. Such techniques are described in Remington, The Science and Practice of Pharmacy, 20th ed. Mack Publishing (2000).

[00275] Sustained-release preparations can be made. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices can be in the form of molded articles, for example, films or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (e.g., poly(2-hydroxyethyl methacrylate) or poly(vinyl alcohol)), polylactides (U.S. Patent No. 3,773,919), L-glutamic acid and 7-ethyl-L-glutamate copolymers, non-degradable ethylene vinyl acetate, degradable lactic-glycolic acid copolymers such as LUPRON DEPOT™ (injectable microspheres composed of lactic-glycolic acid copolymer and leuprolide acetate), sucrose acetate isobutyrate, and poly-D-(-)-3-hydroxybutyric acid.

[00276] Formulations to be used for in vivo administration must be sterile. This is easily achieved, for example, by filtration through Petition 870250104631, dated 11 / 14 / 2025, pp. 261 / 355 104 / 147 sterile filtration membranes. Anti-TL1A antibody therapeutic compositions are generally packaged in a container with a sterile access port, for example, a bag or vial for intravenous solution with a cap that can be pierced with a hypodermic needle.

[00277] The compositions according to the disclosure may be in unit dosage forms, such as tablets, pills, capsules, powders, granules, solutions or suspensions, or suppositories, for oral, parenteral or rectal administration, or administration by inhalation or insufflation.

[00278] For the preparation of solid compositions, such as tablets, the main active ingredient is mixed with a pharmaceutical vehicle, for example, conventional ingredients for tablet compression, such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, for example, water, to form a preformulation solid composition containing a homogeneous mixture of a disclosure compound, or a pharmaceutically acceptable and non-toxic salt thereof. When we refer to these preformulation compositions as homogeneous, we understand that the active ingredient is uniformly dispersed throughout the composition, so that the composition can be easily subdivided into equally effective unit dosage forms, such as tablets, pills and capsules.This solid pre-formulation composition is then subdivided into unit dosage forms of the type described above, containing from about 0.1 to about 500 mg of the active ingredient of the present disclosure. The tablets or pills of the new composition may be coated or otherwise formulated to provide a dosage form that offers the advantage of prolonged action. For example, a tablet or pill may consist of an inner dosage and an outer dosage, the latter in the form of an envelope over the former. The two components may be separated by a layer. Petition 870250104631, dated 11 / 14 / 2025, pp. 262 / 355 105 / 147 enteric coating that serves to resist disintegration in the stomach and allows the internal component to pass intact into the duodenum or to delay its release. A variety of materials can be used for these enteric layers or coatings, including various polymeric acids and mixtures of polymeric acids with materials such as shellac, cetyl alcohol, and cellulose acetate.

[00279] Suitable surfactants include, in particular, non-ionic agents such as polyoxyethylene sorbitans (e.g., Tween™ 20, 40, 60, 80 or 85) and other sorbitans (e.g., Span™ 20, 40, 60, 80 or 85). Compositions with a surfactant generally contain between 0.05% and 5% surfactant, but may vary between 0.1% and 2.5%. Other ingredients may be added, such as mannitol or other pharmaceutically acceptable carriers, if necessary.

[00280] Suitable emulsions can be prepared using commercially available lipid emulsions such as INTRALIPID™, LIPOSYN™, INFONUTROL™, LIPOFUNDIN™ and LIPIPHYSAN™. The active ingredient can be dissolved in a premixed emulsion composition or, alternatively, it can be dissolved in an oil (e.g., soybean oil, safflower oil, cottonseed oil, sesame oil, corn oil or almond oil) and an emulsion formed by mixing with a phospholipid (e.g., egg phospholipids, soy phospholipids or soy lecithin) and water. It should be noted that other ingredients may be added, e.g., glycerol or glucose, to adjust the tonicity of the emulsion.

[00281] Suitable emulsions typically contain up to 20% oil, for example, between 5 and 20%. The fat emulsion may contain fat droplets between 0.1 and 1.0 pm, particularly between 0.1 and 0.5 pm, and have a pH in the range of 5.5 to 8.0.

[00282] Emulsion compositions can be prepared by Petition 870250104631, dated 11 / 14 / 2025, pp. 263 / 355 106 / 147 mixture of an anti-TL1A antibody with Intralipid™ or components thereof (soybean oil, egg phospholipids, glycerol and water).

[00283] Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable aqueous or organic solvents, or mixtures thereof, and powders. Liquid or solid compositions may contain suitable pharmaceutically acceptable excipients, as described above. In some respects, the compositions are administered orally or nasally for local or systemic effect. Compositions in pharmaceutically acceptable solvents, preferably sterile, may be nebulized using gases. Nebulized solutions may be inhaled directly from the nebulizing device, or the nebulizing device may be attached to a face mask, tent, or intermittent positive pressure breathing apparatus. Compositions in solution, suspension, or powder may be administered, preferably orally or nasally, through devices that deliver the formulation appropriately.

[00284] In aspects relating to a method of treating IBD as described herein, such aspects are also additional aspects relating to an anti-TL1A antibody for use in that treatment, or alternatively, to the use of an anti-TL1A antibody in the manufacture of a medicament for use in that treatment. VII. General Techniques

[00285] Unless otherwise indicated, the practice of the present disclosure employs conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry, and immunology, which are within the art. Such techniques are explained in detail in the literature, such as in: Molecular Cloning: A Laboratory Manual, second edition (Sambrook et al., 1989) Cold Spring Harbor Press; Oligonucleotide Synthesis (MJ Gait, ed., 1984); Methods in Molecular Biology, Humana Press; Cell Petition 870250104631, dated 11 / 14 / 2025, pp. 264 / 355 107 / 147 Biology: A Laboratory Notebook (J.E. Cellis, ed., 1998) Academic Press; Animal Cell Culture (R.l. Freshney, ed., 1987); Introduction to Cell and Tissue Culture (J.P. Mather e P.E. Roberts, 1998) Plenum Press; Cell and Tissue Culture: Laboratory Procedures (A. Doyle, J.B. Griffiths, e D.G. Newell, eds., 1993-1998) J. Wiley e Sons; Methods in Enzymology (Academic Press, Inc.); Handbook of Experimental Immunology (D.M. Weir e C.C. Blackwell, eds.); Gene Transfer Vectors for Mammalian Cells (J.M. Miller e M.P. Calos, eds., 1987); Current Protocols in Molecular Biology (F.M. Ausubel et al., eds., 1987); PCR: The Polymerase Chain Reaction, (Mullis et al., eds., 1994); Current Protocols in Immunology (J.E. Coligan et al., eds., 1991); Short Protocols in Molecular Biology (Wley e Sons, 1999); Immunobiology (C.A. Janeway e P. Travers, 1997); Antibodies (P. Finch, 1997); Antibodies: a practical approach (D. Catty., ed., IRL Press, 1988-1989); Monoclonal antibodies: a practical approach (P.Shepherd and C. Dean, eds., Oxford University Press, 2000); Using Antibodies: A Laboratory Handbook (E. Harlow and D. Lane (Cold Spring Harbor Laboratory Press, 1999); The Antibodies (M. Zanetti and J.D. Capra, eds., Harwood Academic Publishers, 1995). VIII. Definitions

[00286] The following terms, unless otherwise indicated, should be understood as having the following meanings: As used in this document, “afimkibart” (also known as RO7790121, RVT-3101 or PF-06480605) is an antibody that binds to the TNF-like 1A (TL1A) tumor necrosis factor (TNF) superfamily protein and comprises the heavy chain sequence of SEQ ID NO: 9 and the light chain sequence of SEQ ID NO: 10; An “antibody” is an immunoglobulin molecule capable of specifically binding to a target, such as a carbohydrate, polynucleotide, lipid, polypeptide, etc., through at least one recognition site. Petition 870250104631, dated 11 / 14 / 2025, pp. 265 / 355 108 / 147 antigen, located in the variable region of the immunoglobulin molecule. As used in this document, the term encompasses not only intact polyclonal or monoclonal antibodies, but also, unless otherwise indicated, any antigen-binding portion thereof that competes with the intact antibody for specific binding, fusion proteins comprising an antigen-binding portion, and any other modified configuration of the immunoglobulin molecule comprising an antigen recognition site.Antigen-binding parts include, for example, Fab, Fab', F(ab')2, Fd, Fv, domain antibodies (dAbs, e.g., shark and camelid antibodies), fragments including complementarity-determining regions (CDRs), single-chain variable fragment antibodies (scFv), maxibodies, minibodies, intrabodies, diabodies, triabodies, tetrabodies, v-NAR and bis-scFv, and polypeptides containing at least one part of an immunoglobulin sufficient to confer specific antigen binding to the polypeptide. An antibody includes an antibody of any class, such as IgG, IgA, or IgM (or a subclass thereof), and the antibody does not need to be of a specific class. Depending on the amino acid sequence of the antibody's constant region of its heavy chains, immunoglobulins can be classified into different classes.There are five main classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these can be further subdivided into subclasses (isotypes), for example IgGi, IgG2, IgG3, IgG4, IgAi, and IgA2. The constant regions of the heavy chain that correspond to the different classes of immunoglobulins are called alpha, delta, epsilon, gamma, and mu, respectively. The subunit structures and three-dimensional configurations of the different classes of immunoglobulins are well known. An antibody's "variable region" refers to the antibody's light chain variable region or the antibody's heavy chain variable region. Petition 870250104631, dated 11 / 14 / 2025, pp. 266 / 355 109 / 147 individually or in combination. As is known in the art, the variable regions of the heavy and light chains consist of four structure regions (FRs) connected by three complementarity-determining regions (CDRs), also known as hypervariable regions, and contribute to the formation of the antigen-binding site of antibodies. If variants of a given variable region are desired, particularly with substitution at amino acid residues outside a CDR region (i.e., in the structure region), the appropriate amino acid substitution, preferably conservative, can be identified by comparing the variable region in question with the variable regions of other antibodies containing CDR1 and CDR2 sequences in the same canonical class as the variable region in question (Chothia and Lesk, J Mol Biol 196(4): 901-917, 1987).

[00287] In some respects, the definitive delimitation of a CDR and the identification of the residues that make up the antibody binding site are achieved by resolving the antibody structure and / or the structure of the antibody-ligand complex. In some respects, this can be achieved through various techniques known to those skilled in the art, such as X-ray crystallography. In other respects, various analytical methods can be employed to identify or approximate CDR regions. Examples of such methods include, but are not limited to, the Kabat definition, the Chothia definition, the AbM definition, the contact definition, and the conformational definition.

[00288] The Kabat definition is a standard for numbering residues in an antibody and is typically used to identify CDR regions. See, for example, Johnson & Wu, 2000, Nucleic Acids Res., 28: 214-8. The Chothia definition is similar to the Kabat definition, but the Chothia definition takes into account the positions of certain structural loop regions. Petition 870250104631, dated 11 / 14 / 2025, pp. 267 / 355 110 / 147 See, for example, Chothia et al., 1986, J. Mol. Biol., 196: 901-17; Chothia et al., 1989, Nature, 342: 877-83. The AbM definition uses an integrated set of computer programs produced by the Oxford Molecular Group that model the structure of antibodies. See, for example, Martin et al., 1989, Proc Natl Acad Sci (USA), 86:9268-9272; “AbM™, A Computer Program for Modeling Variable Regions of Antibodies”, Oxford, UK.

[00289] Oxford Molecular, Ltd. The AbM definition models the tertiary structure of an antibody from the primary sequence using a combination of knowledge databases and ab initio methods, such as those described by Samudrala et al., 1999, “Ab Initio Protein Structure Prediction Using a Combined Hierarchical Approach”, in PROTEINS, Structure, Function and Genetics Suppl., 3:194-198. The contact definition is based on an analysis of available complex crystal structures. See, for example, MacCallum et al., 1996, J. Mol. Biol., 5:732-45. In another approach, referred to in this document as the “conformational definition” of CDRs, the positions of the CDRs can be identified as the residues that make enthalpic contributions to antigen binding. See, for example, Makabe et al., 2008, Journal of Biological Chemistry, 283:1156-1166.Other definitions of CDR boundaries may not strictly follow one of the above approaches, but will still overlap with at least some of Kabat's CDRs, although they may be shortened or lengthened in light of predictions or experimental findings that certain residues or groups of residues do not significantly impact antigen binding. As used herein, a CDR may refer to CDRs defined by any approach known in the art, including combinations of approaches. The methods used herein may utilize CDRs defined according to any of these approaches. For any specific embodiment containing more than one CDR, the CDRs may be defined accordingly. Petition 870250104631, dated 11 / 14 / 2025, pp. 268 / 355 111 / 147 any of the definitions of Kabat, Chothia, extended, AbM, contact and / or conformal.

[00290] As is known in the art, a “constant region” of an antibody refers to the constant region of the antibody light chain or the constant region of the antibody heavy chain, alone or in combination.

[00291] As used in this document, “monoclonal antibody” refers to an antibody obtained from a substantially homogeneous population of antibodies, that is, the individual antibodies comprising the population are identical except for possible natural mutations that may be present in minor quantities. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, unlike polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. The monoclonal modifier indicates the characteristic of the antibody as being obtained from a substantially homogeneous population of antibodies and should not be interpreted as requiring the production of the antibody by any specific method.For example, the monoclonal antibodies to be used in accordance with this disclosure may be produced by the hybridoma method initially described by Kohler and Milstein, 1975, Nature 256:495, or may be produced by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. Monoclonal antibodies may also be isolated from phage libraries generated using the techniques described in McCafferty et al., 1990, Nature 348:552-554, for example.

[00292] As is known in the field, “polynucleotide” or “nucleic acid,” used interchangeably in this document, refer to chains Petition 870250104631, dated 11 / 14 / 2025, pp. 269 / 355 112 / 147 of nucleotides of any length, including DNA and RNA. Nucleotides may be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases and / or their analogues, or any substrate that can be incorporated into a chain by DNA or RNA polymerase. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and their analogues. If present, the modification to the nucleotide structure may be introduced before or after chain assembly. The nucleotide sequence may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, for example, by conjugation with a labeling component.Other types of modifications include, for example, caps, substitution of one or more naturally occurring nucleotides by an analog, internucleotide modifications, such as those with uncharged bonds (e.g., methylphosphonates, phosphotriesters, phosphoamidates, carbamates, etc.) and with charged bonds (e.g., phosphorothioates, phosphorodithioates, etc.), those containing pendant portions, such as proteins (e.g., nucleases, toxins, antibodies, signaling peptides, poly-L-lysine, etc.), those with intercalators (e.g., acridine, psoralen, etc.), those containing chelating agents (e.g., metals, radioactive metals, boron, oxidizing metals, etc.), those containing alkylating agents, those with modified bonds (e.g., alpha anomeric nucleic acids, etc.), as well as unmodified forms of the polynucleotide(s).Additionally, any of the hydroxyl groups normally present in sugars can be replaced, for example, by phosphonate groups, phosphate groups, protected by standard protecting groups, or activated to prepare additional linkages with additional nucleotides, or it can be conjugated to solid supports. The 5' and 3' OH terminus can be phosphorylated or replaced by amines or organic protecting moieties of 1 to 20 carbon atoms. Other hydroxyl groups. Petition 870250104631, dated 11 / 14 / 2025, pp. 270 / 355 113 / 147 can also be derived with standard protecting groups. Polynucleotides may also contain analogous forms of ribose or deoxyribose sugars generally known in the art, including, for example, 2'-O-methyl-, 2'-O-allyl, 2'-fluoro- or 2'-azido-ribose, analogs of carbocyclic sugars, alpha or beta anomeric sugars, epimeric sugars such as arabinose, xyloses or lycoses, pyranose sugars, furanose sugars, sedoheptuloses, acyclic analogs and analogs of abasic nucleosides, such as methyl riboside. One or more phosphodiester linkages may be replaced by alternative linking groups.These alternative linkage groups include, but are not limited to, aspects in which the phosphate is replaced by P(O)S (“thioate”), P(S)S (“dithioate”), (O)NR2 (“amidate”), P(O)R, P(O)OR', CO or CH2 (“formacetal”), wherein each R or R' is independently H or substituted or unsubstituted alkyl (1-20 C), optionally containing an ether (-O-), aryl, alkenyl, cycloalkyl, cycloalkenyl or araldyl linkage. Not all linkages in a polynucleotide need be identical. The foregoing description applies to all polynucleotides mentioned herein, including RNA and DNA.

[00293] An antibody that “binds preferentially” or “binds specifically” (used interchangeably in this document) to an epitope is a well-understood term in the art, and the methods for determining such specific or preferential binding are also well known in the art. A molecule is said to exhibit “specific binding” or “preferential binding” if it reacts or associates more frequently, more rapidly, for a longer duration, and / or with greater affinity to a particular cell or substance than to other cells or substances. An antibody “binds specifically” or “binds preferentially” to a target if it binds with greater affinity, avidity, more readily, and / or for a longer duration than it binds to other substances. For example, an antibody that binds specifically or preferentially to a target epitope (e.g., TL1A) is an antibody that binds to that epitope with Petition 870250104631, dated 11 / 14 / 2025, pp. 271 / 355 114 / 147 greater affinity, avidity, more easily and / or with greater duration than it binds to other target epitopes or non-target epitopes. When reading this definition, it is also understood that, for example, an antibody (or portion or epitope) that binds specifically or preferentially to a first target may or may not bind specifically or preferentially to a second target. Thus, “specific binding” or “preferential binding” does not necessarily require (although it may include) exclusive binding. Generally, but not necessarily, the reference to binding means preferential binding.

[00294] As used in this document, “substantially pure” refers to material with a purity of at least 50% (i.e., free from contaminants), more preferably with a purity of at least 90%, more preferably with a purity of at least 95%, even more preferably with a purity of at least 98%, and most preferably with a purity of at least 99%.

[00295] A “host cell” includes an individual cell or cell culture that may be or has been a recipient of vector(s) for the incorporation of polynucleotide inserts. Host cells include the progeny of a single host cell, and the progeny may not necessarily be completely identical (in morphology or in complement of genomic DNA) to the original parent cell due to natural, accidental, or deliberate mutation. A host cell includes cells transfected in vivo with one or more polynucleotide(s) of this disclosure.

[00296] As is known in the art, the term “Fc region” is used to define a C-terminal region of an immunoglobulin heavy chain. The “Fc region” can be a native sequence Fc region or a variant Fc region. Although the boundaries of the Fc region of an immunoglobulin heavy chain may vary, the human IgG heavy chain Fc region is generally defined as extending from an amino acid residue in Petition 870250104631, dated 11 / 14 / 2025, pp. 272 / 355 115 / 147 position Cys226, or Pro230, to the carboxyl-terminal of the same. The numbering of residues in the Fc region follows the EU index, as described in Kabat. Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991. The Fc region of an immunoglobulin generally comprises two constant domains, CH2 and CH3. As is known in the art, an Fc region can be present in dimeric or monomeric form.

[00297] As used in the technique, Fc receptor and FcR describe a receptor that binds to the Fc region of an antibody. The preferred FcR is a native human sequence FcR. In addition, a preferred FcR is one that binds to an IgG antibody (a gamma receptor) and includes receptors of the FcyRI, FcyRII, and FcyRIII subclasses, including allele variants and alternative splicing forms of these receptors. FcyRII receptors include FcyRIIA (an activator receptor) and FcyRIIB (an inhibitor receptor), which have similar amino acid sequences that differ primarily in cytoplasmic domains. FcRs are reviewed in Ravetch and Kinet, 1991, Ann. Rev. Immunol., 9:457-92; Capel et al., 1994, Immunomethods, 4:25-34; and de Haas et al., 1995, J. Lab. Clin. Med., 126:330-41. “FcR” also includes the neonatal receptor, FcRn, which is responsible for the transfer of maternal IgGs to the fetus (Guyer et al., 1976, J. Immunol., 117:587; and Kim et al., 1994, J. Immunol., 24:249).

[00298] The term “compete,” as used in this document in relation to an antibody, means that a first antibody, or an antigen-binding portion thereof, binds to an epitope in a manner sufficiently similar to the binding of a second antibody, or an antigen-binding portion thereof, such that the result of the binding of the first antibody to its cognate epitope is detectably reduced in the presence of the second antibody compared with the binding of the first. Petition 870250104631, dated 11 / 14 / 2025, pp. 273 / 355 116 / 147 antibody in the absence of the second antibody. The alternative, in which the binding of the second antibody to its epitope is also detectably reduced in the presence of the first antibody, may, but does not necessarily, occur. That is, a first antibody may inhibit the binding of a second antibody to its epitope without that second antibody inhibiting the binding of the first antibody to its respective epitope. However, when each antibody detectably inhibits the binding of the other antibody to its epitope or cognate ligand, to the same, greater or lesser extent, the antibodies are said to cross-compete for binding to their respective epitope(s). Both competing and cross-competing antibodies are covered in this disclosure.Regardless of the mechanism by which such competition or cross-competition occurs (e.g., steric hindrance, conformational change, or binding to a common epitope or part thereof), those skilled in the art will understand, based on the teachings provided in this document, that such competing and / or cross-competing antibodies are covered and may be useful for the methods disclosed in this document.

[00299] As used in this document, treatment refers to an approach to achieve beneficial or desired clinical outcomes. For the purposes of this disclosure, beneficial or desired clinical outcomes include the reduction or improvement of signs and symptoms of inflammatory bowel disease (IBD) (e.g., ulcerative colitis (UC) or Crohn's disease (CD)), for example, compared to the period prior to administration of the anti-TL1A antibody.

[00300] Improvement means a decrease or improvement in one or more signs or symptoms of IBD (e.g., UC or CD), for example, compared to not administering an anti-TL1A antibody as described herein. Improvement also includes a reduction or Petition 870250104631, dated 11 / 14 / 2025, pp. 274 / 355 117 / 147 decrease in the duration of a symptom.

[00301] As used in this document, an “effective dose” or “effective amount” of a drug, compound, or pharmaceutical composition is an amount sufficient to produce one or more beneficial or desired outcomes. More specifically, an effective amount prevents, alleviates, or improves the signs or symptoms of IBD and / or prolongs the survival of the individual undergoing treatment. For prophylactic use, beneficial or desired outcomes include eliminating or reducing the risk, decreasing the severity, or delaying the onset of the disease, including biochemical, histological, and / or behavioral symptoms of the disease, its complications, and intermediate pathological phenotypes that present during the development of the disease.For therapeutic use, beneficial or desired outcomes include clinical results such as the reduction of one or more signs or symptoms of IBD, the decrease in the dose of other medications needed to treat the disease, the increase in the effect of another medication, and / or the delay in disease progression in patients. An effective dosage may be administered in one or more administrations. For the purposes of this disclosure, an effective dosage of a drug, compound, or pharmaceutical composition is an amount sufficient to achieve prophylactic or therapeutic treatment, directly or indirectly. As understood in the clinical context, an effective dosage of a drug, compound, or pharmaceutical composition may or may not be achieved in conjunction with another drug, compound, or pharmaceutical composition.Thus, an “effective dosage” can be considered in the context of administering one or more therapeutic agents, and a single agent can be considered administered in an effective quantity if, in conjunction with one or more other agents, a desirable result can be or is achieved.

[00302] The treatment “effectively improves” or “effectively reduces” when the assessment of the sign or symptom of IBD is quantified by Petition 870250104631, dated 11 / 14 / 2025, pp. 275 / 355 118 / 147 The mean of a clinical measure in relation to baseline and during and / or after the treatment period. The difference between the clinical measure at baseline and during / after treatment is compared and used to determine if the sign or symptom has improved and if the treatment is effective. This comparison may include comparison with placebo or with one or more prior therapies.

[00303] The term “mucosal healing” refers to an endoscopic Mayo subscore of 0 or 1 and a histological Geboes score of 0 or 1. Aranzazu, JE., et al. Journal of Crohn's and Colitis, Volume 11(3), 2017, 305-313. In one aspect, mucosal healing was defined as endoscopic improvement + histological improvement (endoscopic Mayo subscore <= 1 and Geboes <= 3.1). Histological Improvement was defined as <5% neutrophil involvement in the epithelial crypts (Geboes <= 3.1). Histological Remission was defined as absence of crypt involvement in the epithelium (Geboes < 2).

[00304] In this document, effective amount refers to the amount of a therapeutic agent (e.g., an anti-TL1A antibody (e.g., RO7790121) or a combination of therapeutic agents (e.g., an anti-TL1A antibody and one or more additional therapeutic agents)) that produces a therapeutic result. In some examples, the effective amount of a therapeutic agent or a combination of therapeutic agents is the amount of the agent or combination of agents that achieves a clinical outcome of clinical remission, clinical response (e.g., improvement in modified Mayo score (mMS) or partially modified Mayo score (pmMS)), endoscopic improvement, endoscopic remission, mucosal histological-endoscopic improvement, histological-endoscopic remission, and / or corticosteroid-free remission.The improvement (e.g., in terms of clinical remission) may be related to appropriate reference treatment, for example, a treatment that does not include the anti-TL1A antibody. Petition 870250104631, dated 11 / 14 / 2025, pp. 276 / 355 119 / 147

[00305] As used in this document, the term “induction phase” refers to a series of one or more doses or dosing cycles (e.g., approximately 2 to 6 doses or dosing cycles) of one or more therapeutic agents (e.g., an anti-TL1A antibody (e.g., RO7790121)) administered to an individual, wherein one or more doses or dosing cycles are optionally followed by a maintenance phase.

[00306] The term “maintenance phase,” as used in this document, refers to a series of one or more doses or dosing cycles of one or more therapeutic agents (e.g., an anti-TL1A antibody (e.g., RO7790121)) that are administered to an individual following an induction phase, without any relevant intervening surgery (i.e., no intervening surgery related to the disease or condition intended to be treated with the one or more therapeutic agents). In some respects, the maintenance phase is initiated only if the individual does not experience disease progression or unacceptable toxicity during the induction phase. The induction phase and the maintenance phase may or may not involve the use of the same therapeutic agents.

[00307] The terms “patient”, “individual” or “guinea pig”, used interchangeably in this document, refer to a mammal, most preferably a human being. Mammals also include, but are not limited to, farm animals (e.g., cows, pigs, horses, chickens, etc.), sport animals, pets, primates, horses, dogs, cats, mice and rats.

[00308] As used in this document, “pharmaceutically acceptable vehicle” or “pharmaceutically acceptable excipient” includes any material that, when combined with an active ingredient, allows the ingredient to maintain its biological activity and not react with the individual’s immune system. Examples include, but are not limited to, any Petition 870250104631, dated 11 / 14 / 2025, pp. 277 / 355 120 / 147 of standard pharmaceutical vehicles, such as phosphate-buffered saline, water, emulsions such as oil-in-water emulsion, and various types of wetting agents. The preferred diluents for aerosol or parenteral administration are phosphate-buffered saline (PBS) or normal saline (0.9%). Compositions that include these vehicles are formulated by well-known conventional methods (see, for example, Remington's Pharmaceutical Sciences, 18th edition, A. Gennaro, ed., Mack Publishing Co., Easton, PA, 1990; and Remington, The Science and Practice of Pharmacy, 20th ed., Mack Publishing, 2000).

[00309] The reference to about a value or parameter in this document includes (and describes) aspects that relate to that value or parameter itself. For example, the description that refers to about X includes the description of X. Numerical ranges include the numbers that define the range. In general, the term about refers to the stated value of the variable and to all values ​​of the variable that are within the experimental margin of error of the stated value (e.g., within the 95% confidence interval for the mean) or within 10% of the stated value, whichever is greater. When the term about is used in the context of a period of time (years, months, weeks, days, etc.), the term about means that period of time plus or minus a value of the immediately lower period of time (e.g., approximately 1 year means 11 to 13 months; approximately 6 months means 6 months plus or minus 1 week; approximately 1 week means 6 to 8 days; etc.).), or within 10% of the indicated value, whichever is greater.

[00310] The term “subcutaneous administration” refers to the administration of a substance into the subcutaneous layer.

[00311] The term “prevent” or “impede” refers to (a) preventing the occurrence of a disorder or (b) delaying the onset of a disorder or the onset of symptoms of a disorder. Petition 870250104631, dated 11 / 14 / 2025, pp. 278 / 355 121 / 147

[00312] It is understood that, whenever aspects are described in this document using the language “including”, analogous aspects described in terms of “consisting of” and / or “consisting essentially of” will also be provided.

[00313] When aspects or features of the disclosure are described in terms of a Markush group or other grouping of alternatives, this disclosure covers not only the entire group listed as a whole, but each member of the group individually and all possible subgroups of the main group, as well as the main group in the absence of one or more members. This disclosure also provides for the explicit exclusion of one or more of the group members in the claimed disclosure.

[00314] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as is commonly understood by a person skilled in the art to which this disclosure pertains. In case of conflict, this descriptive report, including the definitions, shall prevail. Throughout this descriptive report and claims, the word "include," or variations such as "includes" or "comprising," shall be understood as implying the inclusion of a specified integer or group of integers, but not the exclusion of any other integer or group of integers. Unless otherwise required by the context, singular terms include plural terms and plural terms include singular terms. The example(s) following the term "for example" shall not be considered exhaustive or limiting.

[00315] Illustrative methods and materials are described herein, although similar or equivalent methods and materials may also be used in practice or in testing the disclosure. The materials, methods and examples are for illustrative purposes only and should not be considered limiting. Petition 870250104631, dated 11 / 14 / 2025, pp. 279 / 355 122 / 147 IX. Examples Example 1. TNFSF15 haplotype SNP combinations

[00316] In this experiment, a computational algorithm was developed to determine, based on DNA sequencing data (e.g., genomic sequencing data), whether an individual is a carrier for a TNFSF15 haplotype that is haplotype B (i.e., whether an individual is a haplotype B carrier) based on a selected number of single nucleotide polymorphisms (SNPs).

[00317] As shown in Figure 1, haplotype B is defined as a TNFSF15 gene region that has the nucleotides T / C / A / T / C at positions 15,524; 9,706; -358; -638; and -12,506, respectively, based on the GenBank reference sequence NM_005118.2, where the first nucleotide of the exon 1 start site is designated as position 1 (haplotype positions 26 / 31 / 35 / 36 / 41, respectively, as provided in Yamazaki et al., Human Molecular Genetics, 14(22): 3499-3506, 2005), in the TNFSF15 gene region, which encodes the TL1A gene (Table 3). An individual is identified as haplotype B if the individual is heterozygous or homozygous for haplotype B, that is, one or both copies of the gene region are of haplotype B (i.e., one or both TNFSF15 gene regions have the nucleotides T / C / A / T / C at the haplotype positions 15,524; 9,706; -358; 638; and -12,506 (26 / 31 / 35 / 36 / 41)).

[00318] The haplotype positions 15,524; 9,706; -358; -638; and 12,506 (26, 31, 35, 36, and 41) correspond to the SNP sites rs3810936, rs6478108, rs6478109, rs7848647, and rs7869487, respectively, as identified in the NIH NCBI dbSNP database (see Table 3). The B haplotype comprises the reference nucleotide at each of these positions: therefore, a TNFSF15 B haplotype of the gene region can be identified by the absence of each of the SNPs rs3810936, rs6478108, Petition 870250104631, dated 11 / 14 / 2025, pp. 280 / 355 123 / 147 rs6478109, rs7848647 and rs7869487 (i.e., the presence of the wild-type allele at each of these sites).

[00319] Non-vehicle individuals with haplotype B are defined as individuals who do not possess a TNFSF15 haplotype B gene region. For example, a non-vehicle individual with haplotype B may be homozygous for a non-haplotype B allele, for example, haplotype A, as shown in Figure 1 (Michelsen et al., PLoS One, 4(3): e4719, 2009) (for example, it may have the nucleotides C / T / G / C / T at haplotype positions 26 / 31 / 35 / 36 / 41). Table 3. SNPs of interest in the TNFSF15 gene region SNP Position number according to Yamazaki et al., 2005 Position number relative to GenBank NM_005118.2, where the first nucleotide of the exon 1 start site is designated as position 1 NIH Reference SNP identifier (rs) Position in the hg38 version of the human genome Reference nucleotide snp B haplotype nucleotide SNP 1 26 15.524 rs3810936 chr9:114790605 t C t SNP 2 31 9.706 rs6478108 chr9:114796423 CG or TC SNP 3 35 -358 rs6478109 chr9:114806486 AGA SNP 4 36 -638 rs7848647 chr9:114806766 t C t SNP 5 41 -12,506 rs7869487 chr9:114818634 C t C

[00320] In the development of the algorithm, different combinations of five SNP sites, rs3810936 (SNP 1), rs6478108 (SNP 2), rs6478109 (SNP 3), rs7848647 (SNP 4), and rs7869487 (SNP 5), including all viable combinations of 2, 3, and 4 SNPs selected from SNP 1, SNP 2, SNP 3, SNP 4, and SNP 5, were used to determine whether an individual was a haplotype B carrier or a non-haplotype B carrier. An individual was defined as a non-haplotype B carrier if both copies of the gene region corresponding to either Petition 870250104631, dated 11 / 14 / 2025, pp. 281 / 355 124 / 147 one of the five SNP sites did not contain the nucleotide corresponding to the B haplotype nucleotide at that SNP site, for example, CC / TT / GG / CC / TT in SNP1-SNP5. For each SNP combination, if the first SNP site of the tested combination was of a haplotype different from haplotype B in both copies of the gene region (i.e., referred to hereafter as “Not homozygous for haplotype B”), then the individual was considered a non-carrier of haplotype B. If the first SNP site of the tested combination was homozygous or heterozygous for haplotype B (i.e., if one or both copies of the gene region corresponding to the SNP site contained the nucleotide corresponding to the haplotype B nucleotide at the SNP site), the next SNP site in the combination was tested until an SNP site was determined to be Not homozygous for haplotype B, in which case the individual was considered a non-carrier of haplotype B, or until all SNP sites in the combination were tested.If no SNP site was determined to be non-homozygous for haplotype B, the individual was considered a carrier of haplotype B. The final step of this algorithm was where misclassifications could occur. Therefore, testing all SNP combinations allowed determining which SNP combination produced the fewest misclassifications.

[00321] Iterations of the algorithm, comprising different combinations of SNPs, were applied to genomic sequence data (a total of 2504 individuals) from the 1000 Genomes Project (Sudmant et al., Nature 526, 75-81 (2015)), and the rates of true positives, true negatives, false positives, and false negatives were determined for each SNP combination in order to determine the ideal combination of SNPs that can effectively identify haplotype B vehicles and non-haplotype B vehicles. As shown in Table 4, the combination of SNP 1 (rs3810936) and SNP 5 (rs7869487) showed the highest accuracy among the various combinations of two Petition 870250104631, dated 11 / 14 / 2025, pp. 282 / 355 125 / 147 SNP, and the accuracy rate is comparable to the best-performing combinations of three SNP sites and four SNP sites. Table 4. Precision of SNP combinations in determining whether a INDIVIDUAL IS A VEHICLE OF TNFSF15 HAPLOTYPE B (DATA FROM THE GENOME PROJECT) 1000) SNP Combination True Positive True Negative False Positive False Negative Correct Number Incorrect Number Correct Percentage Incorrect Percentage (1, 2) 1444 889 0 171 2333 171 0.931709265 0.068290735 (1, 3) 1456 889 0 159 2345 159 0.936501597 0.063498403 (1, 4) 1455 889 0 160 2344 160 0.936102236 0.063897764 (1, 5) 1595 889 0 20 2484 20 0.99201278 0.00798722 (2, 1) 1444 889 0 171 2333 171 0.931709265 0.068290735 (2, 3) 1368 889 0 247 2257 247 0.901357827 0.098642173 (2, 4) 1365 889 0 250 2254 250 0.900159744 0.099840256 (5, 3, 2) 1533 889 0 82 2422 82 0.967252396 0.032747604 (5, 3, 4) 1534 889 0 81 2423 81 0.967651757 0.032348243 (5, 4, 1) 1603 889 0 12 2492 12 0.995207668 0.004792332 (5, 4, 2) 1533 889 0 82 2422 82 0.967252396 0.032747604 (5, 4, 3) 1534 889 0 81 2423 81 0.967651757 0.032348243 (1, 2, 3, 4) 1456 889 0 159 2345 159 0.936501597 0.063498403 (1, 2, 3, 5) 1604 889 0 11 2493 11 0.995607029 0.004392971 (1, 2, 4, 3) 1456 889 0 159 2345 159 0.936501597 0,063498403 (1, 2, 4, 5) 1603 889 0 12 2492 12 0.995207668 0.004792332 (1, 2, 5, 3) 1604 889 0 11 2493 11 0.995607029 0.004392971

[00322] The algorithm was additionally applied to genomic sequence data (a total of 4151 samples, with 2501 samples overlapping with the Genomes 1000 Project) from the Genome Diversity Project. Petition 870250104631, dated 11 / 14 / 2025, pp. 283 / 355 126 / 147 Human (Bergstrom et al., Science 367 (6484), eaay5012 (2020)). The Human Genome Diversity Project data were not phased, unlike the Genomes 1000 data, and individuals incorrectly classified in the overlapping dataset have different truth values ​​due to the lack of phasing. Table 5 shows the results of the analysis from the Human Genome Diversity Project. Notably, the combination of three SNP sites, SNP1 (rs3810936), SNP 3 (rs6478109), and SNP 5 (rs7869487), resulted in 0 incorrect classifications. Table 6 shows the accuracy rates for certain combinations of SNP sites evaluated using the Human Genome Diversity Project. Table 5. Precision of SNP combinations in determining whether an individual is a TNFSF15 HAPLOTYPE B VEHICLE (DATA FROM THE DIVERSITY PROJECT OF Human Genome SNP Combination True Positive True Negative False Positive False Negative Correct Number Incorrect Number Correct Percentage Incorrect Percentage (1,2) 2408 1470 0 273 3878 273 0.934232715 0.065767285 (1,3) 2425 1470 0 256 3895 256 0.938328114 0.061671886 (1,4) 2425 1470 0 256 3895 256 0.938328114 0.061671886 (1,5) 2668 1470 0 13 4138 13 0.996868225 0.003131775 (2,1) 2408 1470 0 273 3878 273 0.934232715 0.065767285 (2, 3) 2291 1470 0 390 3761 390 0.906046736 0.093953264 (2, 4) 2288 1470 0 393 3758 393 0.905324018 0.094675982 (1,3, 5) 2681 1470 0 0 4151 0 1 0 (5, 3, 2) 2575 1470 0 106 4045 106 0.974463985 0.025536015 (5, 3, 4) 2576 1470 0 105 4046 105 0.97470489 0.02529511 (5, 4, 1) 2680 1470 0 1 4150 1 0.999759094 0.000240906 (5, 4, 2) 2575 1470 0 106 4045 106 0.974463985 0.025536015 (5, 4, 3) 2576 1470 0 105 4046 105 0.97470489 0.02529511 Petition 870250104631, dated 11 / 14 / 2025, pp. 284 / 355 127 / 147 Combination of SNPs True Positive True Negative False Positive False Negative Correct Number Incorrect Number Correct Percentage Incorrect Percentage (1,2, 3, 4) 2426 1470 0 255 3896 255 0.93856902 0.06143098 (1,2, 3, 5) 2681 1470 0 0 4151 0 1 0 (1,2, 4, 3) 2426 1470 0 255 3896 255 0.93856902 0.06143098 (1,2, 4, 5) 2680 1470 0 1 4150 1 0.999759094 0.000240906 (1,2, 5, 3) 2681 1470 0 0 4151 0 1 0 Table 6. Accuracy rates of SNP combinations in determining whether a INDIVIDUAL IS A TNFSF15 HAPLOTYPE B VEHICLE (DESIGN DATA) Human Genome Diversity SNP Combination Correct Part Number of SNPs evaluated (1,3,5) 0.9998 3 (1,3, 4, 5) 0.9998 4 (1,2, 3, 5) 0.9998 4 (1,2, 4, 5) 0.9995 4 (1,4,5) 0.9995 3 (1,2,5) 0.9966 3 (1,5) 0.9966 2 (3, 4, 5) 0.9745 3 (2, 3, 4, 5) 0.9745 4 (4,5) 0.9742 2 (3,5) 0.9742 2 (2, 3, 5) 0.9742 3 (2, 4, 5) 0.9742 3 (2,5) 0.9639 2 (1,2, 3) 0.9383 3 (1,3, 4) 0.9383 3 (1,2, 3, 4) 0.9383 4 (1,2, 4) 0.9381 3 (1,3) 0.9381 2 (1,4) 0.9381 2 (1,2) 0.9340 2 (2, 3, 4) 0.9063 3 (2,3) 0.9058 2 Petition 870250104631, dated 11 / 14 / 2025, pages 285 / 355 128 / 147 SNP Combination Correct Part Number of SNPs evaluated (2, 4) 0.9051 2 (3, 4) 0.9046 2 Example 2. 2-SNP multiplex qPCR assay

[00323] The SNP TL1A test is a multiplex qPCR-based assay that detects the presence of two germline-specific SNPs, rs3810936 (SNP 1) and rs7869487 (SNP 5), which identify non-vehicle patients with TNFSF15 haplotype B who may potentially benefit from afimkibart therapy (see Example 1), in a patient biological sample. In the assay, short DNA targets (amplicons) are amplified exponentially over multiple cycles. Fluorescently labeled probes, designed to bind to amplicons, allow for proper discrimination between the presence of an SNP (Mutant / MUT; also called “alternative” or “Alt”) or the absence of an SNP (Wild-type / WT; “Ref”). A sample with mixed amplicons will present a mixture of WT and MUT probes linked to the amplifications, thus allowing the discrimination of Heterozygous (HET) samples.The probes are constructed with a reporter dye (FAM, SUN, TAMRA, and Cy5) at the 5' end and a suppressor dye (BHQ-1 and BHQ-2) at the 3' end. While the probe remains intact, the proximity of the suppressor dye significantly reduces the fluorescence emitted by the reporter dye through fluorescence resonance energy transfer (FRET). If the target sequence is present, the probe anneals to its specific complementary region in the amplicon and is cleaved by the 5' nuclease activity of Taq DNA polymerase as this primer is extended. Cleavage separates the reporter dye from the suppressor dye, resulting in an increase in the reporter dye signal. Additional reporter dyes are cleaved from their probes at each cycle, resulting in an increase in fluorescence intensity proportional to the amount of amplicon. Petition 870250104631, dated 11 / 14 / 2025, pp. 286 / 355 129 / 147 produced. The fluorescence signal is monitored after each cycle and the proprietary automatic calling feature of the QuantStudio™ 5 Dx software determines the genotype calls.

[00324] Once the genotypes of the two target SNP sites have been identified, the patient's B haplotype vehicle / non-vehicle status can be determined by comparing the SNP alleles with the reference table provided below (see Table 7 and Figure 2). For rs3810936 (SNP 1), the reference allele (“Ref”) is T and the alternative allele (“Alt”) is C. For 7869487 (SNP 5), the reference allele (“Ref”) is C and the alternative allele (“Alt”) is T.

[00325] Patients identified as haplotype B carriers are classified as having a negative biomarker status. Patients identified as non-haplotype B carriers are classified as having a positive biomarker status (i.e., they are identified as patients who may potentially obtain additional benefit from afimkibart therapy). Table 7. Reference Table of TNFSF15 Biomarker Status SNP 1 rs3810936 (T>C) SNP 5 rs7869487 (C>T) Haplotype B Vehicle Status Biomarker Status Ref:Ref Ref:Ref Negative Vehicle Ref:Ref Ref:Alt Negative Vehicle Ref:Ref Alt:Alt Positive Non-Vehicle Ref:Alt Ref:Ref Negative Vehicle Ref:Alt Ref:Alt Negative Vehicle / Non-Vehicle 1 Ref:Alt Alt:Alt Positive Non-Vehicle Alt:Alt Ref:Ref Positive Non-Vehicle Alt:Alt Ref:Alt Positive Non-Vehicle Alt:Alt Alt:Alt Positive Non-Vehicle Petition 870250104631, dated 11 / 14 / 2025, pp. 287 / 355 130 / 1471 Based on the Genomes 1000 Project database, 97.3% of individuals in these categories are haplotype B carriers (see Example 1); 2Presumed negative for the biomarker based on the overall misclassification rate of ~1% from the 1000 Genomes Project database (see Example 1). Example 3. Efficacy and safety of RO7790121, a fully human monoclonal antibody blocking TL1A in severely active moderate ulcerative colitis: Results from a randomized, double-blind, placebo-controlled, dose-ranging Phase 2b TUSCANY-2 study. Introduction

[00326] Tumor necrosis factor-like ligand 1A (TL1A) is a novel therapeutic target for inflammatory bowel disease. Patients with moderately to severely active ulcerative colitis (UC) treated with the anti-TL1A antibody afimkibart (RO7790121) (a fully human neutralizing monoclonal antibody against TL1A) showed significant endoscopic improvement and adequate safety in the phase 2a study. TUSCANY-1 (Danese et al., Clin Gastroenterol Hepatol, 19:2324-32.e6, 2021).

[00327] This example provides data from the phase 2b study. TUSCANY-2 global, randomized, double-blind, placebo-controlled, dose-ranging trial (NCT04090411) evaluating the efficacy and safety of various subcutaneous (SC) doses of afimkibart administered every four weeks (Q4W) in male or female patients aged 18–75 years with moderately to severely active UC (total Mayo score > 6, endoscopic subscore > 2) who had experienced treatment failure or intolerance to > 1 line of conventional or advanced treatment (selected from the following classes: steroids, immunosuppressants, anti-TNFs, integrin inhibitors, IL-12 / 23 inhibitors, and JAK inhibitors). Petition 870250104631, dated 11 / 14 / 2025, pp. 288 / 355 131 / 147 Objectives and methods

[00328] Patients were randomized to receive afimkibart SC 50 mg, 150 mg, 450 mg, or matching placebo (PBO) monthly during a 12-week induction period and afimkibart SC 50, 150, or 450 mg monthly during a 40-week maintenance period (Figure 3). Efficacy outcomes were assessed at Weeks 14 and 56 in the induction and maintenance intention-to-treat analysis sets, respectively. The primary outcomes were clinical remission at Week 14 by total Mayo Score (MS) and safety at Weeks 14 and 56. The pre-specified fundamental secondary outcome of clinical remission, using the modified Mayo Score (mMS), is aligned with updated FDA guidelines. Other secondary outcomes included clinical remission (by total MS and mMS) at week 56 and endoscopic improvement at weeks 14 and 56. An efficacy analysis by predefined biomarker subgroups was also performed.

[00329] Table 8 presents the definitions of the efficacy results from the TUSCANY-2 study. Table 8. Definition of effectiveness outcomes Outcome Definition: Clinical remission. Mayo Score: Total <2, with no individual subscores >1. Clinical Remission 2: Mayo Total Score <2, rectal bleeding subscore = 0, endoscopic subscore = 0 or 1, stool frequency subscore = 0 or 1, and physician global assessment = 0 or 1. Modified Remission 1 (FDA definition 1): Endoscopic subscore = 0 or 1, stool frequency subscore = 0, and rectal bleeding subscore = 0. Modified Remission 2 (FDA definition 2): Endoscopic subscore = 0 or 1, reduction >1 point from baseline to achieve a stool frequency subscore = 0 or 1 and rectal bleeding subscore = 0. Endoscopic Improvement: Endoscopic subscore = 0 or 1. Endoscopic Remission: Endoscopic subscore = 0. Petition 870250104631, dated 11 / 14 / 2025, pp. 289 / 355 132 / 147 Outcome Definition Clinical Response Reduction >3 points and >30% from baseline in Total Mayo Scores, with a concomitant reduction of >1 point in the rectal bleeding subscore or absolute rectal bleeding subscore = 0 or 1. Modified Clinical Response Decrease >3 points and >30% from baseline in the Modified Mayo Scores, accompanied by a decrease >1 point in the rectal bleeding subscore or absolute rectal bleeding subscore = 0 or 1. Symptomatic Remission Total Mayo Score <2, with no individual subscore >1 and with stool frequency and rectal bleeding subscores equal to 0. Deep Remission Total Mayo Score <2, with no individual subscore >1 and with endoscopic and rectal bleeding subscores equal to 0.

[00330] “Mayo score” refers to the Mayo score according to the Mayo Scoring System for Assessment of Ulcerative Colitis Activity. Study project

[00331] TUSCANY-2 was a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy, safety, and PK of PF-06480605 in participants with moderate to severe active UC. Approximately 240 participants were planned for randomization, of whom 216 were expected to complete the induction period, considering a dropout rate of 10%. Participants were randomly allocated to 1 of 9 treatment sequences, using an allocation ratio of 2:2:2:2:2:3:1:1:1 (Table 9). TABLE 9. TREATMENT SEQUENCE Treatment Sequence Description of Treatment Sequence Planned Participants Sample Size Induction Period Chronic Therapy Period A (450 mg ^ 450 mg) 450 mg of PF-06480605 SC Q4W 450 mg of PF06480605 SC Q4W 30 B (450 mg ^ 150 mg) 450 mg of PF-06480605 SC Q4W 150 mg of PF06480605 SC Q4W 30 C (450 mg ^ 50 mg) 450 mg of PF-06480605 SC Q4W 50 mg of PF-06480605 SC Q4W 30 Petition 870250104631, dated 11 / 14 / 2025, pp. 290 / 355 133 / 147 Treatment Sequence Description of Treatment Sequence Planned Participants Sample Size Induction Period Chronic Therapy Period D (150 mg ^ 150 mg) 150 mg of PF-06480605 SC Q4W 150 mg of PF06480605 SC Q4W 30 E (150 mg ^ 50 mg) 150 mg of PF-06480605 SC Q4W 50 mg of PF-06480605 SC Q4W 30 F (50 mg ^ 50 mg) 50 mg of PF-06480605 SC Q4W 50 mg of PF-06480605 SC Q4W 45 G (placebo ^ 450 mg) Placebo SC Q4W 450 mg of PF06480605 SC Q4W 15 H (placebo ^ 150 mg) Placebo SC Q4W 150 mg of PF06480605 SC Q4W 15 I (placebo^50 mg) Placebo SC Q4W 50 mg of PF-06480605 SC Q4W 15 SC = subcutaneous; Q4W = every 4 weeks.

[00332] The study took place over 4 periods: screening, induction, chronic therapy, and follow-up. The screening period lasted up to 6 weeks to assess eligibility. During the 12-week induction period, participants were randomized to receive 50 mg, 150 mg, 450 mg, or a matching placebo by subcutaneous administration every 4 weeks. During the 40-week chronic therapy period, all participants received the active drug: 50 mg, 150 mg, or 450 mg by subcutaneous administration every 4 weeks. During the 12-week follow-up period, final safety and efficacy assessments were planned. Overall, each participant's participation in the study lasted up to 70 weeks. Participants who discontinued the study at any time proceeded to the follow-up period with an early withdrawal visit.Any participant who prematurely withdrew from the treatment period (after randomization and during the active intervention phase of the study) was followed up with 3 study visits (one of which was the Early Withdrawal Visit), totaling 12 weeks from the last dose of the intervention product. Petition 870250104631, dated 11 / 14 / 2025, pp. 291 / 355 134 / 147

[00333] Two interim analyses were conducted for the study. The first analysis was conducted when 100% of participants had completed or had the opportunity to complete the Week 14 Visit. The second interim analysis was conducted when all participants had completed or had the opportunity to complete the induction period and approximately 100% of them had completed or had the opportunity to complete at least 6 months of chronic therapy. Results

[00334] A total of 246 participants were enrolled at 114 centers in 23 countries. Overall, 245 patients entered the induction phase (received at least one induction dose); 228 patients completed the induction phase and 224 patients entered the maintenance period of the study (received at least one maintenance dose).

[00335] During the induction period, all 245 treated participants (45, 47, 62, and 91 in the placebo, 50 mg, 150 mg, and 450 mg PF06480605 groups, respectively) were included in the safety and intention-to-treat (ITT) analyses; 240 participants (40, 47, 62, and 91 in the four groups, respectively) were included in the biomarker analysis population; 239 participants (40, 47, 62, and 90 in the four groups, respectively) were included in the immunogenicity analysis population.

[00336] During the chronic therapy period, a total of 224 participants (12 participants [placebo ^ 50 mg], 14 participants [placebo ^ 150 mg], 14 participants [placebo ^ 450 mg], 46 participants [50 mg ^ 50 mg], 27 participants [150 mg ^ 50 mg], 30 participants [150 mg ^ 150 mg], 26 participants [450 mg ^ 50 mg], 26 participants [450 mg ^ 150 mg] and 29 participants [450 mg ^ 450 mg]) were included in the maintenance intention-to-treat (mITT) analysis. Petition 870250104631, dated 11 / 14 / 2025, pp. 292 / 355 135 / 147 A. Demographics and baseline characteristics

[00337] The demographic and baseline characteristics of patients treated in the TUSCANY-2 study are shown in Table 10. Demographic characteristics were generally similar between the placebo and PF-06480605 groups. Table 10. Demographics and baseline characteristics Induction Arm Placebo (N=45) 50 mg (N=47) 150 mg (N=62) 450 mg (N=91) Overall (N=245) Age (years) Mean (SD) 39.9 (12.90) 37.8 (13.91) 42.2 (13.02) 41.6 (13.79) 40.7 (13.48) Median (range) 38 (19-66) 34 (18-73) 41 (20-70) 40 (19-73) 39 (18-73) Male sex, n (%) 24 (53.3) 28 (59.6) 39 (62.9) 55 (60.4) 146 (59.6) Race, n (%) White 30 (66.7) 35 (74.5) 49 (79.0) 70 (76.9) 184 (75.1) Black or African American 1 (2.2) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.4) Asian 13 (28.9) 9 (19.1) 9 (14.5) 18 (19.8) 49 (20.0) Other or not informed 1 (2.2) 3 (6.4) 4 (6.5) 3 (3.3) 11 (4.5) Region, n (%) USA / Canada / Australia 5 (11.1) 5 (10.6) 4 (6.5) 15 (16.5) 29 (11.8) Europe 25 (55.6) 31 (66.0) 47 (75.8) 54 (59.3) 157 (64.1) Asia 13 (28.9) 9 (19.1) 9 (14.5) 17 (18.7) 48 (19.6) Others 2 (4.4) 2 (4.3) 2 (3.2) 5 (5.5) 11 (4.5) Height (cm), median (range) 167.6 (151-192) 171.0 (154-192) 170.0 (149-185) 172.0 (146-196) 170.0 (146-196) Weight (kg), median (range) 66.0 (50.0-113) 69.1 (45.0-130) 70.6 (33,9112) 68.5 (37.7115) 68.2 (33.9-130) Advanced Therapy Inadequate Response (IR), n (%) 17 (37.8) 19 (40.4) 21 (33.9) 39 (42.9) 96 (39.2) Baseline Total Mayo Score (MS) Mean (SD) 9.0 (1.8) 8.6 (1.5) 9.0 (1.6) 9.3 (1.5) 9.0 (1.6) > 10, n (%) 17 (37.8) 17 (36.2) 29 (46.8) 46 (50.5) 109 (44.5) Petition 870250104631, dated 11 / 14 / 2025, pp. 293 / 355 136 / 147

[00338] Among participants treated during the induction period, the median disease duration was 4.70 years, ranging from 0.25 to 36.2 years. Baseline disease characteristics were balanced between the placebo group and the three groups treated with PF-06480605.

[00339] Among participants treated during the induction period, the majority of participants presented with left-sided colitis disease extension (43.3%), followed by pancolitis (diagnosed in 39.2% of participants). Disease extent was generally balanced between the placebo group and the three groups treated with PF-06480605.

[00340] Among the participants treated during the induction period, a total of 95.5%, 41.2%, 38.8%, and 23.7% of participants had received prior treatment with steroids, biologics, anti-TNF, and / or anti-integrin, respectively. Prior medical experience (i.e., steroids, biologics, anti-TNF, anti-integrin, azathioprine, 6-MP, methotrexate, IL-12 / 23 inhibitors, and JAK inhibitor) was generally balanced between the placebo group and the three groups treated with PF-06480605.

[00341] Among participants treated during the chronic therapy period, a total of 96.0%, 41.5%, 39.3%, and 24.1% of participants had received prior treatment with steroids, biologics, anti-TNF, and / or anti-integrin, respectively. Prior medical experience was generally balanced across all treatment sequences.

[00342] Among participants treated during the induction period, 97.1% of participants received general concomitant medications. A total of 73.1% of participants received mesalazine (ranging from 67.7% to 80.2% between the placebo group and the three PF-06480605 groups).

[00343] Among participants treated during the chronic therapy period, 76.8% of participants received concomitant general medications.

[00344] Among the participants treated during the period of Petition 870250104631, dated 11 / 14 / 2025, pp. 294 / 355 In the 137 / 147 induction group, 90 of the 245 participants were using steroids at baseline. Of these 90 participants, 89 (98.9%) did not change their steroid dose.

[00345] Among the participants treated during the chronic therapy period, 86 of 224 participants were using steroids at baseline. Of these 86 participants, 43 (50.0%) did not change their steroid dose. B. Effectiveness

[00346] At Week 14, 25.5%, 23.3%, and 23.9% of patients in the 50 mg, 150 mg, and 450 mg afimkibart arms, respectively, vs. 11.6% in the placebo arm, had clinical remission, according to the total Mayo Score (p-value > 0.05 (Table 11).

[00347] The proportion of patients who achieved clinical remission, according to the modified Mayo Score (mMS), at Week 14 was 29.8%, 35.0%, and 31.8% in the afimkibart 50 mg, 150 mg, and 450 mg arms, respectively, vs. 11.6% in placebo (p < 0.05) (Table 11 and Figure 4A). Consistent and statistically significant effects were observed at Week 14 across all outcomes and patient populations. As shown in Figures 7A and 7B, afimkibart achieved clinical remission rates (according to mMS) and endoscopic improvement superior to placebo, both in all patients and in the patient population with positive TNFSF15 biomarker (non-B haplotype vehicles; “positive biomarker”).

[00348] Improvements in clinical remission were maintained during maintenance (Table 11 and Figure 5).

[00349] Furthermore, a greater proportion of patients demonstrated endoscopic improvement at all doses of afimkibart vs. placebo at Week 14 and Week 56 (Table 11 and Figures 4B and 6). Trends toward numerically greater treatment effects were observed in patients with positive biomarkers compared to all patients. Petition 870250104631, dated 11 / 14 / 2025, pages 295 / 355 138 / 147 Table 11. Summary of efficacy outcomes at Week 14 and Week 56 Induction, Week 14 Placebo (n = 43) 50 mg (n = 47) 150 mg (n = 60) 450 mg (n = 88) Clinical remission by total Mayo Score*, % (90% CI) 11.6 (5.8, 22.9) 25.5 (15.4, 37.2) 23.3 (15.0, 34.0) 23.9 (16.6, 32.1) Clinical remission by modified Mayo Score (mMS),* % (90% CI) 11.6 (5.8, 22.9) 29.8 (19.9, 42.3) 35.0 (25.1, 45.2) 31.8 (23.7, 40.8) Endoscopic improvement,* % (90% CI) 90%) 18.6 (9.6, 30.2) 40.4 (28.3, 53.5) 38.3 (27.8, 48.6) 40.9 (32.1, 50.0) Maintenance, Week 56§ N / Av 50 mg (n = 42) 150 mg (n = 26) 450 mg (n = 28) Clinical remission by total Mayo score*, % (90% CI) 31.0 (19.4, 43.3) 34.6 (20.9, 52.6) 39.3 (23.8, 56.5) Clinical remission by mMS*, % (90% CI) 31.0 (19.4, 43.3) 38.5 (23.3, 56.4) 35.7 (20.9, 52.7) Endoscopic improvement,* % (90% CI) 38.1 (25.6, 52.0) 39.3** (23.8, 56.5) 50.0 (33.3, 66.7) n = number of participants in the analysis set with observed data or imputation of non-respondents (NRI), excluding a total of seven participants with missing data due to medical or operational complications resulting from COVID-19; *Primary outcome: Defined as a total Mayo score < 2, with no individual subscores > 1; Secondary outcome: defined according to the Food and Drug Administration (FDA) definition with a mMS (endoscopic subscore = 0 or 1, reduction > 1 point from baseline to achieve a stool frequency subscore = 0 or 1 and rectal bleeding subscore = 0); * Defined as endoscopic subscore = 0 or 1; § Analyses were conducted for all dose groups; however, maintenance efficacy results are presented only for patients who received the same dose during both the induction and maintenance periods; ^ Since the placebo was not administered during the period of Petition 870250104631, dated 11 / 14 / 2025, pp. 296 / 355 139 / 147 maintenance, no data is shown for Week 56; **For the outcome of endoscopic improvement at Week 56 with the 150 mg dose, data were available for n = 28 patients.**

[00350] Statistically significant and clinically relevant efficacy results were observed at all doses tested, both in the general population and in the population of patients with positive biomarkers. Results with the 450 mg dose at Week 14 are presented in Table 12 below. Prior experience with biologics is defined as prior experience with an anti-TNF agent, an anti-integrin agent, and / or an anti-IL-12 / 23 agent. Table 12. Summary of efficacy outcomes at the 450 mg dose in Week General Population at a Dose of 450 mg Population with Positive Biomarker at a Dose of 450 mg Population with Prior Experience with Biologics with Positive Biomarker at a Dose of 450 mg Clinical Remission 31% 40% 41% Endoscopic Improvement 40% 56% 56%

[00351] Efficacy results in individuals who experienced intolerance, inadequate response, or loss of response to previously administered therapy are shown in Figures 8A, 8B, 8B, and 9B. Figures 8A and 8B show the rates of clinical remission and endoscopic improvement in patients who experienced intolerance, inadequate response, or loss of response to prior advanced therapy (an antitumor necrosis factor (TNF) agent, anti-integrin agent, anti-IL-12 / 23 agent, and / or a Janus kinase (JAK) inhibitor). Figures 8A and 8B show the rates of clinical remission and endoscopic improvement in patients who experienced intolerance, inadequate response, or loss of response to prior therapy with an anti-TNF agent. Petition 870250104631, dated 11 / 14 / 2025, pp. 297 / 355 140 / 147 C. Security

[00352] Afimkibart was well tolerated, with no safety warning signs identified. No dose-related trends were observed with respect to adverse events.

[00353] During the induction period, 47.8% (117 / 245) of patients reported >1 treatment-emergent adverse event (TEAE) (Tables 13 and 14). The most common TEAEs (occurring in > 5% of patients), according to the preferred term, were: anemia (5.3%) and headache (5.3%) (Table 15). As shown in Table 14, the treatment-emergent adverse events 'infections', 'anemia', and 'injection site reactions' were evenly distributed between the treatment arms. In total, 10 patients experienced serious TEAEs (placebo = 4 patients; 50 mg = 3 patients; 450 mg = 3 patients) up to Week 14. Serious and severe adverse events were sporadic and generally considered unrelated to the study drug. No patients discontinued the study due to TEAEs. A similar security profile was observed during the maintenance period. Table 13. Treatment-related adverse events observed in TUSCANY-2 safety analysis defined during the induction period. Placebo (N=45) RO7790121 50 mg (N=47) RO7790121 150 mg (N=62) RO7790121 450 mg (N=91) Overall (N=245) Number of adverse events (AEs) 4 15 13 21 53 Participants with adverse events, n (%) 4 (8.9) 6 (12.8) 9 (14.5) 13 (14.3) 32 (13.1) Participants with severe adverse events, n (%) 1 (2.2) 1 (2.1) 0 (0.0) 1 (1.1) 3 (1.2) Participants with serious adverse events, n (%) 1 (2.2) 0 (0.0) 0 (0.0) 1 (1.1) 2 (0.8) Participants discontinued from the study due to adverse events1, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) Petition 870250104631, dated 11 / 14 / 2025, pp. 298 / 355 141 / 147 Placebo (N=45) RO7790121 50 mg (N=47) RO7790121 150 mg (N=62) RO7790121 450 mg (N=91) Overall (N=245) Participants who discontinued the study drug due to adverse events and continued in the study*, n (%) 1 (2.2) 0 (0.0) 1 (1.6) 0 (0.0) 2 (0.8) Participants with reduced dose or temporary discontinuation due to adverse events, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) fParticipants who had an AE record indicating that the AE caused the participant to discontinue the study. ^Participants who had an AE record indicating that the action taken in relation to the study treatment was discontinuation of the drug, but the AE did not lead to the participant's discontinuation of the study; Adverse events were classified based on MedDRA version 25.1; Abbreviations: mg = milligram. Table 14. Treatment-related adverse events observed in TUSCANY-2 in the defined safety analysis during the induction period (data (GROUPED) Placebo (n=45) Pooled (n=200) 450 mg Dose Participants with adverse events 56% 45% 53% Participants with severe adverse events 7% 2% 2% Participants with serious adverse events 7% 4% 3% Participants who discontinued the study due to adverse events 0% 0% 0% Participants who discontinued the study drug due to adverse events 4% 1% 1% Petition 870250104631, dated 11 / 14 / 2025, pp. 299 / 355 142 / 147 Placebo (n=45) Pooled (n=200) 450 mg dose Participants with dose reduction or temporary discontinuation due to adverse events 0% 0% 0% Deaths 0% 0% 0% Most common adverse events / Adverse events of interest Infection and infestations 9% 10% 9% Anemia 9% 4% 2% Injection site reaction 2% 5% 5% COVID-19 2% 1% 1% Table 15. Treatment-related adverse events observed in >5% of participants in the defined safety analysis during the period of INDUCTION Placebo (N=45) RO7790121 50 mg (N=47) RO7790121 150 mg (N=62) RO7790121 450 mg (N=91) General (N=245) With any adverse event 25 (55.6) 16 (34.0) 28 (45.2) 48 (52.7) 117 (47.8) Blood and lymphatic system disorders 6 (13.3) 2 (4.3) 7 (11.3) 5 (5.5) 20 (8.2) Anemia 4 (8.9) 2 (4.3) 5 (8.1) 2 (2.2) 13 (5.3) Gastrointestinal disorders 7 (15.6) 7 (14.9) 4 (6.5) 16 (17.6) 34 (13.9) Ulcerative colitis 1 (2.2) 3 (6.4) 1 (1.6) 4 (4.4) 9 (3.7) Nausea 1 (2.2) 3 (6.4) 2 (3.2) 2 (2.2) 8 (3.3) General disorders and administration site conditions 3 (6.7) 1 (2.1) 6 (9.7) 11 (12.1) 21 (8.6) Fatigue 0 (0.0) 0 (0.0) 1 (1.6) 5 (5.5) 6 (2.4) Pyrexia 1 (2.2) 0 (0.0) 1 (1.6) 5 (5.5) 7 (2.9) Infections and infestations 3 (6.7) 6 (12,8) 5 (8,1) 8 (8,8) 22 (9,0) Petition 870250104631, dated 11 / 14 / 2025, pages 300 / 355 143 / 147 Placebo (N=45) RO7790121 50 mg (N=47) RO7790121 150 mg (N=62) RO7790121 450 mg (N=91) General (N=245) Urinary tract infection 0 (0.0) 3 (6.4) 0 (0.0) 2 (2.2) 5 (2.0) Nervous system disorders 3 (6.7) 4 (8.5) 6 (9.7) 13 (14.3) 26 (10.6) Headache 1 (2.2) 2 (4.3) 1 (1.6) 9 (9.9) 13 (5.3) All values ​​are η (%); Adverse events were classified based on MedDRA version 25.1.

[00354] No impact of immunogenicity on clinical efficacy or safety results was observed. At Week 14, with the 450 mg dose, the anti-drug antibody (ADA) rate was 46% and the neutralizing antibody (NAb) rate was 8%. These immunogenicity results are consistent with approved biologics: Humira showed ADA rates of 32-46% and neutralizing antibody rates of 11-23% at Week 24 (Hanauer et al., 2021; Weinblatte et al., 2017; Cohen et al., 2019), and Skyrizi showed ADA rates of 19% and neutralizing antibody rates of 8% at Week 16 (Skyrizi (risankizumab) FDA Approval Summary Baseline). As shown in Table 16, higher ADA levels were associated with lower doses of subcutaneous (SC) administration. The median times to first detection of ADAs and NAbs were 30 to 57 days and 58 to 85 days, respectively, during induction with the SC regimen. Table 16. Immunogenicity per dose 50 mg (N = 47) 150 mg (N = 62) 450 mg (N = 91) Percentage of individuals with positive antidrug antibodies (% ADA+) 91.1 64.8 39.8 Percentage of individuals with positive neutralizing antibodies (% nAb) 33.3 17.9 7.9 Petition 870250104631, dated 11 / 14 / 2025, pp. 301 / 355 144 / 147 50 mg (N = 47) 150 mg (N = 62) 450 mg (N = 91) Median time to first ADA (days) 30 57 56 Median time to nAb (days) 58 84 85 C. Induction and maintenance of exposure-response

[00355] As shown in Table 17, higher exposures to afimkibart (per 14-week Cave term) in the induction phase were associated with higher outcome rates at Week 14. 14-week Cave term is the predicted mean concentration of afimkibart up to Week 14. Table 17. Response to 14-week Cave tertile exposure 1st Tertile 2nd Tertile 3rd Tertile Difference from 3rd Tertile to 1st Tertile Difference from 3rd Tertile to 2nd Tertile mMS remission (ES = 0 or 1 at Week 14, SFS = 0 or 1 and less than baseline, RBS = 0) 26.2% 32.3% 38.5% 12.3%; 1.5 times 6.2%; 1.2 times Endoscopic improvement 33.8% 38.5% 47.4% 13.6%; 1.4 times 8.9%; 1.2 times mMS remission (experience with biologics) 14.8% 22.2% 32.1% 17.3%; 2.2 times 9.9%; 1.4 times improvement in endoscopy (experience with biologics) 25.9% 22.2% 39.3% 13.4%; 1.5 times 17.1%; 1.8 times

[00356] As shown in Table 18, higher exposures to afimkibart (per tertile of Cave at Week 56) were associated with higher outcome rates at Week 56 in induction responders who continued at the same dose into the maintenance phase. Cave at Week 56 is the predicted mean concentration of afimkibart up to Week 56. Petition 870250104631, dated 11 / 14 / 2025, pp. 302 / 355 145 / 147 Table 18. Response to 56-week Cave tertile exposure 1st Tertile n / N2 (%) 2nd Tertile n / N2 (%) 3rd Tertile n / N2 (%) Absolute difference: 3rd vs. 1st Tertile Absolute difference: 3rd vs. 2nd Tertile mMS remission (ES = 0 or 1 at Week 56, SFS = 0 or 1 and less than baseline, RBS = 0) 9 / 32 (28.1%) 11 / 32 (34.4%) 13 / 32 (40.6%) 12.5% ​​6.2% Endoscopic improvement 13 / 33 (39.4%) 11 / 32 (34.4%) 17 / 33 (51.5%) 12.1% 17.1%

[00357] As shown in Table 19, almost all patients who received the 450 mg dose (approximately 74% of patients in the induction phase and approximately 96% of patients in the maintenance phase) have exposures in the highest tertile, indicating that this dose was necessary to achieve systemic exposures that corresponded to maximum and sustained efficacy. Table 19. Pharmacokinetic exposure during induction and maintenance. 1st Tertile 2nd Tertile 3rd Tertile Induction Number of patients in Cave at 14 weeks and (%) per dose The sample size was n=65 each in the 1st, 2nd and 3rd tertiles. 50 mg (n=47) 47 (100%) 0 (0%) 0 (0%) 150 mg (n=60) 17 (28.3%) 43 (71.7%) 0 (0%) 450 mg (n=88) 1 (1.1%) 22 (25%) 65 (73.9%) Maintenance2 Number of patients in Cave at 56 weeks and (%) per dose The sample size was n=32 each in the 1st, 2nd and 3rd tertiles. 50 mg ^ 50 mg (n=42) 30 (71.4%) 12 (28.6%) 0 (0%) 150 mg ^ 150 mg (n=26) 2 (7.7%) 19 (73.1%) 5 (19.2%) 450 mg ^ 450 mg (n=28) 0 (0%) 1 (3.6%) 27 (96.4%) D. A dose of 450 mg

[00358] The 450 mg Q4W SC dosing regimen was the only dose arm that showed a trend toward increasing efficacy over time. Petition 870250104631, dated 11 / 14 / 2025, pp. 303 / 355 146 / 147

[00359] At the 450 mg dose, superior efficacy was observed at Week 52 vs. Week 14 (all patients 36% vs 29%; patients with positive biomarkers 43% vs 33%).

[00360] The percentage of patients with sustained clinical response (when receiving the same dose in the induction and maintenance phases) was higher at the 450 mg dose (75%) (i.e., greater efficacy was observed in participants who maintained the same 450 mg dose during the induction and maintenance phases, compared to participants who received lower doses (50 mg or 150 mg).

[00361] Greater efficacy was observed in participants who maintained the same dose of 450 mg during the maintenance phase, compared with patients who received lower doses (e.g., 50 mg or 150 mg).

[00362] As shown above, an exposure-response analysis with individual exposures suggested that participants with the highest mean PK concentration tertile over 56 weeks had numerically greater modified remission (mMS remission), endoscopic improvement, sustained modified remission, and sustained endoscopic improvement response than the two lowest tertiles. Almost all patients who received the 450 mg dose in the maintenance phase (approximately 96%) had exposures in the highest tertile, indicating that this dose was necessary to achieve systemic exposures corresponding to maximum and sustained long-term efficacy.

[00363] Additionally, during the maintenance phase of the study, the persistent response rates of antidrug antibodies (ADA) and neutralizing antibodies (NAb) in the 450 mg treatment sequence arm (450 mg dose administered in the induction and maintenance phases) were the lowest compared to other treatment sequence rates. Petition 870250104631, dated 11 / 14 / 2025, pp. 304 / 355 147 / 147 (see Table 16). Minimal or no impact of ADA status on serum afimkibart was observed in the 450 mg ^ 450 mg sequence. E. Conclusions

[00364] Data from the Phase 2b TUSCANY-2 dose-ranging study demonstrate that afimkibart has a positive benefit / risk profile, with clinically significant improvements in patients with moderate to severe active UC. Petition 870250104631, dated 11 / 14 / 2025, pages 305 / 355

Claims

1 / 36 Claims 1. METHOD FOR DETERMINING THE RISK OF A PATIENT BEING NON-RESPONSIVE TO A THERAPEUTIC DOSE OF AN ANTI-TNF ligand 1A-like ANTIBODY (TL1A), characterized by comprising: performing a genotyping assay on a biological sample from the patient to determine whether the patient is a haplotype B carrier or a non-haplotype B carrier for TNFSF15, the assay comprising determining the presence of at least two single nucleotide polymorphisms (SNPs) selected from rs3810936, rs6478108, rs6478109, rs7848647 and rs7869487 in a biological sample from the patient; and to determine the risk of being unresponsive to a therapeutic dose of an anti-TL1A antibody, where the risk is greater in a patient carrying haplotype B than in a patient not carrying haplotype B.

2. METHOD, according to claim 1, characterized by the patient having inflammatory bowel disease (IBD).

3. METHOD FOR TREATING INFLAMMATORY BOWEL DISEASE (IBD) in a patient, the method characterized by comprising: (a) performing a genotyping assay to determine whether the patient is a haplotype B carrier or a non-haplotype B carrier for TNFSF15, the assay comprising determining the presence of at least two single nucleotide polymorphisms (SNPs) selected from rs3810936, rs6478108, rs6478109, rs7848647 and rs7869487 in a biological sample from the patient; and (b) administering to the patient an effective amount of an anti-TL1A antibody, where the patient has been determined to be a non-haplotype B carrier.

4. METHOD, according to claim 3, characterized by the anti-TL1A antibody being administered to the patient in an induction dosage regimen sufficient to improve the signs and symptoms of IBD for at least 12 weeks after the start of treatment with the anti-TL1A antibody, said induction dosage regimen comprising a plurality of individual induction doses.

5. METHOD, according to claim 3, characterized in that the anti-TL1A antibody is administered to the patient in a maintenance dosing regimen after completion of an induction dosing regimen, said maintenance dosing regimen comprising a plurality of individual maintenance doses separated from each other by at least 2 weeks.

6. METHOD FOR TREATING IBD in a patient, the method characterized by comprising: (a) performing a genotyping assay to determine whether the patient is a haplotype B carrier or a non-haplotype B carrier for TNFSF15, the assay comprising determining the presence of at least two SNPs selected from rs3810936, rs6478108, rs6478109, rs7848647 and rs7869487 in a biological sample from the patient; (b) administering to the patient an anti-TL1A antibody in an induction dosing regimen sufficient to improve the signs and symptoms of IBD for at least 12 weeks after the start of treatment with the anti-TL1A antibody, said induction dosing regimen comprising a plurality of individual induction doses, wherein the patient was determined to be a non-haplotype B carrier;and (c) administer to the patient a subsequent maintenance dosing regimen after completion of the induction dosing regimen, said maintenance dosing regimen comprising a plurality of individual maintenance doses separated from each other by at least 2 weeks.; 7. METHOD, according to any of the claims in Petition 870250104631, dated 11 / 14 / 2025, pp. 307 / 355 3 / 36 6, characterized by IBD being ulcerative colitis (UC).

8. METHOD, according to claim 7, characterized in that the UC is moderate to severe.

9. METHOD, according to any one of claims 2 to 6, characterized in that IBD is Crohn's disease (CD).

10. METHOD, according to any one of claims 1 to 9, characterized in that at least two SNPs are SNP rs3810936 and SNP rs7869487.

11. METHOD, according to claim 10, characterized by the genotyping assay comprising determining the presence of only two SNPs in the patient's biological sample, wherein the two SNPs are SNP rs3810936 and SNP rs7869487.

12. METHOD, according to any one of claims 10 to 11, characterized in that the patient is determined to be a non-carrier of haplotype B by any one of the following biomarker statuses in the patient's biological sample: (i) the sample genotype is homozygous for the reference allele at rs3810936 and is homozygous for the alternative allele at rs7869487; (ii) the sample genotype is heterozygous for the reference allele at rs3810936 and is homozygous for the alternative allele at rs7869487; (iii) the sample genotype is homozygous for the alternative allele at rs3810936 and is homozygous for the reference allele at rs7869487; (iv) the sample genotype is homozygous for the alternative allele at rs3810936 and is heterozygous for the reference allele at rs7869487; or (v) the sample genotype is homozygous for the alternative allele at rs3810936 and is homozygous for the alternative allele at rs7869487.

13. METHOD, according to claim 10, characterized by (a) the genotyping assay comprises determining the presence of SNP Petition 870250104631, dated 11 / 14 / 2025, p. 308 / 355 4 / 36 rs3810936, SNP rs7869487 and SNP rs7848647 in the patient's biological sample; or (b) the genotyping assay comprises determining the presence of SNP rs3810936, SNP rs7869487 and SNP rs6478109 in the patient's biological sample.

14. METHOD, according to claim 10, characterized by the genotyping assay comprising determining the presence of SNP rs3810936, SNP rs7869487, SNP rs6478108 and SNP rs6478109 in the patient's biological sample.

15. METHOD, according to any one of claims 1 to 14, characterized by a genotyping assay comprising qPCR.

16. METHOD, according to any one of claims 1 to 15, characterized by a genotyping assay comprising sequencing.

17. METHOD, according to any one of claims 1 to 16, characterized by a genotyping assay comprising long sequencing.

18. METHOD, according to any one of claims 1 to 17, characterized in that the genotyping assay is performed on a microarray.

19. METHOD, according to any one of claims 1 to 18, characterized in that the genotyping assay is a fluorescence-based assay.

20. METHOD, according to any one of claims 1 to 19, characterized in that the biological sample is blood.

21. METHOD, according to any one of claims 1 to 19, characterized in that the biological sample is buccal cells.

22. METHOD FOR DETERMINING THE RISK OF A PATIENT BEING NON-RESPONSIVE TO A THERAPEUTIC DOSE OF AN ANTI-TL1A ANTIBODY, where the patient has inflammatory bowel disease (IBD), the method characterized by comprising: (a) performing a genotyping assay on a biological sample Petition 870250104631, dated 11 / 14 / 2025, p. 309 / 355 5 / 36 of the patient to determine whether the patient is a haplotype B carrier or a non-haplotype B carrier for TNFSF15, wherein the assay comprises determining the presence of SNP rs3810936 and SNP rs7869487 in a biological sample from the patient, and wherein a non-haplotype B carrier for TNFSF15 is identified by either of the following biomarker statuses in the biological sample from the patient: (i) the sample genotype is homozygous for the reference allele at rs3810936 and is homozygous for the alternative allele at rs7869487; (ii) the sample genotype is heterozygous for the reference allele at rs3810936 and is homozygous for the alternative allele at rs7869487;(iii) the sample genotype is homozygous for the alternative allele at rs3810936 and is homozygous for the reference allele at rs7869487; (iv) the sample genotype is homozygous for the alternative allele at rs3810936 and is heterozygous for the reference allele at rs7869487; or (v) the sample genotype is homozygous for the alternative allele at rs3810936 and is homozygous for the alternative allele at rs7869487; and (b) identify the patient as having a high risk of being unresponsive to a therapeutic dose of an anti-TL1A antibody if the patient is a haplotype B carrier; or (c) identify the patient as having a low risk of being unresponsive to a therapeutic dose of an anti-TL1A antibody if the patient is a non-haplotype B carrier.

23. METHOD, according to claim 22, characterized in that the patient has been determined to be a non-B haplotype carrier for TNFSF15, and the method further comprises administering to the patient an effective amount of an anti-TL1A antibody.

24. METHOD, according to claim 23, characterized by the anti-TL1A antibody being administered to the patient in an induction dosage regimen sufficient to improve the signs and symptoms of IBD for at least 12 weeks after the start of treatment with the anti-TL1A antibody, said induction dosage regimen comprising a plurality of individual induction doses.

25. METHOD, according to claim 23, characterized in that the anti-TL1A antibody is administered to the patient in a maintenance dosing regimen after completion of an induction dosing regimen, said maintenance dosing regimen comprising a plurality of individual maintenance doses separated from each other by at least 2 weeks.

26. METHOD FOR TREATING IBD in a patient, the method characterized by comprising: (a) performing a genotyping assay on a biological sample from the patient to determine whether the patient is a haplotype B carrier or a non-haplotype B carrier for TNFSF15, wherein the assay comprises determining the presence of SNP rs3810936 and SNP rs7869487 in a biological sample from the patient, and wherein a non-haplotype B carrier for TNFSF15 is identified by either of the following biomarker statuses in the biological sample from the patient: (i) the sample genotype is homozygous for the reference allele at rs3810936 and is homozygous for the alternative allele at rs7869487; (ii) the sample genotype is heterozygous for the reference allele at rs3810936 and is homozygous for the alternative allele at rs7869487; (iii) the sample genotype is homozygous for the alternative allele at rs3810936 and is homozygous for the reference allele at rs7869487;(iv) the sample genotype is homozygous for the alternative allele at rs3810936 and is heterozygous for the reference allele at rs7869487; or (v) the sample genotype is homozygous for the alternative allele at Petition 870250104631, dated 11 / 14 / 2025, p. 311 / 355 7 / 36 rs3810936 and is homozygous for the alternative allele at rs7869487; and (b) administer to the patient an effective amount of an anti-TL1A antibody, in which the patient has been determined to be a non-vehicle of haplotype B.; 27. METHOD, according to claim 26, characterized in that the anti-TL1A antibody is administered to the patient in an induction dosage regimen sufficient to improve signs and symptoms of IBD for at least 12 weeks after the start of treatment with the anti-TL1A antibody, said induction dosage regimen comprising a plurality of individual induction doses.

28. METHOD, according to claim 26, characterized in that the anti-TL1A antibody is administered to the patient in a subsequent maintenance dosing regimen after completion of an induction dosing regimen, said maintenance dosing regimen comprising a plurality of individual maintenance doses separated from each other by at least 2 weeks.

29. METHOD FOR TREATING IBD in a patient, the method characterized by comprising administering to the patient an effective amount of an anti-TL1A antibody; wherein the patient has been determined to be a non-vehicle of haplotype B for TNFSF15 by any of the following biomarker statuses in a biological sample from the patient: (i) the sample genotype is homozygous for the reference allele at rs3810936 and is homozygous for the alternative allele at rs7869487; (ii) the sample genotype is heterozygous for the reference allele at rs3810936 and is homozygous for the alternative allele at rs7869487; (iii) the sample genotype is homozygous for the alternative allele at rs3810936 and is homozygous for the reference allele at rs7869487; Petition 870250104631, dated 11 / 14 / 2025, p.312 / 355 8 / 36 (iv) the sample genotype is homozygous for the alternative allele at rs3810936 and is heterozygous for the reference allele at rs7869487; or (v) the sample genotype is homozygous for the alternative allele at rs3810936 and is homozygous for the alternative allele at rs7869487.

30. METHOD, according to claim 29, characterized in that the anti-TL1A antibody is administered to the patient in an induction dosage regimen sufficient to improve signs and symptoms of IBD for at least 12 weeks after the start of treatment with the anti-TL1A antibody, said induction dosage regimen comprising a plurality of individual induction doses.

31. METHOD, according to claim 29, characterized in that the anti-TL1A antibody is administered to the patient in a subsequent maintenance dosing regimen after completion of an induction dosing regimen, said maintenance dosing regimen comprising a plurality of individual maintenance doses separated from each other by at least 2 weeks.

32. METHOD, according to any one of claims 4, 6 to 21, 24, 27 and 30, characterized in that the individual induction doses are separated from each other by at least 1 week, at least 2 weeks, at least 3 weeks or at least 4 weeks.

33. METHOD, according to any one of claims 4, 6 to 21, 24, 27, 30 and 32, characterized in that the individual induction doses are separated from each other by at least 1 month.

34. METHOD, according to claim 32, characterized by the individual induction doses being administered at 4-week intervals.

35. METHOD, according to any of claims 4, 6 to 21, 24, 27, 30 and 32 to 34, characterized in that the individual induction dose is administered intravenously or subcutaneously.

36. METHOD, according to claim 35, characterized in that each of the individual induction doses is administered subcutaneously.

37. METHOD, according to any one of claims 4, 6 to 21, 24, 27, 30 and 32 to 36, characterized by the individual induction dose being administered at 50, 150 or 450 mg.

38. METHOD, according to claim 37, characterized in that each of the individual induction doses is administered in a dose of 50 mg.

39. METHOD, according to claim 37, characterized in that each of the individual induction doses is administered in a dose of 150 mg.

40. METHOD, according to claim 37, characterized in that each of the individual induction doses is administered in a dose of 450 mg.

41. METHOD, according to any one of claims 4 to 21 and 24 to 40, characterized by the induction dosing regimen comprising four individual induction doses.

42. METHOD, according to any one of claims 4 to 21, 24, 25, 27, 28 and 30 to 41, characterized by the induction dosing regimen comprising four individual induction doses administered at 4-week intervals, wherein each of the individual induction doses is administered subcutaneously at a dose of 50, 150 or 450 mg.

43. METHOD, according to any one of claims 5 to 21, 25, 28, 31, 41 and 42, characterized in that individual maintenance doses are administered at least 2 weeks apart, at least 3 weeks apart or at least 4 weeks apart.

44. METHOD, according to any of the claims in Petition 870250104631, dated 11 / 14 / 2025, pp. 314 / 355 10 / 36 21, 25, 28, 31 and 41 to 43, characterized by the individual maintenance doses being administered at intervals of at least 1 month.

45. METHOD, according to claim 43, characterized by individual maintenance doses being administered at 4-week intervals.

46. ​​METHOD, according to any one of claims 5 to 21, 25, 28 and 41 to 45, characterized in that the individual maintenance dose is administered intravenously or subcutaneously.

47. METHOD, according to claim 46, characterized in that each of the individual maintenance doses is administered subcutaneously.

48. METHOD, according to any one of claims 5 to 21, 25, 28 and 41 to 47, characterized in that the individual maintenance dose is administered at 50, 150 or 450 mg.

49. METHOD, according to claim 48, characterized in that each of the individual maintenance doses is administered in a dose of 50 mg.

50. METHOD, according to claim 48, characterized in that each of the individual maintenance doses is administered in a dose of 150 mg.

51. METHOD, according to claim 48, characterized in that each of the individual maintenance doses is administered in a dose of 450 mg.

52. METHOD, according to any one of claims 5 to 21, 25, 28 and 41 to 51, characterized in that the maintenance dosing regimen comprises at least ten individual maintenance doses.

53. METHOD, according to any one of claims 5 to 21, 25, 28 and 41 to 52, characterized by the induction dosage regimen Petition 870250104631, dated 11 / 14 / 2025, p. 315 / 355 11 / 36 comprising ten individual maintenance doses administered at 4-week intervals, wherein each of the individual maintenance doses is administered subcutaneously at a dose of 50, 150 or 450 mg.

54. METHOD, according to claim 53, characterized in that each of the individual maintenance doses is administered subcutaneously in a dose of 450 mg.

55. METHOD, according to any one of claims 3 to 54, characterized by further comprising: (a) determining the expression level of one or more candidate genes in a biological sample from the patient, and (b) identifying that the biological sample contains an abnormal expression level of one or more candidate genes.

56. METHOD, according to claim 55, characterized by one or more candidate genes being selected from the group consisting of SOWAHB, COLCA2, TBX20, FRZB, HOXB5, NET1, FOXD2, DESI1, PARK2, PKDREJ, IL-1 B, IL-23A, IFNG, IL-12RB1, IL-21 R, IRF4, BATF, CD80 / 86, HLA-DRB5 / DQB1 / DRB1, HLA-DRA, CD40, ICOS, MMP3, MMP7, MMP10 and CHI3L.

57. METHOD, according to claim 56, characterized in that one or more candidate genes are selected from the group consisting of SOWAHB, COLCA2, TBX20, FRZB, HOXB5, NET1, FOXD2, DESI1, PARK2 and PKDREJ.

58. METHOD, according to any one of claims 55 to 57, characterized in that the expression level of one or more candidate genes is compared to a baseline expression level that is a) based on the expression level of one or more candidate genes for a healthy individual who does not suffer from IBD or UC; or b) based on an estimated expression level for individuals who are unresponsive to anti-TL1A antibody treatment. Petition 870250104631, dated 11 / 14 / 2025, p. 316 / 355 12 / 36 59. METHOD, according to claim 58, characterized in that the abnormal expression level of one or more candidate genes is at least 50% higher or lower than the baseline level.

60. METHOD, according to any one of claims 3 to 59, characterized by further comprising: a) determining the expression level of one or more candidate bacterial strains in a stool sample from the patient, and b) identifying whether the sample contains an increased or decreased level of one or more candidate bacterial strains.

61. METHOD, according to claim 60, characterized in that the level of the candidate bacterial strain is increased and the candidate bacterial strain is selected from the group consisting of Streptococcus salivarius, Streptococcus parasanguinis and Haemophilus parainfluenzae.

62. METHOD, according to claim 61, characterized in that the level of the candidate bacterial strain is decreased and the candidate bacterial strain is selected from the group consisting of Ruminococcus albus, Ruminococcus callidus, Ruminococcus bromii, Ruminococcus gnavus and Bifidobacterium bifidum.

63. METHOD, according to any one of claims 1 to 62, characterized by the anti-TL1A antibody comprising three CDRs of the variable heavy chain region with the sequence shown in SEQ ID NO: 1 and three CDRs of the variable light chain region with the sequence shown in SEQ ID NO:

2.

64. METHOD, according to any one of claims 1 to 62, characterized by the anti-TL1A antibody comprising an HCDR1 with the sequence shown in SEQ ID NO: 3, an HCDR2 with the sequence shown in SEQ ID NO: 4, an HCDR3 with the sequence shown in SEQ ID NO: 5, an LCDR1 with the sequence shown in SEQ ID NO: 6, an LCDR2 with the sequence shown in SEQ ID NO: 7 and an LCDR3 with the sequence shown in SEQ ID NO:

8.

65. METHOD, according to any one of claims 1 to 64, characterized by the anti-TL1A antibody comprising a variable heavy chain region with the sequence shown in SEQ ID NO: 1 and a variable light chain region with the sequence shown in SEQ ID NO:

2.

66. METHOD, according to any one of claims 1 to 65, characterized by the anti-TL1A antibody comprising a heavy chain with the sequence shown in SEQ ID NO: 9 and a light chain with the sequence shown in SEQ ID NO:

10.

67. METHOD, according to any one of claims 1 to 66, characterized by the anti-TL1A antibody being afimkibart.

68. METHOD FOR TREATING INFLAMMATORY BOWEL DISEASE (IBD) in a patient, the method characterized by comprising: (a) performing a genotyping assay to determine whether the patient is a haplotype B carrier or a non-haplotype B carrier for TNFSF15, the assay comprising determining the presence of at least two single nucleotide polymorphisms (SNPs) selected from rs3810936, rs6478108, rs6478109, rs7848647 and rs7869487 in a biological sample from the patient; and (b) administering to the patient an effective amount of an anti-TL1A antibody, where the patient has been determined to be a non-haplotype B carrier;wherein the anti-TL1A antibody comprises an HCDR1 with the sequence shown in SEQ ID NO: 3, an HCDR2 with the sequence shown in SEQ ID NO: 4, an HCDR3 with the sequence shown in SEQ ID NO: 5, an LCDR1 with the sequence shown in SEQ ID NO: 6, an LCDR2 with the sequence shown in SEQ ID NO: 7 and an LCDR3 with the sequence shown in SEQ ID NO:

8.

69. METHOD, according to claim 68, characterized in that at least two SNPs are SNP rs3810936 and SNP rs7869487.

70. METHOD, according to claim 69, characterized by the assay comprising determining the presence of only two SNPs in the patient's biological sample, wherein the two SNPs are SNP rs3810936 and SNP rs7869487.

71. METHOD, according to any one of claims 1 to 62, characterized by the anti-TL1A antibody comprising sequence pairs selected from the group consisting of SEQ ID NOs: 2 and 11; SEQ ID NOs: 2 and 12; SEQ ID NOs: 2 and 13; SEQ ID NOs: 2 and 14; SEQ ID NOs: 2 and 15; SEQ ID NOs: 2 and 16; SEQ ID NOs: 2 and 17; SEQ ID NOs: 2 and 18; SEQ ID NOs: 2 and 19; SEQ ID NOs: 20 and 24; SEQ ID NOs: 21 and 25; SEQ ID NOs: 22 and 26; SEQ ID NOs: 23 and 27; SEQ ID NOs: 28 and 29; SEQ ID NOs: 30 and 31; SEQ ID NOs: 32 and 33; SEQ ID NOs: 35 and 44; SEQ ID NOs: 53 and 54; SEQ ID NOs: 61 and 62; SEQ ID NOs: 63 and 64; SEQ ID NOs: 65 and 64; SEQ ID NOs: 66 and 64; and SEQ ID NOs: 67 and 64.

72. METHOD, according to any one of claims 1 to 62, characterized by the anti-TL1A antibody comprising three CDRs of the variable heavy chain region with the sequence shown in SEQ ID NO: 53 and three CDRs of the variable light chain region with the sequence shown in SEQ ID NO:

54.

73. METHOD, according to any one of claims 1 to 62, characterized by the anti-TL1A antibody comprising an HCDR1 with the sequence shown in SEQ ID NO: 37, an HCDR2 with the sequence shown in SEQ ID NO: 39, an HCDR3 with the sequence shown in SEQ ID NO: 41, an LCDR1 with the sequence shown in SEQ ID NO: 46, an LCDR2 with the sequence shown in SEQ ID NO: 48 and an LCDR3 with the sequence shown in SEQ ID NO:

50.

74. METHOD, according to any one of claims 1 to 62, 72 and 73, characterized by the anti-TL1A antibody comprising a variable heavy chain region with the sequence shown in SEQ ID NO: 53 and a variable light chain region with the sequence shown in SEQ ID NO:

54.

75. METHOD, according to any one of claims 1 to 62 and 72 to 74, characterized by the anti-TL1A antibody comprising a heavy chain with the sequence shown in SEQ ID NO: 35 and a light chain with the sequence shown in SEQ ID NO:

44.

76. METHOD, according to any one of claims 1 to 62 and 72 to 75, characterized in that the anti-TL1A antibody is tulisoquibart.

77. METHOD FOR TREATING INFLAMMATORY BOWEL DISEASE (IBD) in a patient, the method characterized by comprising: (a) performing a genotyping assay to determine whether the patient is a haplotype B carrier or a non-haplotype B carrier for TNFSF15, the assay comprising determining the presence of at least two single nucleotide polymorphisms (SNPs) selected from rs3810936, rs6478108, rs6478109, rs7848647 and rs7869487 in a biological sample from the patient; and (b) administering to the patient an anti-TL1A antibody, where the patient has been determined to be a non-haplotype B carrier; wherein the anti-TL1A antibody comprises an HCDR1 with the sequence shown in SEQ ID NO: 37, an HCDR2 with the sequence shown in SEQ ID NO: 39, an HCDR3 with the sequence shown in SEQ ID NO: 41, an LCDR1 with the sequence shown in SEQ ID NO: 46, an LCDR2 with the sequence shown in SEQ ID NO: 48 and an LCDR3 with the sequence shown in SEQ ID NO:

50.

78. METHOD, according to claim 77, characterized by Petition 870250104631, dated 11 / 14 / 2025, p. 320 / 355 16 / 36, the at least two SNPs being SNP rs3810936 and SNP rs7869487.

79. METHOD, according to claim 78, characterized by the assay comprising determining the presence of only two SNPs in the patient's biological sample, where the two SNPs are SNP rs3810936 and SNP rs7869487.

80. METHOD, according to any one of claims 3 to 79, characterized by further comprising treatment with an IL-23 antagonist.

81. METHOD, according to any one of claims 22 to 31, 68 to 70 and 77 to 79, characterized in that IBD is ulcerative colitis (UC).

82. METHOD, according to claim 81, characterized in that the UC is moderate to severe UC.

83. METHOD, according to any one of claims 22 to 31, 68 to 70 and 77 to 79, characterized in that IBD is Crohn's disease (CD).

84. METHOD, according to any one of claims 1 to 83, characterized in that the patient is a human.

85. METHOD FOR TREATING AN INFLAMMATORY BOWEL DISEASE (IBD) in a patient, the method characterized by comprising administering to the patient an effective amount of an anti-TNF ligand-like antibody (TL1A) in a dosing regimen comprising an induction dosing regimen and a subsequent maintenance dosing regimen; wherein the induction dosing regimen comprises a plurality of individual induction doses and the maintenance dosing regimen comprises a plurality of individual maintenance doses; wherein the anti-TL1A antibody is administered subcutaneously in the maintenance phase, and wherein the anti-TL1A antibody comprises: an HCDR1 with the sequence shown in SEQ ID NO: 3, Petition 870250104631, dated 11 / 14 / 2025, p.321 / 355 17 / 36 an HCDR2 with the sequence shown in SEQ ID NO: 4, an HCDR3 with the sequence shown in SEQ ID NO: 5, an LCDR1 with the sequence shown in SEQ ID NO: 6, an LCDR2 with the sequence shown in SEQ ID NO: 7, and an LCDR3 with the sequence shown in SEQ ID NO:

8.

86. METHOD, according to claim 85, characterized in that the individual induction doses are separated by at least 1 week, at least 2 weeks, at least 3 weeks, or at least 4 weeks.

87. METHOD, according to any one of claims 85 to 86, characterized in that the individual induction doses are separated from each other by at least 1 month.

88. METHOD, according to claim 86, characterized in that individual induction doses are administered 4 weeks apart.

89. METHOD, according to any one of claims 85 to 88, characterized in that the individual induction dose is administered intravenously or subcutaneously.

90. METHOD, according to claim 89, characterized in that each of the individual induction doses is administered subcutaneously.

91. METHOD, according to any one of claims 85 to 90, characterized in that the individual induction dose is administered in 50, 150 or 450 mg doses.

92. METHOD, according to claim 91, characterized in that each of the individual induction doses is administered in a dose of 50 mg.

93. METHOD, according to claim 91, characterized in that each of the individual induction doses is administered at a dose of Petition 870250104631, dated 11 / 14 / 2025, page 322 / 355 18 / 36 150 mg.

94. METHOD, according to claim 91, characterized in that each of the individual induction doses is administered in a dose of 450 mg.

95. METHOD, according to any one of claims 85 to 94, characterized by the induction dosing regimen comprising four individual induction doses.

96. METHOD, according to any one of claims 85 to 95, characterized by the induction dosing regimen comprising four individual induction doses administered at 4-week intervals, wherein each of the individual induction doses is administered subcutaneously at a dose of 50, 150 or 450 mg.

97. METHOD, according to any one of claims 85 to 96, characterized in that individual maintenance doses are administered at intervals of at least 2 weeks, at least 3 weeks, or at least 4 weeks.

98. METHOD, according to any one of claims 85 to 97, characterized in that individual maintenance doses are administered at intervals of at least 1 month.

99. METHOD, according to claim 97, characterized by individual maintenance doses being administered at 4-week intervals.

100. METHOD, according to any one of claims 85 to 99, characterized in that the individual maintenance dose is administered at 50, 150 or 450 mg.

101. METHOD, according to claim 100, characterized in that each of the individual maintenance doses is administered in a dose of 50 mg. Petition 870250104631, dated 11 / 14 / 2025, pp. 323 / 355 19 / 36 102. METHOD, according to claim 100, characterized in that each of the individual maintenance doses is administered in a dose of 150 mg.

103. METHOD, according to claim 100, characterized in that each of the individual maintenance doses is administered in a dose of 450 mg.

104. METHOD, according to any one of claims 85 to 103, characterized by a maintenance dosing regimen comprising at least ten individual maintenance doses.

105. METHOD, according to any one of claims 85 to 104, characterized by an induction dosing regimen comprising ten individual maintenance doses administered at 4-week intervals, wherein each of the individual maintenance doses is administered subcutaneously at a dose of 50, 150 or 450 mg.

106. METHOD, according to claim 105, characterized in that each of the individual maintenance doses is administered subcutaneously in a dose of 450 mg.

107. METHOD FOR TREATING AN INFLAMMATORY BOWEL DISEASE (IBD) in a patient, the method characterized by comprising administering to the patient an effective amount of an anti-TNF ligand-like antibody (TL1A) in a dosing regimen comprising an induction dosing regimen and a subsequent maintenance dosing regimen; wherein: (a) the induction dosing regimen comprises the subcutaneous administration of four individual induction doses of the anti-TL1A antibody at a dose of approximately 50 mg, 150 mg or 450 mg, wherein the individual induction doses are administered 4 weeks apart; and (b) the maintenance dosing regimen comprises Petition 870250104631, dated 11 / 14 / 2025, p.324 / 355 20 / 36 subcutaneous administration of a plurality of individual maintenance doses of anti-TL1A antibody at a dose of approximately 50 mg, 150 mg, or 450 mg, wherein the individual maintenance doses are administered at 4-week intervals; and wherein the anti-TL1A antibody comprises: an HCDR1 with the sequence shown in SEQ ID NO: 3, an HCDR2 with the sequence shown in SEQ ID NO: 4, an HCDR3 with the sequence shown in SEQ ID NO: 5, an LCDR1 with the sequence shown in SEQ ID NO: 6, an LCDR2 with the sequence shown in SEQ ID NO: 7, and an LCDR3 with the sequence shown in SEQ ID NO:

8.

108. METHOD FOR TREATING AN INFLAMMATORY BOWEL DISEASE (IBD) in a patient, the method characterized by comprising administering to the patient an effective amount of an anti-TNF ligand 1A-like antibody (TL1A) in a dosing regimen comprising an induction dosing regimen and a subsequent maintenance dosing regimen; wherein: (a) the induction dosing regimen comprises a plurality of individual induction doses, wherein the individual induction doses are separated from each other by at least 1 week, at least 2 weeks, at least 3 weeks, or at least 4 weeks; and (b) the maintenance dosing regimen comprises the subcutaneous administration of a plurality of individual maintenance doses of the anti-TL1A antibody at a dose of approximately 450 mg, wherein the individual maintenance doses are administered at 4-week intervals;and wherein the anti-TL1A antibody comprises: an HCDR1 with the sequence shown in SEQ ID NO: 3, Petition 870250104631, dated 11 / 14 / 2025, p. 325 / 355 21 / 36, an HCDR2 with the sequence shown in SEQ ID NO: 4, an HCDR3 with the sequence shown in SEQ ID NO: 5, an LCDR1 with the sequence shown in SEQ ID NO: 6, an LCDR2 with the sequence shown in SEQ ID NO: 7, and an LCDR3 with the sequence shown in SEQ ID NO: 8.; 109. METHOD, according to claim 108, characterized by the induction dosing regimen comprising the subcutaneous administration of four individual induction doses of anti-TL1A antibody at a dose of approximately 450 mg, wherein the individual induction doses are administered at 4-week intervals.

110. METHOD, according to any one of claims 85 to 109, characterized in that the first dose of the maintenance phase is administered approximately two weeks after the administration of the final dose of the induction phase.

111. METHOD, according to any one of claims 85 to 110, characterized in that the dosing regimen has a duration of approximately 52 weeks.

112. METHOD, according to any one of claims 85 to 111, characterized by the anti-TL1A antibody comprising a variable heavy chain region with the sequence shown in SEQ ID NO: 1 and a variable light chain region with the sequence shown in SEQ ID NO:

2.

113. METHOD, according to any one of claims 85 to 112, characterized by the anti-TL1A antibody comprising a heavy chain with the sequence shown in SEQ ID NO: 9 and a light chain with the sequence shown in SEQ ID NO:

10.

114. METHOD, according to any one of claims 85 to 113, characterized by the anti-TL1A antibody being afimkibart.

115. METHOD, according to any of the claims Petition 870250104631, dated 11 / 14 / 2025, pp. 326 / 355 22 / 36 85 to 114, characterized by the patient having been determined as a non-vehicle of haplotype B for TNFSF15.

116. METHOD, according to any one of claims 85 to 115, characterized in that IBD is ulcerative colitis (UC).

117. METHOD, according to claim 116, characterized in that UC is moderate to severe UC.

118. METHOD, according to any one of claims 85 to 117, characterized in that the patient is a human.

119. METHOD, according to any one of claims 85 to 118, characterized in that, in a population of patients treated according to the method, the treatment results in an increase in the proportion of patients who achieved clinical remission at the end of the induction phase, compared with a reference population.

120. METHOD, according to claim 119, characterized in that the induction phase has a duration of approximately 14 weeks and the treatment results in an increase in the proportion of patients who achieved clinical remission by Week 14.

121. METHOD, according to claim 120, characterized in that at least about 15% of patients in the patient population achieve clinical remission by Week 14.

122. METHOD, according to claim 121, characterized in that at least about 40% of patients in the patient population achieve clinical remission by Week 14.

123. METHOD, according to any one of claims 85 to 122, characterized in that, in a population of patients treated according to the method, the treatment results in an increase in the proportion of patients who achieved clinical remission at the end of the maintenance phase compared with a reference population. Petition 870250104631, dated 11 / 14 / 2025, pp. 327 / 355 23 / 36 124. METHOD, according to claim 123, characterized in that the dosage regimen has a duration of approximately 56 weeks and the treatment results in an increase in the proportion of patients who achieved clinical remission by Week 56.

125. METHOD, according to claim 124, characterized in that at least about 20% of patients in the patient population achieve clinical remission by Week 56.

126. METHOD, according to claim 125, characterized in that at least about 55% of patients in the patient population achieve clinical remission by Week 56.

127. METHOD, according to any one of claims 119 to 126, characterized by clinical remission being a total Mayo score < 2, with no individual subscore >1.

128. METHOD, according to any one of claims 119 to 126, characterized by clinical remission being a Modified Mayo Score (mMS) < 2 with stool frequency (SFS) subscore = 0 or 1, rectal bleeding (RBS) subscore = 0 and endoscopic subscore (ES) = 0 or 1.

129. METHOD, according to any one of claims 85 to 128, characterized in that, in a population of patients treated according to the method, the treatment results in an increase in the proportion of patients who achieved endoscopic improvement at the end of the induction phase compared with a reference population.

130. METHOD, according to claim 129, characterized in that the induction phase has a duration of approximately 14 weeks and the treatment results in an increase in the proportion of patients who achieved endoscopic improvement at Week 14.

131. METHOD, according to claim 130, characterized by at least about 25% of patients in the patient population achieving endoscopic improvement in Week 14.

132. METHOD, according to claim 131, characterized in that at least about 50% of patients in the patient population achieve endoscopic improvement by Week 14.

133. METHOD, according to any one of claims 85 to 132, characterized in that, in a population of patients treated according to the method, the treatment results in an increase in the proportion of patients who achieved endoscopic improvement at the end of the maintenance phase compared with a reference population.

134. METHOD, according to claim 133, characterized in that the dosage regimen has a duration of approximately 56 weeks and the treatment results in an increase in the proportion of patients who achieved endoscopic improvement at Week 56.

135. METHOD, according to claim 134, characterized in that at least about 20% of patients in the patient population achieve endoscopic improvement by Week 56.

136. METHOD, according to claim 135, characterized in that at least about 65% of patients in the patient population achieve endoscopic improvement by Week 56.

137. METHOD, according to any one of claims 129 to 136, characterized in that clinical remission is an endoscopic subscore of 0 or 1.

138. METHOD, according to any one of claims 85 to 137, characterized in that, in a population of patients treated according to the method, the treatment results in an increase in the proportion of patients who achieved endoscopic remission, clinical response, symptomatic remission, or deep remission at the end of the induction phase, compared with a reference population.

139. METHOD, according to any one of claims 85 to 138, characterized in that, in a population of patients treated according to the method, the treatment results in an increase in the proportion of patients who achieved endoscopic remission, clinical response, symptomatic remission, or deep remission at the end of the maintenance phase, compared with a reference population.

140. METHOD, according to any one of claims 119 to 139, characterized in that the reference population is a population of patients who have not been treated with an anti-TL1A antibody.

141. METHOD, according to claim 140, characterized in that the reference population is a population of patients who were treated with a placebo.

142. KIT, characterized by comprising an antibody similar to the TNF ligand 1A (TL1A) and a package insert containing instructions for the use of the antibody for the treatment of inflammatory bowel disease (IBD) in a patient requiring it, according to the method as defined in any one of claims 1 to 141.

143. Anti-TL1A antibody for use in the treatment of IBD in a patient, characterized by: (a) a genotyping assay being performed to determine whether the patient is a haplotype B vehicle or a non-haplotype B vehicle for TNFSF15, the assay comprising determining the presence of at least two single nucleotide polymorphisms (SNPs) selected from rs3810936, rs6478108, rs6478109, rs7848647 and rs7869487 in a biological sample from the patient; and (b) an effective amount of anti-TL1A antibody being administered to the patient, wherein it has been determined that the patient is a non-haplotype B vehicle.

144. Anti-TL1A antibody for use in the treatment of IBD in a patient, characterized by: (a) a genotyping assay being performed to determine whether the patient is a haplotype B carrier or a non-haplotype B carrier for TNFSF15, the assay comprising determining the presence of at least two SNPs selected from rs3810936, rs6478108, rs6478109, rs7848647 and rs7869487 in a biological sample from the patient; (b) the anti-TL1A antibody being administered to the patient in an induction dosing regimen sufficient to improve the signs and symptoms of IBD for at least 12 weeks after initiation of treatment with the anti-TL1A antibody, said induction dosing regimen comprising a plurality of individual induction doses, in which the patient was determined to be a non-haplotype B carrier;and (c) the anti-TL1A antibody should be administered to the patient in a subsequent maintenance dosing regimen after completion of the induction dosing regimen, said maintenance dosing regimen comprising a plurality of individual maintenance doses separated from each other by at least 2 weeks.; 145. Anti-TL1A antibody for use in the treatment of IBD in a patient, characterized by: (a) a genotyping assay to be performed on a biological sample from the patient to determine whether the patient is a haplotype B vehicle or a non-haplotype B vehicle for TNFSF15, wherein the assay comprises determining the presence of SNP rs3810936 and SNP rs7869487 in a biological sample from the patient, and wherein a non-haplotype B vehicle for TNFSF15 is identified by any of the following biomarker statuses in the biological sample from the patient: Petition 870250104631, dated 11 / 14 / 2025, p.331 / 355 27 / 36 (i) the sample genotype is homozygous for the reference allele at rs3810936 and is homozygous for the alternative allele at rs7869487; (ii) the sample genotype is heterozygous for the reference allele at rs3810936 and is homozygous for the alternative allele at rs7869487; (iii) the sample genotype is homozygous for the alternative allele at rs3810936 and is homozygous for the reference allele at rs7869487; (iv) the sample genotype is homozygous for the alternative allele at rs3810936 and is heterozygous for the reference allele at rs7869487; or (v) the sample genotype is homozygous for the alternative allele at rs3810936 and is homozygous for the alternative allele at rs7869487; and (b) an effective amount of anti-TL1A antibody must be administered to the patient, where it has been determined that the patient is a non-vehicle of haplotype B.

146. Anti-TL1A antibody for use in the treatment of IBD in a patient, characterized by an effective amount of anti-TL1A antibody being administered to the patient; wherein the patient has been determined to be a non-vehicle of haplotype B for TNFSF15 by any of the following biomarker statuses in a biological sample from the patient: (i) the sample genotype is homozygous for the reference allele at rs3810936 and is homozygous for the alternative allele at rs7869487; (ii) the sample genotype is heterozygous for the reference allele at rs3810936 and is homozygous for the alternative allele at rs7869487; (iii) the sample genotype is homozygous for the alternative allele at rs3810936 and is homozygous for the reference allele at rs7869487; (iv) the sample genotype is homozygous for the alternative allele at rs3810936 and is heterozygous for the reference allele at rs7869487; or (v) the sample genotype is homozygous for the alternative allele at Petition 870250104631, dated 11 / 14 / 2025, p.332 / 355 28 / 36 rs3810936 and is homozygous for the alternative allele at rs7869487.

147. Anti-TL1A antibody for use in the treatment of IBD in a patient, characterized by: (a) a genotyping assay being performed to determine whether the patient is a haplotype B vehicle or a non-haplotype B vehicle for TNFSF15, the assay comprising determining the presence of at least two SNPs selected from rs3810936, rs6478108, rs6478109, rs7848647 and rs7869487 in a biological sample from the patient; and (b) an effective amount of anti-TL1A antibody being administered to the patient, wherein the patient was determined to be a non-haplotype B vehicle; wherein the anti-TL1A antibody comprises an HCDR1 with the sequence shown in SEQ ID NO: 3, an HCDR2 with the sequence shown in SEQ ID NO: 4, an HCDR3 with the sequence shown in SEQ ID NO: 5, an LCDR1 with the sequence shown in SEQ ID NO: 6, an LCDR2 with the sequence shown in SEQ ID NO: 7 and an LCDR3 with the sequence shown in SEQ ID NO:

8.

148. Anti-TL1A antibody for use in the treatment of IBD in a patient, characterized by: (a) a genotyping assay being performed to determine whether the patient is a haplotype B carrier or a non-haplotype B carrier for TNFSF15, the assay comprising determining the presence of at least two SNPs selected from rs3810936, rs6478108, rs6478109, rs7848647 and rs7869487 in a biological sample from the patient; and (b) the anti-TL1A antibody being administered to the patient, in whom it has been determined that the patient is a non-haplotype B carrier; wherein the anti-TL1A antibody comprises an HCDR1 with the sequence shown in SEQ ID NO: 37, an HCDR2 with the sequence shown in SEQ ID NO: 39, an HCDR3 with the sequence shown in SEQ ID NO: 41, an LCDR1 with the sequence shown in SEQ ID NO: 46, an LCDR2 with the sequence shown in SEQ ID NO: 48 and an LCDR3 with the sequence shown in SEQ ID NO:

50.

149. Anti-TL1A antibody for use in the treatment of IBD in a patient, characterized in that an effective amount of anti-TL1A antibody must be administered to the individual in a dosing regimen comprising an induction dosing regimen and a subsequent maintenance dosing regimen; wherein the induction dosing regimen comprises a plurality of individual induction doses and the maintenance dosing regimen comprises a plurality of individual maintenance doses; wherein the anti-TL1A antibody is administered subcutaneously in the maintenance phase, and wherein the anti-TL1A antibody comprises: an HCDR1 with the sequence shown in SEQ ID NO: 3, an HCDR2 with the sequence shown in SEQ ID NO: 4, an HCDR3 with the sequence shown in SEQ ID NO: 5, an LCDR1 with the sequence shown in SEQ ID NO: 6, an LCDR2 with the sequence shown in SEQ ID NO: 7, and an LCDR3 with the sequence shown in SEQ ID NO:

8.

150. Anti-TL1A antibody for use in the treatment of an IBD in a patient, characterized by an effective amount of anti-TL1A antibody being administered to the individual in a dosing regimen comprising an induction dosing regimen and a subsequent maintenance dosing regimen, wherein: (a) the induction dosing regimen comprises the subcutaneous administration of four individual induction doses of anti-TL1A antibody at a dose of approximately 50 mg, 150 mg or 450 mg, wherein the doses Petition 870250104631, dated 11 / 14 / 2025, p.(a) Individual induction doses of 334 / 355 30 / 36 are administered at 4-week intervals; and (b) The maintenance dosing regimen comprises the subcutaneous administration of a plurality of individual maintenance doses of anti-TL1A antibody at a dose of approximately 50 mg, 150 mg, or 450 mg, wherein the individual maintenance doses are administered at 4-week intervals, and wherein the anti-TL1A antibody comprises: an HCDR1 with the sequence shown in SEQ ID NO: 3, an HCDR2 with the sequence shown in SEQ ID NO: 4, an HCDR3 with the sequence shown in SEQ ID NO: 5, an LCDR1 with the sequence shown in SEQ ID NO: 6, an LCDR2 with the sequence shown in SEQ ID NO: 7, and an LCDR3 with the sequence shown in SEQ ID NO:

8.

151. Anti-TL1A antibody for use in the treatment of inflammatory bowel disease (IBD) in a patient, characterized in that an effective amount of anti-TL1A antibody must be administered to the individual in a dosing regimen comprising an induction dosing regimen and a subsequent maintenance dosing regimen, wherein: (a) the induction dosing regimen comprises a plurality of individual induction doses, wherein the individual induction doses are separated from each other by at least 1 week, at least 2 weeks, at least 3 weeks, or at least 4 weeks; and (b) the maintenance dosing regimen comprises the subcutaneous administration of a plurality of individual maintenance doses of anti-TL1A antibody at a dose of approximately 450 mg, wherein the individual maintenance doses are administered at 4-week intervals, and wherein the anti-TL1A antibody comprises: Petition 870250104631, dated 11 / 14 / 2025, p.335 / 355 31 / 36 an HCDR1 with the sequence shown in SEQ ID NO: 3, an HCDR2 with the sequence shown in SEQ ID NO: 4, an HCDR3 with the sequence shown in SEQ ID NO: 5, an LCDR1 with the sequence shown in SEQ ID NO: 6, an LCDR2 with the sequence shown in SEQ ID NO: 7, and an LCDR3 with the sequence shown in SEQ ID NO:

8.

152. USE OF AN ANTI-TL1A ANTIBODY in the manufacture of a medicament to treat IBD in a patient, characterized by: (a) a genotyping assay being performed to determine whether the patient is a haplotype B carrier or a non-haplotype B carrier for TNFSF15, the assay comprising determining the presence of at least two SNPs selected from rs3810936, rs6478108, rs6478109, rs7848647 and rs7869487 in a biological sample from the patient; and (b) an effective amount of the anti-TL1A antibody being administered to the patient, wherein the patient has been determined to be a non-haplotype B carrier.

153. USE OF AN ANTI-TL1A ANTIBODY in the manufacture of a medicament to treat IBD in a patient, characterized by: (a) a genotyping assay being performed to determine whether the patient is a haplotype B vehicle or a non-haplotype B vehicle for TNFSF15, the assay comprising determining the presence of at least two SNPs selected from rs3810936, rs6478108, rs6478109, rs7848647 and rs7869487 in a biological sample from the patient; (b) the anti-TL1A antibody should be administered to the patient in an induction dosage regimen sufficient to improve the signs and symptoms of IBD for at least 12 weeks after the start of treatment with the anti-TL1A antibody, said induction dosage regimen comprising a plurality of individual induction doses, in which the patient was determined Petition 870250104631, dated 11 / 14 / 2025, p.336 / 355 32 / 36 as a non-B haplotype vehicle; and (c) the anti-TL1A antibody should be administered to the patient in a subsequent maintenance dosing regimen after completion of the induction dosing regimen, said maintenance dosing regimen comprising a plurality of individual maintenance doses separated from each other by at least 2 weeks.

154. USE OF AN ANTI-TL1A ANTIBODY in the manufacture of a medicament to treat IBD in a patient, characterized by: (a) a genotyping assay being performed on a biological sample from the patient to determine whether the patient is a haplotype B carrier or a non-haplotype B carrier for TNFSF15, wherein the assay comprises determining the presence of SNP rs3810936 and SNP rs7869487 in a biological sample from the patient, and wherein a non-haplotype B carrier for TNFSF15 is identified by any of the following biomarker statuses in the biological sample from the patient: (i) the sample genotype is homozygous for the reference allele at rs3810936 and is homozygous for the alternative allele at rs7869487; (ii) the sample genotype is heterozygous for the reference allele at rs3810936 and is homozygous for the alternative allele at rs7869487; (iii) the sample genotype is homozygous for the alternative allele at rs3810936 and is homozygous for the reference allele at rs7869487;(iv) the sample genotype is homozygous for the alternative allele at rs3810936 and is heterozygous for the reference allele at rs7869487; or (v) the sample genotype is homozygous for the alternative allele at rs3810936 and is homozygous for the alternative allele at rs7869487; and (b) an effective amount of anti-TL1A antibody should be administered to the patient, where the patient has been determined to be a non-vehicle of haplotype B. Petition 870250104631, dated 11 / 14 / 2025, pp. 337 / 355 33 / 36; 155. USE OF AN ANTI-TL1A ANTIBODY in the manufacture of a medicament to treat IBD in a patient, characterized in that an effective amount of the anti-TL1A antibody must be administered to the patient, and in which the patient has been determined to be a non-vehicle of haplotype B for TNFSF15 by any of the following biomarker statuses in a biological sample from the patient: (i) the sample genotype is homozygous for the reference allele at rs3810936 and is homozygous for the alternative allele at rs7869487; (ii) the sample genotype is heterozygous for the reference allele at rs3810936 and is homozygous for the alternative allele at rs7869487; (iii) the sample genotype is homozygous for the alternative allele at rs3810936 and is homozygous for the reference allele at rs7869487; (iv) the sample genotype is homozygous for the alternative allele at rs3810936 and is heterozygous for the reference allele at rs7869487;or (v) the sample genotype is homozygous for the alternative allele at rs3810936 and is homozygous for the alternative allele at rs7869487.; 156. USE OF AN ANTI-TL1A ANTIBODY in the manufacture of a medicament to treat IBD in a patient, characterized by: (a) a genotyping assay being performed to determine whether the patient is a haplotype B vehicle or a non-haplotype B vehicle for TNFSF15, the assay comprising determining the presence of at least two SNPs selected from rs3810936, rs6478108, rs6478109, rs7848647 and rs7869487 in a biological sample from the patient; and (b) an effective amount of anti-TL1A antibody must be administered to the patient, wherein the patient has been determined to be a non-vehicle of haplotype B, and wherein the anti-TL1A antibody comprises an HCDR1 with the sequence shown in SEQ ID NO: 3, an HCDR2 with the sequence shown in Petition 870250104631, dated 11 / 14 / 2025, p.338 / 355 34 / 36 in SEQ ID NO: 4, an HCDR3 with the sequence shown in SEQ ID NO: 5, an LCDR1 with the sequence shown in SEQ ID NO: 6, an LCDR2 with the sequence shown in SEQ ID NO: 7 and an LCDR3 with the sequence shown in SEQ ID NO:

8.

157. USE OF AN ANTI-TL1A ANTIBODY in the manufacture of a medicament to treat IBD in a patient, characterized by: (a) a genotyping assay being performed to determine whether the patient is a haplotype B vehicle or a non-haplotype B vehicle for TNFSF15, the assay comprising determining the presence of at least two SNPs selected from rs3810936, rs6478108, rs6478109, rs7848647 and rs7869487 in a biological sample from the patient; and (b) the anti-TL1A antibody should be administered to the patient, wherein the patient has been determined to be a non-vehicle of haplotype B, and wherein the anti-TL1A antibody comprises an HCDR1 with the sequence shown in SEQ ID NO: 37, an HCDR2 with the sequence shown in SEQ ID NO: 39, an HCDR3 with the sequence shown in SEQ ID NO: 41, an LCDR1 with the sequence shown in SEQ ID NO: 46, an LCDR2 with the sequence shown in SEQ ID NO: 48 and an LCDR3 with the sequence shown in SEQ ID NO:

50.

158. USE OF AN ANTI-TL1A ANTIBODY in the manufacture of a medicament to treat IBD in a patient, characterized in that an effective amount of the anti-TL1A antibody must be administered to the individual in a dosing regimen comprising an induction dosing regimen and a subsequent maintenance dosing regimen; wherein the induction dosing regimen comprises a plurality of individual induction doses and the maintenance dosing regimen comprises a plurality of individual maintenance doses; wherein the anti-TL1A antibody is administered subcutaneously. Petition 870250104631, dated 11 / 14 / 2025, p.339 / 355 35 / 36 in the maintenance phase, and wherein the anti-TL1A antibody comprises: an HCDR1 with the sequence shown in SEQ ID NO: 3, an HCDR2 with the sequence shown in SEQ ID NO: 4, an HCDR3 with the sequence shown in SEQ ID NO: 5, an LCDR1 with the sequence shown in SEQ ID NO: 6, an LCDR2 with the sequence shown in SEQ ID NO: 7, and an LCDR3 with the sequence shown in SEQ ID NO:

8.

159. USE OF AN ANTI-TL1A ANTIBODY in the manufacture of a medicament for treating an IBD in a patient, characterized in that an effective amount of the anti-TL1A antibody must be administered to the individual in a dosing regimen comprising an induction dosing regimen and a subsequent maintenance dosing regimen, wherein: (a) the induction dosing regimen comprises the subcutaneous administration of four individual induction doses of the anti-TL1A antibody at a dose of approximately 50 mg, 150 mg or 450 mg, wherein the individual induction doses are administered 4 weeks apart;(b) the maintenance dosing regimen comprises the subcutaneous administration of a plurality of individual maintenance doses of anti-TL1A antibody at a dose of approximately 50 mg, 150 mg, or 450 mg, wherein the individual maintenance doses are administered at 4-week intervals, and wherein the anti-TL1A antibody comprises: an HCDR1 with the sequence shown in SEQ ID NO: 3, an HCDR2 with the sequence shown in SEQ ID NO: 4, an HCDR3 with the sequence shown in SEQ ID NO: 5, an LCDR1 with the sequence shown in SEQ ID NO: 6, an LCDR2 with the sequence shown in SEQ ID NO: 7, and an LCDR3 with the sequence shown in SEQ ID NO:

8. Petition 870250104631, dated 11 / 14 / 2025, pp. 340 / 355;